

# **CURRICULUM VITAE**

**Thomas J Slaga**

## **GENERAL INFORMATION**

### **PERSONAL DATA:**

**Date of Preparation:** 12/15/2015

**Address:** 7703 Floyd Curl Drive - MC 7764  
San Antonio, TX 78230

**Phone Number:** (210) 567-4231

**Fax Number:**

**Email Address:** slagat@uthscsa.edu

### **SELF DESCRIPTION:**

Dr. Thomas Slaga has more than 45 years of experience in studying the mechanisms of carcinogenesis and chemoprevention and directing and establishing research centers. He is currently a Professor in the Department of Pharmacology, Associate Director for Basic Research of the NCI designated Cancer Center, Director of the Texas Consortium of Chronic Disease Prevention and Director of the Regional Health Science Center at Edinburg. Dr. Slaga started an active leadership role when he became head of an interactive research program on carcinogenesis and chemoprevention at the Oak Ridge National Laboratory. Later he became Director of the UTMDACC-SP whose mission was multidisciplinary and interactive research on cancer causation and prevention. Dr. Slaga became Scientific Director at the AMC Cancer Research Center and Deputy Director of the University of Colorado Comprehensive Cancer Center. Dr. Slaga has an important leadership role nationally and internationally in carcinogenesis and cancer prevention having started the Journal of Molecular Carcinogenesis. He has served on many review committees such as a full member and chair of the Chemical Pathology Study Section, American Cancer Society review groups, Cancer Center review groups and program project review committees. He also served on several NIEHS, EPA and FDA review committees. Dr. Slaga also serves on the Board of Directors for the Aspen Cancer Conference and several scientific advisory committees. He has a very active and funded research program. Continuously funded since 1974, his research program is currently supported by several R01 grants. He has over 300 peer reviewed publications and over 200 invited review articles, book chapters and scientific books on cancer as well as a lay book entitled, "The Detox Revolution" which emphasizes the importance of diet, nutrition and phytonutrients in chronic disease prevention.

### **EDUCATION:**

<u>Year</u>	<u>Degree</u>	<u>Discipline</u>	<u>Institution/Location</u>
1969	PhD	Physiology/Biophysics	The University of Arkansas Medical Center, Little Rock, AR
1964	BA	Biology/Chemistry	The College of Steubenville, Steubenville, OHG

**TRAINING:**

***Post Doctoral Fellowship***

<u>Year</u>	<u>Discipline</u>	<u>Institution/Location</u>
1968-1971		McArdle Laboratory for Cancer Research, University of Wisconsin, Madison, WI

**ACADEMIC APPOINTMENTS:**

09/2015 - 08/2020	A. B. Alexander Professorship in Cancer Research	The University of Texas Health Science Center at San Antonio, San Antonio, TX
04/2005 - Present	Professor	University of Texas Health Science Center, Department of Pharmacology, San Antonio, TX
09/1988 - 08/1997	Olga Keith Weiss Chair	University of Texas M.D. Anderson Cancer Center, Houston, TX
09/1986 - 08/1997	Adjunct Professor	College of Pharmacy, University of Texas, Austin, TX
09/1984 - 09/1988	Ruth and Walger Gage Sterling Professorship	University of Texas M.D. Anderson Cancer Center Science Park, Smithville, TX

01/1982 - 09/1997	Professor of Carcinogenesis	MD Anderson Cancer Center, Science Park - Research Division, Smithville, TX
02/1979 - 09/1982	Group Leader and Senior Staff II	Biology Division, Oak Ridge National Lab, Oak Ridge, TN
03/1976 - 09/1982	Lecturer	University of Tennessee Oak Ridge Graduate School of Biomedical Sciences, University of Tennessee, Oak Ridge, TN
02/1976 - 09/1979	Group Leader and Research Staff Member II	Skin Carcinogenesis and Tumor Protection, Cancer and Toxicology Program Biology Division, Oak Ridge National Lab, Oak Ridge, TN
01/1975 - 06/1975	Visiting Staff	National Cancer Institute, NIH, Bethesda, MD
12/1974 - 01/1976	Assistant Professor	Department of Pharmacology, University of Washington Medical School, Seattle, WA
03/1973 - 01/1976	Assistant Member	Fred Hutchinson Cancer Research Center, Seattle, WA
09/1971 - 03/1973	Research Investigator	Department of Chemical Carcinogenesis, Pacific Northwest Research Foundation, Seattle, WA

**NON-ACADEMIC APPOINTMENTS:**

09/2009 - Present	Director	Research Division, ERAHC, Edinburg, TX
01/2008 - 08/2009	Interim Director	Research Division, ERAHC, Edinburg, TX

01/2008 - Present	Chief Scientific Officer	Cancer Therapy and Research Center (UTHSCSA), San Antonio, TX
09/2006 - 12/2007	Deputy Director	San Antonio Cancer Institute (SACI), San Antonio, TX
09/2005 - 09/2006	Interim Director	San Antonio Cancer Institute (SACI), San Antonio, TX
03/2002 - 03/2005	Scientific Director	AMC Cancer Research Center, Denver, CO
01/2000 - 05/2005	Deputy Director	University of Colorado Health Sciences Center, Denver, CO
01/2000 - 03/2002	President and CEO	AMC Cancer Research Center, Denver, CO
01/1999 - 12/1999	Interim Deputy Director	University of Colorado Health Science Center, Denver, CO
07/1998 - 01/2001	Executive Vice President for Research	AMC Cancer Research Center, Denver, CO
08/1997 - 05/2005	Chair	AMC Cancer Research Center, Denver, CO
01/1983 - 08/1997	Director	University of Texas, MD Anderson Cancer Center, Smithville, TX

**HONORS AND AWARDS:**

09/2015 A.B. Alexander Professorship in Cancer Research: Holder - five year term

06/2011 Doctor Honoris Causa of Pharmacy: Medical University of Lodz (Poland)

01/1992 UTMDACC Executive Development Program

01/1991 Fairchild/LeMaster Inc. Media Training

01/1990 Who's Who Worldwide Registry, Sterling Registry

**TEACHING**

**OTHER TEACHING:**

***Membership on Supervising Committee***

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
-------------	--------------------	--------------------	-------------------

09/2015 - Present	Lisa Tremmel	The University of Texas Health Science Center at San Antonio	1
	<i>Dissertation Committee member</i>		
09/2014 - Present	Andrew Robles	The University of Texas Health Science Center at San Antonio	
	<i>Dissertation Committee</i>		
06/2014 - 08/2014	Huiyoung Yun	The University of Texas Health Science Center at San Antonio	
	<i>Qualifying Exam Committee</i>		
04/2014 - 06/2014	Nicholas F. Dybdal- Hargreaves	The University of Texas Health Science Center at San Antonio	
	<i>Qualifying Exam Committee</i>		
03/2014 - 06/2014	Andrew Robles	The University of Texas Health Science Center at San Antonio	
	<i>Qualifying Exam Committee</i>		
10/2013 - Present	Tiffani Horton	The University of Texas Health Science Center at San Antonio	
	<i>Dissertation Committee</i>		
08/2013 - Present	Heather Hambright	The University of Texas Health Science Center at San Antonio	
	<i>Dissertation Committee</i>		
04/2013 - 06/2013	Heather Hambright	The University of Texas Health Science Center at San Antonio	
	<i>Qualifying Exam Committee</i>		
05/2012 - 06/2012	Peter Lococo	The University of Texas Health Science Center	

*Qualifying Exam Committee*

at San Antonio

09/2010 - 08/2013 Jingjing Gong

The University of Texas Health Science Center  
at San Antonio

*Dissertation Committee*

09/2005 - 08/2008 D. Shanmugarajah

The University of Texas Health Science Center  
at San Antonio

09/1998 - 06/2003 N. French

Colorado State University (Cell and Molecular  
Biology)

09/1992 - 06/1996 J. Blake

Texas A&M University (Toxicology)

09/1990 - 06/1994 M. A. Belury

University of Texas Austin (Nutrition)

09/1988 - 06/1992 M. Lochniskar

University of Texas Austin (Nutrition)

06/1977 - 01/1981 K.C. Klann

University of Tennessee Oak Ridge Graduate  
School of Biomedical Sciences

02/1976 - 09/1981 S. LeClerc

University of Tennessee Oak Ridge Graduate  
School of Biomedical Sciences

***Ph.D. Dissertations Directed***

<b><u>Date</u></b>	<b><u>Description</u></b>	<b><u>Institution</u></b>	<b><u># Students</u></b>
09/2008 - 08/2013	Jacob Junco	The University of Texas Health Science Center at San Antonio	
06/1978 - 10/1983	Donald R. Miller	Biomedical Sciences, University of Tennessee, Oak Ridge Graduate School of Biomedical	

Sciences

06/1978 - 10/1982 Karen Nelson Biomedical Sciences, University of Tennessee,  
Oak Ridge Graduate School of Biomedical  
Sciences

06/1974 - 10/1979 John Di Giovanni Pharmacology, University of Washington  
Medical School

***Post-Doctoral Student Supervision***

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
06/2006 - 06/2008	T. Kinjo	University of Ryukyuo, Okinawa, Japan	
11/2005 - 10/2010	P. Kowalczyk	Medical Centre of Postgraduate Education, Warsaw Poland	
11/2005 - 10/2010	M. Kowalczyk	Warsaw Agricultural University, Poland	
02/2000 - 12/2003	A. V. Gasparian, M.D.	Moscow University	
10/1996 - 08/1999	V. Spiegelman, M.D.	Moscow University	
06/1996 - 10/1998	H. Kang, M.D.	Korea University	
02/1994 - 10/1996	J. P. Volpe, Ph.D.	University of California	
10/1992 - 11/1994	N. Yoshimi, M.D.	Tokyo University	
06/1991 - 12/1993	L. D. Weinberg, Ph.D.	University of Kansas	
06/1990 - 11/1992	T.K.O. Vo, Ph.D.	Belgium University	

05/1988 - 10/1990 J. B. Rotstein, Ph.D. Toronto University

02/1988 - 12/1993 K. C. Klann, Ph.D. University of Tennessee Oak Ridge Graduate  
School of Biomedical Sciences

06/1986 - 10/1989 G. J. Patsakan, Ph.D. University of Cincinnati

08/1985 - 11/1988 J. O'Connell, Ph.D. Iowa University

06/1984 - 09/1986 C. M. Aldaz, M.D. Buenos Aires University

02/1984 - 10/1987 R. J. Morris, Ph.D. Syracuse University

05/1983 - 10/1984 S. W. Ashurst, Ph.D. Gifford University

02/1983 - 11/1985 M. Mamrack Baylor University

06/1982 - 08/1985 J. J. Reiners, Ph.D. Baylor University

05/1981 - 09/1984 J.C. Pelling, Ph.D. University of Michigan

08/1980 - 10/1982 V. Solanki, Ph.D. Aldelaide University

07/1980 - 06/1982 J. Bohrman, Ph.D. Pacific University

06/1980 - 11/1982 L.P. Yotti, Ph.D. Michigan State University

05/1980 - 09/1982 K. Davidson, Ph.D. University of Tennessee

02/1980 - 11/1982	John Di Giovanni, Ph.D.	University of Washington Medical School
06/1979 - 10/1982	S. M. Fischer, Ph.D.	University of Wyoming
06/1979 - 10/1982	R. P. Iyer, Ph.D.	Pacific University
06/1978 - 09/1982	C. E. Weeks, Ph.D.	University of Minnesota
02/1978 - 08/1982	A. Koostra, Ph.D.	New Zealand
02/1976 - 10/1980	D. L. Berry, Ph.D.	Utah State University
00/0000 - Present	Gunjan Malik, Ph.D.	The University of Texas Health Science Center at San Antonio

***Pre-Doctoral Student Supervision***

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
09/2010 - Present	Anna Mancha	The University of Texas Health Science Center at San Antonio	

***Rotation Student Supervision***

<u>Date</u>	<u>Description</u>	<u>Institution</u>	<u># Students</u>
09/2015 - 12/2015	Xiaoyu Yang	The University of Texas Health Science Center at San Antonio	1
01/2015 - 04/2015	Erin Niblick	The University of Texas Health Science Center at San Antonio	1
09/2014 - 12/2014	Erin Niblick	The University of Texas Health Science Center	1

at San Antonio

01/2014 - 03/2014	Kevin Downs	The University of Texas Health Science Center at San Antonio
09/2013 - 12/2013	Kevin Downs	The University of Texas Health Science Center at San Antonio
09/2012 - 01/2013	Anna Mancha	The University of Texas Health Science Center at San Antonio

## **RESEARCH**

### **EXPERTISE:**

**Expertise and Experience** - Dr. Thomas Slaga has and continues to be very active scientifically and administratively with over 40 years of experience studying the mechanisms of carcinogenesis and chemoprevention and directing and establishing research centers. Dr. Slaga is currently a Professor in the Department of Pharmacology, Director of the Medical Research Division of the Regional Academic Health Center, Director of the Texas Consortium of Chronic Disease Prevention and Interim Deputy Director of the NCI designated Cancer Center (CTRC) at UTHSCSA. Dr. Slaga has a very active and funded research program. Continuously funded since 1974, his research program is currently supported by two R01 grants on which he is Principle Investigator and two NIH grants on which he is a Co-Investigator. Dr. Slaga is a world renowned expert in cancer causation and prevention. His overall research interests are not only in cancer research but also nutrition, endocrinology and environmental toxicology. His studies address how diet and nutrition, lifestyle, environmental factors and the complex interactions of our genes can affect one's health, especially related to chronic diseases such as cancer, diabetes and obesity. A strong focal point of this research has and continues to be studying the mechanisms involved in chronic inflammation and cell proliferation on disease causation and prevention especially as related to epithelial cancers such as skin, prostate, breast and lung. In terms of inhibiting the induction of epithelial cancers by photonutrients, his research has studied the mechanisms of action of flavonoids, phenolic and polyphenolic antioxidants, triterpenoids, carotenoids, D-glucarates, chlorophyllins, vitamins and minerals including resveratrol and ursolic acid, the two compounds that he is presenting pursuing. In addition, several steroidal and non-steroidal anti-inflammatory agents have been investigated. Of the many possible mechanisms effective in counteracting the induction of cancer by dietary and/or chemopreventative means, his research has shown that the most promising are compounds with anti-inflammatory and anti-proliferative activities and compounds that increase apoptosis. Dr. Slaga's extensive publication record documents the many important and critical contributions he has made in carcinogenesis and cancer prevention. Dr. Slaga has contributed significantly to the critical role of specific mutations, chronic inflammation and cell proliferation in multistage carcinogenesis. He has made many important contributions related to the activation and detoxification of polycyclic aromatic hydrocarbons (PAH) a very important class of chemical carcinogens. In relation to PAH, Dr. Slaga was very active in the determining that the diolepoxide was the critical ultimate reactive carcinogen involved in tumor initiation leading to a specific mutation in HRAS oncogene. He found that certain flavonoids are very effective in counteracting the metabolic activation of

PAH carcinogens. Dr. Slaga developed a very potent suicide substrate that prevented the activation of several PAH carcinogens. Dr. Slaga was the leading researcher showing that glucocorticoids and derivatives are very potent anti-inflammatory, anti-proliferative and anti-tumor promoting agents. Furthermore, he found that the glucocorticoid receptor is a tumor suppressor gene in mice overexpressing the receptor in the skin of mice. Recently he found that the transpression and transactivation activities of the receptor can be dissociated by a number of steroid and non-steroid derivatives. Dr. Slaga started an active leadership role in 1976 when he became head of an interactive research program on skin carcinogenesis and chemoprevention at the Oak Ridge National Laboratory. In 1982, Dr. Slaga became Director of UTMADACC-SP of the UT MD Anderson Cancer Center whose mission was multidisciplinary and interactive research on cancer causation and prevention. At UTMADACC-SP, he was successful in obtaining several long standing training grants, several program grants, and ACS Institutional Program grant for 10 years and an NIEHS Center Grant with Dr. John DiGiovanni as Center Director. In addition, Dr. Slaga was active in helping UT MD Anderson Cancer Center in several competitive renewals of its NCI Comprehensive Cancer Center. Dr. Slaga also served on major institutional strategic committees such as the Executive Committee of the Science Faculty, the research council and the President's Advisory Board. In 1998, Dr. Slaga became Executive Vice President for Research (Scientific Director) at the AMC Cancer Research Center and Deputy Director of the University of Colorado Comprehensive Cancer Center. The overall mission of the AMC Cancer Research Center was multidisciplinary and interactive research programs on cancer causation, prevention and control at the University of Colorado Health Science Center, University of Colorado and Colorado State university which were part of University of Colorado Comprehensive Cancer Center. Dr. Slaga has an important leadership role nationally and internationally in carcinogenesis and cancer prevention having started the Molecular Carcinogenesis Journal with Dr. Yuspa and serving as editor-in-chief for many years. Dr. Slaga has served on many review committees such as a full member and chair of the Chemical Pathology Study Section, American Cancer Society review groups, Cancer Center review groups and program project review committees. He also served on several NIEHS, EPA and FDA review committees. Dr. Slaga also serves on Board of Directors for the Aspen Cancer Conference and several scientific advisory committees. He has over 500 publications with more than 300 of them being peer-reviewed as well as a lay book entitled "The Detox Revolution" which emphasizes the importance of diet, nutrition and phytonutrients in chronic disease.

**Faculty Research Profile** - The research in Dr. Thomas Slaga's laboratory is focused on glucocorticoid hormones (GC), very potent inhibitors of physiological DNA synthesis in keratinocytes in vivo. These hormones are also very effective in preventing carcinogen- and tumor promoter-induced skin hyperplasia, inflammation, and mouse skin tumor formation when applied to skin together with a carcinogen or a tumor promoter. We and others have shown, however, that the GC do not affect the growth of either established papillomas, squamous cell carcinomas (SCC), or transformed keratinocytes in vitro. In addition, we recently found that the GC do not affect glucocorticoid-responsive genes in transformed keratinocytes both in vitro and in vivo. We have generated skin-targeted transgenic mice over-expressing the GR under the control of the keratin 5 (K5) promoter. These adult transgenic mice have impaired proliferative and inflammatory responses to skin tumor promoters. Our initial studies showed that the K5.GR transgenic animals are resistant to ras-induced tumorigenesis. The constitutively nuclear overexpression and activation of the GR in the epidermis dramatically inhibited skin tumor development in K5.GR/ras+ double transgenic mice in terms of number of animals that develop tumors, number of tumors per animal, and tumor size. In another study we plan to determine the mechanism(s) of synergistic action of the natural source compounds, known to inhibit one or more stages of skin carcinogenesis, i.e., initiation and promotion/progression. The concurrent topical and systemic (i.e., dietary) treatment with selected natural source inhibitors of different stages of skin carcinogenesis result in synergistic effects leading to more efficient prevention of skin cancer. The natural source inhibitors to be tested include ellagic acid, imperatorin from the family of coumarins, proanthocyanidin B-2-gallate, (-)-

epigallocatechin from the family of green tea polyphenols, N-acetylcysteine, calcium D-glucarate, lycopene, carnosol and ursolic acid from rosemary extract, and resveratrol. We propose to initially utilize a number of very predictive short-term in vitro and in vivo tests in order to identify the mechanism(s) and to differentiate the potencies of selected inhibitors at various concentrations under standard conditions. The most effective compounds will then be studied in long-term tumor experiments utilizing a 7,12-dimethylbenz[a]anthracene (DMBA)-induced 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted multistage carcinogenesis model in SENCAR mice.

**PUBLICATIONS: (\* *indicates Peer Reviewed*)**

***Abstract***

1. Lee H, Morales L, Slaga TJ, Kim DJ. Activation of T-cell protein tyrosine phosphatase suppresses keratinocyte survival and proliferation following UVB irradiation 2015 Mar. (Presented at the 54th Annual Meeting of the Society of Toxicology).
2. Shin JW, Lee H, Morales L, Slaga TJ, Kim DJ. TC-PTP inhibits UVB-induced keratinocyte survival and proliferation by regulating Stat3 signaling 2014 Mar. (Presented at the 53rd Annual Meeting of the Society of Toxicology).
3. Shin, JW, Lee H, Morales L, Slaga TJ, Kim DJ. T-cell protein tyrosine phosphatase (TC-PTP) inhibits UVB-induced keratinocyte survival and proliferation by regulating Stat3 signaling 2013 Oct. (Presented at the Lone Star Regional Chapter (LSSOT) Annual Meeting, Society of Toxicology).
4. Lee YS, Shin JW, Morales L, Slaga TJ, Kim DJ. The role of T-cell protein tyrosine phosphatase (TC-PTP) in UVB-induced epidermal cell proliferation and survival 2013. p. #3586. (Presented at the 104th Annual Meeting of American Association for Cancer Research).
5. Shin JW, Lee YS, Morales L, Slaga TJ, Kim DJ. TC-PTP regulates UVB-induced epidermal cell proliferation and survival by modulating Stat3 signaling 2013. (Presented at the Aspen Cancer Conference).
- \* 6. Fiume MM, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of bis-diglyceryl polyacyladipate-2 and bis-diglyceryl polyacyladipate-1 as used in cosmetics 2013. p. 56S-64S. (Int J Toxicol; vol. 32, no. 5S).
7. Junco J, Malik G, Mancha A, Slaga TJ. Resveratrol and ursolic acid synergize with chloroquine to inhibit B16F10 melanoma cell viability and autophagy 2012 Nov. (Presented at the Society for Melanoma Research 2012 Congress).
8. Junco J, Malik G, Mancha A, Liang H, Slaga TJ. Effect of combination of resveratrol and ursolic acid on skin tumor cell viability 2012 Nov. (Presented at the Cancer Therapy & Research Center Annual Symposium).

9. Lee YS, Morales L, Slaga TJ, DiGiovanni J, Kim DJ. Nuclear translocation of TC-PTP in skin following UVB irradiation 2012 Jun. (Presented at the 10th International Skin Carcinogenesis Conference).
10. Junco J, Cho J, Malik G, Carbajal S, Moore T, Tolstykh O, DiGiovanni J, Slaga TJ. A combination of resveratrol and ursolic acid produces synergistic inhibitory effects on markers of skin tumor promotion 2011 Nov. (Presented at the Cancer Therapy & Research Center Annual Symposium).
11. Junco JJ, Cho J, Malik G, Carbajal S, Moore T, Tolstykh O, DiGiovanni J, Slaga TJ. A combination of resveratrol and ursolic acid produces synergistic inhibitory effects on markers of skin tumor promotion 2011 Sep. (Presented at the 2nd AACR International Conference on Frontiers in Basic Cancer Research).
12. Kowalczyk P, Sosnowska, R, Kowalczyk M, Tolstykh, O, Junco, J, Walaszek Z, Slaga TJ, Hanausek M. The effect of dissociated glucocorticoids on 12-O-tetradecanoylphorbol-13-acetate (TPA) induced skin inflammation in SENCAR mice 2010. (Proceedings of the 101st Annual Meeting of the American Association for Cancer Research).
13. Kowalczyk M, Junco, J, Kowalczyk P, Tolstykh, O, Hanausek M, Slaga TJ, Walaszek Z. Effects of combined photochemicals on skin tumorigenesis in SENCAR mice 2010. (Proceedings of the 101st Annual Meeting of the American Association for Cancer Research).
14. Junco, J, Kowalczyk P, Kowalczyk M, Tolstykh, O, Hanausek M, Walaszek Z, Slaga TJ. Ursolic acid prevents activation of oncogenic factors in UV-treated HaCaT cells 2010. (Proceedings of the 101st Annual Meeting of the American Association for Cancer Research).
15. Junco J, Kowalczyk M, Kowalczyk P, Tolstykh O, Hanausek M, Walaszek Z, Slaga TJ. Differential effects of promising natural source inhibitors on critical features of skin tumor promotion in SENCAR mice 2009 Jul. (Presented at the 24th Aspen Cancer Conference).
16. Junco J, Kowalczyk M, Kowalczyk P, Swan W, Hanausek M, Walaszek Z, Slaga TJ. Differential effects of promising phytonutrients on critical features of skin tumor promotion in SENCAR mice 2009 Apr. (Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; vol. Abstr, no. 3898).
17. Kinjo T, Kowalczyk P, Kowalczyk M, Walaszek Z, Nishimaki T, Slaga TJ, Hanausek M. Cytotoxic effect of desipramine on a mouse skin squamous cell carcinoma cell line 2009 Apr. (Proceedings of the 100th Annual meeting of the American Association for Cancer Research; vol. Abstr, no. 4091).
18. Kowalczyk P, Kowalczyk M, Tolstykh O, Walaszek Z, Slaga TJ, Hanausek M. The effect of Compound A on 12-O-tetradecanoylphorbol-13-acetate induced acute skin inflammation in SENCAR mice 2009 Apr. (Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; vol. Abstr, no. 2622).

19. Kowalczyk M, Kowalczyk P, Tolstykh O, Hanausek M, Slaga TJ, Walaszek Z. Effects of combined natural source phytochemicals on expression of intermediate biomarkers during early stages of skin tumorigenesis in SENCAR mice 2009 Apr. (Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; vol. Abstr, no. 4789).
20. Kowalczyk P, Swan W, Kowalczyk M, Kinjo T, Walaszek Z, Hanausek M, Slaga TJ. The effect of partial agonist of glucocorticoid receptor on TPA-induced skin inflammation and keratinocyte proliferation. 2008 Jul. (Presented at the 23rd Aspen Cancer Conference).
21. Kinjo T, Kowalczyk P, Kowalczyk M, Walaszek Z, Nishimaki T, Slaga TJ, Hanausek M. Desipramine inhibits the growth of a mouse skin squamous cell carcinoma line independently of glucocorticoid receptor-mediated signal transduction 2008 Apr. (Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; vol. Abstr, no. 2216).
22. Kowalczyk M, Kowalczyk P, Swan W, Kinjo T, Grzelak M, Slaga TJ, Hanausek M, Walaszek Z. Combined effects of selected natural source inhibitors in murine skin cancer prevention 2008 Apr. (Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; vol. Abstr, no. 5569).
23. Kowalczyk P, Truong H, Kinjo T, Kowalczyk M, Swan W, Wendel C, Walaszek Z, Slaga TJ, Hanausek M. The effect of compound A on 12-O-tetradecanoylphorbol-13-acetate (TPA) induced skin inflammation and keratinocyte proliferation in SENCAR mice 2008 Apr. (Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; vol. Abstr, no. 2217).
24. Kowalczyk P, Truong H, Kinjo T, Kowalczyk M, Wendel C, Walaszek Z, Slaga TJ, Hanausek M. The effect of compound A on 12-O-tetradecanoylphorbol-13-acetate (TPA) induced skin inflammation and keratinocyte proliferation in SENCAR mice 2008. p. 523-523. (Proc Am Assoc Cancer Res; vol. 49).
25. Zoltaszek R, Grzelak M, Hanausek M, Kilianska Z, Slaga TJ, Walaszek Z. Effects of dietary D-glucarate on biomarkers of inflammation during early post-initiation stages of benzo[a]pyrene (B[a]P)-induced lung tumorigenesis in A/J mice 2008. p. 532-532. (Proc Am Assoc Cancer Res; vol. 49).
26. Kowalczyk M, Kowalczyk P, Swan W, Kinjo T, Grzelak M, Slaga TJ, Hanausek M, Walaszek Z. Combined effects of selected natural source inhibitors in murine skin cancer prevention 2008. p. 1323-1323. (Proc Am Assoc Cancer Res; vol. 49).
27. Kinjo T, Kowalczyk P, Kowalczyk M, Walaszek Z, Nishimaki T, Slaga TJ, Hanausek M. Desipramine inhibits the growth of a mouse skin squamous cell carcinoma line independently of glucocorticoid receptor-mediated signal transduction 2008. p. 523-523. (Proc Am Assoc Cancer Res; vol. 49).
28. Kowalczyk M, Walaszek Z, Kowalczyk P, Slaga TJ, Hanausek M. Antiproliferative and

proapoptotic effects of selected antioxidants in murine skin cancer prevention 2007 Apr. (American Association for Cancer Research Annual Meeting Proceedings; vol. Abstr, no. 30).

29. Kowalczyk P, Kinjo T, Hillis A, Kowalczyk M, Walaszek Z, Slaga TJ, Hanausek M. Differential effect of two phosphodiesterase inhibitors on modulation of glucocorticoid receptor function in mouse skin tumorigenesis 2007 Apr. (American Association for Cancer Research Annual Meeting Proceedings; vol. Abstr, no. 2635).
30. Walaszek Z, Hanausek M, Slaga TJ. D-Glucarates as mimetics of calorie restriction and proapoptotic agents 2007. p. 17. (Acta Biochemica Polonica; vol. 54, no. S5).
31. Zoltaszek R, Hanausek M, Slaga TJ, Walaszek Z. Proapoptotic effects of D-glucarate on chemically induced lung tumorigenesis in A/J mice 2007. p. 795. (Proc Am Assoc Cancer Res; vol. 48).
32. Kowalczyk M, Walaszek Z, Kowalczyk P, Hanausek M, Slaga TJ. Antiproliferative and proapoptotic effects of selected antioxidants in murine skin cancer prevention 2007. p. 8. (Proc Am Assoc Cancer Res; vol. 48).
33. Kowalczyk P, Kinjo T, Hillis A, Kowalczyk M, Walaszek Z, Slaga TJ, Hanausek M. Differential effect of two phosphodiesterase inhibitors on modulation of glucocorticoid receptor function in mouse skin tumorigenesis 2007. p. 628. (Proc Am Assoc Cancer Res; vol. 48).
34. Hanausek M, Walaszek Z, Slaga TJ. Combined natural inhibitors of skin carcinogenesis 2006 Jul. (Aspen Cancer Conference and Satellite Meeting).
35. Walaszek Z, Hanausek M, Szemraj J, Zoltaszek R, Slaga TJ. In vitro growth inhibition of helicobacter pylori by D-glucaric acid derivatives 2006. p. 1129. (Proc Am Assoc Cancer Res; vol. 47).
36. Hanausek M, Walaszek Z, Spears E, Zoltaszek R, Slaga TJ. Grape-derived antioxidants as inhibitors of murine skin carcinogenesis 2006. p. 536. (Proc Am Assoc Cancer Res; vol. 47).
37. Hanausek M, Walaszek Z, Zoltaszek R, Slaga TJ. Combinations of natural inhibitors in skin cancer prevention 2006. (Int J Mol Med).
38. Walaszek Z, Hanausek M, Zoltaszek R, Slaga TJ. Suppression by D-glucarate of carcinogen-induced inflammation in murine lung tumorigenesis 2006. (Int J Mol; vol. 17).
39. Curtin GM, Hanausek M, Walaszek Z, Zoltaszek R, Slaga TJ, Swauger J, Ayres P, Doolittle D. Implications of tobacco smoke-induced apoptosis within the A/J mouse lung model 2006. (Presented at the International Inhalation Symposium).
40. Walaszek Z, Hanausek M, Narog M, Zoltaszek R, Slaga TJ. Modulation of biomarkers of inflammation and inhibition of mouse skin tumorigenesis by a natural  $\beta$ -

glucuronidase inhibitor and its precursor 2005. p. 1016. (Proc. Am. Assoc. Cancer Res.; vol. 46).

41. Walaszek Z, Raich PC, Hanausek M, Szemraj J, Narog M, Zoltaszek R, Slaga TJ. Potential role of D-glucarate supplementation in lung cancer prevention 2005. (Int J Mol Med; vol. 16).
42. Hanausek M, Haridas V, Walaszek Z, Zoltaszek R, Slaga TJ, Gutterman JU. Inhibition of mouse skin tumorigenesis by avicins, new triterpenoid saponins 2005. (Int J Mol Med; vol. 16).
43. Walaszek Z, Hanausek M, Zoltaszek R, Slaga TJ. Inhibitory effect of post-initiation dietary D-glucarate on benzo[a]pyrene-induced inflammation during lung tumorigenesis in A/J mice. 2004. p. 724. (Proc. Am. Assoc. Cancer Res.; vol. 45).
44. Hanausek M, Curtin GM, Walaszek Z, Zoltaszek R, Ayres PH, Swauger JE, Slaga TJ. Microscopic examination of tobacco smoke-induced lung tumorigenicity in A/J mice 2004. p. 352. (Proc. Am. Assoc. Cancer Res.; vol. 45).
45. Hanausek M, Curtin GM, Walaszek Z, Zoltaszek R, Ayres PH, Swauger JE, Slaga TJ. Microscopic examination of tobacco smoke-induced lung tumorigenicity in A/J mice 2004. (Presented at the American Association for Cancer Research Meeting).
46. Curtin GM, Hanausek M, Walaszek Z, Zoltaszek R, Swauger JE, Slaga TJ, Ayres PH. Ornithine decarboxylase as a biomarker of cigarette smoke condensate-induced tumor promotion in mouse skin 2004. (Presented at the Tobacco Science Research Conference).
47. Curtin GM, Hanausek M, Walaszek Z, Zoltaszek R, Swauger JE, Slaga TJ, Ayres PH. Physiological and toxicological consequences of mainstream tobacco smoke exposure in A/J mice 2004. (Presented at the Tobacco Science Research Conference).
48. Curtin GM, Hanausek M, Walaszek Z, Zoltaszek R, Swauger JE, Slaga TJ, Ayres PJ. Ornithine decarboxylase as a biomarker of cigarette smoke condensate-induced tumor promotion in mouse skin 2004. (TSRC).
49. Hanausek M, Walaszek Z, Szemraj J, Slaga TJ. Modulation of biomarkers during chemoprevention of mouse lung tumorigenesis by D-glucarate. 2003 Jun. (Aspen Lung Conference).
50. Walaszek Z, Hanausek M, Narog M, Raich PC, Slaga TJ. Mechanisms of lung cancer chemoprevention by D-glucarate 2003 Jun. (Aspen Lung Conference).
51. Hanausek M, Curtin GM, Walaszek Z, Zoltaszek R, Mosberg AT, Slaga TJ. Short-term SENCAR mouse skin tests and biomarkers of tumor promotion by cigarette smoke condensate 2003. p. 94. (Proc. Am. Assoc. Cancer Res; vol. 44).
52. Walaszek Z, Yoshimi N, Hanausek M, Zoltaszek R, Slaga TJ. Modulation of biomarkers and prevention of mouse skin tumors by natural and synthetic  $\beta$ -

- glucuronidase inhibitors. 2003. p. 204. (Proc. Am. Assoc. Cancer Res.; vol. 44).
53. Hanausek M, Curtin GM, Walaszek Z, Zoltaszek R, Mosberg AT, Slaga TJ. Short-term SENCAR mouse skin tests and biomarkers of tumor promotion by cigarette smoke condensate 2003. (Presented at the American Association for Cancer Research).
54. Kodari E, Hanausek M, Spears E, Walaszek Z, Slaga TJ. Assessment of cancer preventive potential of natural source antioxidants using standardized in vitro assays. 2002. p. 476. (Proc. Am. Assoc. Cancer Res; vol. 43).
55. Spears E, Kodari E, Hanausek M, Walaszek Z, Slaga TJ. Prevention of chemical carcinogen-induced oxidative DNA damage, Ha-ras mutation and epidermal hyperplasia in the mouse skin by natural source antioxidants. 2002. p. 1144. (Proc. Am. Assoc. Cancer Res.; vol. 43).
56. Hanausek M, Walaszek Z, LaBate M, Spears E, Viaje A, Slaga TJ. A Short-Term Mouse Skin Inflammatory-Hyperplasia Test Predictive of the Carcinogenic Treatment Outcomes 2002. p. 1041. (Proc. Am. Assoc. Cancer Res.; vol. 43).
57. Walaszek Z, Raich P, Hanausek M, Szemraj J, Narog M, Slaga TJ. Potential Role of D-Glucaric Acid in Lung Cancer Prevention. 2002. p. 306. (Proc. Am. Assoc. Cancer Res.; vol. 43).
58. Curtin GM, Hanausek M, Walaszek Z, Mosberg AT, Slaga TJ. Short-term biomarkers of tumor promotion in SENCAR mouse skin treated with cigarette smoke condensate 2002. (Presented at the International Skin Carcinogenesis Conference).
59. Fuchs SY, Stavropoulos P, Latres E, Pagano M, Slaga TJ, Spiegelman VS. Induction of beta-TrCP by JNK signaling and its role in the activation of NF-kB by cellular stress 2001 Nov. p. 9-14. (Keystone Symposia, The Molecular Basis of Cancer: Signaling to Cell Growth and Death, Taos, NM).
60. Walaszek Z, Szemraj J, Slaga TJ. Molecular mechanisms of prevention of cancer with D-glucaric acid derivatives 2001. (Int J Mol Med; vol. 8).
61. Curtin GM, Hanausek M, Walaszek Z, Slaga TJ, Mosberg AT. Comparative studies of cigarette smoke condensates (CSC) utilizing epidermal hyperplasia endpoints. 2001. p. 1. (The Toxicologist; vol. 60).
62. Kodari E, Curtin GM, Hanausek M, Walaszek Z, Spears E, Farrell D, Mosberg AT, Slaga TJ. Comparative Studies of Cigarette Smoke Condensates Using In Vitro Assays and Epidermal Hyperplasia Endpoints. 2001. p. 811. (Proc. Am. Assoc. Cancer Res.; vol. 42).
63. Walaszek Z, Szemraj J, Hanausek M, Narog M, Kodari E, Barnett K, Farrell D, Slaga TJ. Effect of Calcium D-Glucarate on Expression of Ki-ras and p53 Genes in Benzo[a]pyrene-Induced Lung Lesions in Female A/J Mice. 2001. p. 265. (Proc. Am. Assoc. Cancer Res; vol. 42).

64. Hanausek M, Walaszek Z, Farrell D, Spears E, Narog M, Barnett K, Slaga TJ, Gutterman JU. Triterpenoid Saponins Reduce Epidermal Hyperplasia, Inflammation and p53 Mutations in UVB-Irradiated Hairless SKH-1 Mice. 2001. p. 463. (Proc. Am. Assoc. Cancer Res.; vol. 42).
65. Spears E, Hanausek M, Walaszek Z, Farrell D, Narog M, Slaga TJ. Grape Seed Extract Modulation of Intermediate Endpoint Biomarkers During Mouse Skin Carcinogenesis. 2001. p. 465. (Proc. Am. Assoc. Cancer Res.; vol. 42).
66. Hanausek M, Walaszek Z, Szemraj J, Slaga TJ. Early Detection of Breast and Prostate Cancers Using the p65 Oncofetal Protein. 2001. p. S10. (Int. J. Mol. Med.; vol. 8).
67. Spiegelman VS, Slaga TJ, Pagano M, Minamoto T, Ronai Z, Fuchs SY. The expression and activity of FBW1a ubiquitin ligase areceptor is regulated by Wnt/beta-catenin signaling 2001 Jan. (Keystone Symposia, The Molecular Basis of Cancer: Signaling to Cell Growth and Death, Taos, NM).
68. Kordari E, Curtin GM, Hanausek M, Walaszek Z, Spears E, Farrell D, Mosberg AT, Slaga TJ. Comparative studies of cigarette smoke condensates using In vitro assays and epidermal hyperplasia endpoints 2001. (Presented at the American Association for Cancer Research).
69. Curtin GM, Hanausek M, Walaszek Z, Slaga TJ, Mosberg AT. Comparative studies of cigarette smoke condensates (CSC) utilizing epidermal hyperplasia endpoints 2001. (Presented at the Society of Toxicology).
70. Curtin GM, Hanausek M, Walaszek Z, Slaga TJ, Mosberg AT. Comparative studies of cigarette smoke condensates (CSC) utilizing short-term in vitro and in vivo assays 2001. (Presented at the Tobacco Science Research Conference).
71. Spiegelman VS, Slaga TJ, Fuchs SY. The role of SCFHOS ubiquitin ligase in skin carcinogenesis 2000 Nov. (International Skin Carcinogenesis Conference, Tucson, Arizona).
72. Slaga TJ, Hanausek M, Walaszek Z. A Short-Term Mouse Skin Inflammatory-Hyperplasia Test Predictive of the Carcinogenic and Chemopreventive Treatment Outcomes. 2000 Jul. (Aspen Biotechnology Conference).
- \* 73. Slaga TJ, Hanausek M, Walaszek Z. A short-term mouse skin inflammatory-hyperplasia test predictive of the carcinogenic and chemopreventive treatment outcomes 2000 Jul. (Aspen Biotechnology Conference).
74. Hanausek M, Ganesh P, Walaszek Z, Slaga TJ, Gutterman JU. Inhibitory effects of triterpenoid saponins from *Acacia victoriae* on dimethylbenz[a]anthracene-induced murine skin carcinogenesis. 2000. p. 663. (Proc. Am. Assoc. Cancer Res.; vol. 41).
75. Walaszek Z, Hanausek M, Narog M, Kordari E, Harper P, Slaga TJ. Chemoprevention of pulmonary tumorigenesis by dietary calcium D-glucarate in female A/J mice. 2000. p. 663. (Proc. Am. Assoc. Cancer Res.; vol. 41).

76. Kordari M, Hanausek M, Narog M, Spears E, Farrell D, Walaszek Z, Slaga TJ. Inhibition of oxygen free radical formation in vitro by natural source and synthetic antioxidants and assessment of their cancer preventive potential. 2000. p. 664. (Proc. Am. Assoc. Cancer Res.; vol. 41).
77. Raich P, Walaszek Z, Hanausek M, Narog M, Harper P, Farrell D, Slaga TJ. Role of D-glucaric acid in cancer prevention. 1999 Nov. (International Symp. Biol. Cancer Prev. Treat.).
78. Spiegelman VS, Slaga TJ. The role of novel tumor suppressor INGI in mouse skin carcinogenesis 1999 Jul. (Aspen Cancer Conference).
79. Budunova IV, Gamel DN, Vaden VR, Slaga TJ. Constitutive activation of NF-kappaB factors in mouse skin tumors as a result of altered expression of NF-kappaB/1kappaB proteins 1999 Mar. (Proc Amer Assoc Cancer Res).
80. Hanausek M, Walaszek Z, Slaga TJ. Genetic susceptibility of mice to spontaneous and chemically induced carcinogenesis and the expression of the oncofetal protein p65 1999. p. 351. (Assoc. Cancer Res.; vol. 40).
81. Kordari E, Walaszek Z, Hanausek M, Narog M, Spears E, Farrell D, Viaje A, Slaga TJ. Inhibition of cellular proliferation, chemical carcinogen-induced hyperplasia, and papilloma formation in SENCAR mice by D-glucaro-1,4-lactone. 1999. p. 742. (Proc. Am. Assoc. Cancer Res.; vol. 40).
82. Nesnow S, Cavanaugh W, Gilmer TM, Kaufman DG, Slaga TJ, Hohman R, Bishop JM, Poirier MC, Hanausek M, Trump BF, Yuspa SH, Pfeifer AM, Sherman MI, Tennant R. Workshop on mechanisms of toxicity and carcinogenesis 1999. p. 99-106. (Mol Carcinog; vol. 25, no. 25462).
83. Budunova IV, Spiegelman VS, Carbajal S, Slaga TJ. Analysis of resistance of transformed mouse keratinocytes to glucocorticoid 1998 Mar. (Proc Amer Assoc Cancer Res).
84. Spiegelman VS, Budunova IV, Slaga TJ. Possible role of alternatively spliced variants of glucocorticoid receptor in the resistance of transformed mouse keratinocytes 1998 Mar. (Keystone Symposia).
85. Spiegelman VS, Budunova IV, Carbajal S, Slaga TJ, Slaga TJ. Implication of glucocorticoid receptor splicing variant in the resistance of transformed keratinocytes to glucocorticoids 1997 Apr. (Proc Amer Assoc Cancer Res).
86. Budunova IV, Spiegelman VS, Carbajal S, Volk M, Slaga TJ. Alteration of NF-kappaB/1kappaB expression during mouse skin carcinogenesis 1997 Apr. (Proc Amer Assoc Cancer Res).
87. Hanausek M, Lai DY, Gimenez-Conti I, Viaje A, Adams AK, Slaga TJ. Short-term tests to predict carcinogenic potential of organic peroxides. 1996 Dec. (10th International

Conference on Carcinogenesis and Risk Assessment).

88. Skisak C, DiGiovanni J, Conti CJ, Slaga TJ, Walborg EF. Short-term biomarkers predictive of petroleum middle distillate-induced tumor promotion in mouse skin 1996 Oct. (Exp Skin Carcinogenesis Conference).
89. Tang M-S, Viaje A, Chen JX, Morris R, Harvey R, Slaga TJ. The tumorigenicity of 7,12-dimethylbenzanthracene syn-diol epoxide and its induction of H-ras mutation 1996 Apr. (Proc Amer Assoc Cancer Res).
90. Budunova IV, Kang HI, Carbajal S, Slaga TJ. Alteration of glucocorticoid receptor expression and function during the tumor promotion stage of mouse skin carcinogenesis 1996 Apr. (Proc Amer Assoc Cancer Res).
91. Volpe JPG, Wang L, Epstein JG, Slaga TJ, Cleaver JE. Absence of ras mutations in UV-induced skin tumors in mice 1995 Mar. (Proc Amer Assoc Cancer Res).
92. Budunova IV, Winberg LD, Slaga TJ. The expression of gap junctional proteins on different stages of SENCAR mouse skin carcinogenesis 1995 Mar. (Proc Amer Assoc Cancer Res).
93. Budunova IV, Winberg LD, Slaga TJ. Connexin expression in epidermal cell lines from different stages of SENCAR mouse skin carcinogenesis 1994 Dec. (American Society for Cell Biology).
94. Gimenez-Conti I, Collet AM, Slaga TJ. Characterization of two-stage carcinogenesis induced lesions in the hamster cheek pouch model 1994 Oct. (Proc Amer Assoc Cancer Res).
95. Tennant RW, Prescott DM, Puck TT, Slaga TJ, Saffiotti U, Wogan GN, Nesnow S, McClain RM. Molecular mechanisms of toxicity in relations to the genetics of animal and human neoplasia 1994 Jul. p. 117-124. (Mol Carcinog; vol. 10, no. 3).
96. Gimenez-Conti IB, Winberg LD, Oubari D, Slaga TJ. Decreased rate of malignant conversion of sensitive sencar inbred (SSIN) papillomas using three stage initiation/promotion/initiation and complete carcinogenesis protocols 1994 May. (Workshop on Human and Experimental Skin Carcinogenesis).
97. Slaga TJ. Skin tumour promotion in mice after exposure to 50 Hz magnetic field 1994 Mar. (3rd Nordic Meeting on Biological Effects of Low-Frequency Electromagnetic Fields).
98. Winberg JD, Gimenez-Conti IB, Oubari D, Slaga TJ. Low rate of malignant conversion of sensitive sencar inbred (SSIN) papillomas using a three stage initiation/promotion/initiation carcinogenesis protocol 1994 Mar. (Proc Amer Assoc Cancer Res).
99. Hanausek M, Walaszek Z, Wang S, Mirowski M, Krokos C, Soriano TF, Slaga TJ. The accurate detection of breast cancer with a new tumor marker 1994. p. 65A-65.

(AACR).

100. Gimenez-Conti IB, Oubari D, Slaga TJ. Dose-response of benzoyl peroxide hyperplastic, promoter and possible complete carcinogenic activities 1993. p. 96-96. (Proceedings of AACR; vol. 45).
101. Holmberg B, Rannug A, Ekstrom T, Milld KI, Gimenez-Conti I, Slaga TJ. Intermittent 50 HwMagnetic field and skin tumour promotion in SENCAR mice 1993. (DOE/EPA/EPRI/NIESH).
102. Slaga TJ. Cellular and molecular mechanisms and human relevance 1992 Oct. (Environmental Skin Cancer: Models, Mechanisms and Human Relevance Conference).
103. Gimenez-Conti I, Chesner J, Welch C, Slaga TJ. Two-stage carcinogenesis in the hamster cheek pouch using benzoyl peroxide 1992 Jul. (IADR).
104. Alworth WL, Sandoval A, Volpe JPG, Warren BS, Viaje A, Conti C, Slaga TJ. Inhibition of two stage carcinogenesis with 1-ethynlpyrene or 2-ethynynaphthalene is associated with a mutational alteration of ras 1992 May. (AACR).
105. Volpe JPG, Warren BS, Slaga TJ. Characterization of mutant H-ras gene expression during in vitro and in vivo growth 1992 May. (AACR).
106. Yoshimi N, Naylor MF, Volpe JPG, Warren BS, Gimenez-Conti I, Viajc A, Sandoval A, Reiners JJ, Gilbert H, Slaga TJ. Effect of glutamyl transpeptidase overexpression on the phenotypic behavior of a papilloma-producing epidermal cell line 1992 May. (AACR).
107. Slaga TJ, Warren BS, Naylor MF, Gimenez-Conti I. Critical changes during skin tumor progression 1991 Dec. (4th Charles Heidelberger Conference).
108. Mirowski M, Hanausek M, Sherman U, Adams, AK, Walaszek Z, Slaga TJ. An ELISA method for the detection of p65 oncofetal protein in tumor-bearing hosts. 1991. p. A883. (FASEB Journal; vol. 5).
109. Warren BS, Davis MM, Wang X-J, DiGiovanni J, Slaga TJ. Continued treatment with a phorbol ester tumor promoter produces a protein kinase C isozyme profile similar to that observed in epidermal tumors 1991. (AACR).
110. Locniskar M, Belury MA, Leyton J, Bechtel DH, Slaga TJ, Fischer SM. Organ specific effects of dietary fat on mammary and skin carcinogenesis 1991. (AACR).
111. Warren BS, Naylor MF, Vo TK-O, Sandoval A, Davis MM, Slaga TJ. Phorbol ester tumor promoter treated epidermis, papillomas, carcinomas, and tumor derived epidermal cell lines have decreased levels of the glucocorticoid receptor 1991. (AACR).
112. Slaga TJ. Mechanisms involved in multistage skin carcinogenesis 1991. (3rd Meeting

of the Pan American Society for Pigment Cell Research).

113. Slaga TJ. Mechanistic approaches to anticarcinogenesis and chemoprevention 1991. (Aspen Cancer Conference).
114. Mirowski M, Sherman U, Adams AK, Walaszek Z, Slaga TJ, Hanausek M. An enzyme-linked immunosorbent assay for p65 oncofetal protein and its potential as a new marker for cancer risk assessment in rodents and humans 1990 Dec. (Conference Relevance of Animal Studies to Evaluate Human Cancer Risk).
115. Morris RJ, Gibson AC, Slaga TJ. Primary in vitro clonogenic epidermal keratinocytes from adult mice during epidermal hyperplasia following treatment in vivo with 12-O-tetradecanoylphorbol-13-acetate 1990 Aug. (Gordon Conference on Cancer).
116. Slaga TJ. Critical determinants in skin tumor promotion and progression 1990 Aug. (15th International Cancer Congress).
117. Slaga TJ. Mechanism-based inhibitors of multistage skin carcinogenesis 1990 Jul. (The Fifth Aspen Cancer Conference).
118. Gimenez-Conti I, Aldaz CM, Bianchi AB, Roop D, Slaga TJ, Conti CJ. Early expression of K13 keratin in the progression of mouse skin papillomas 1990 May. (AACR).
119. Yoshimi N, Gimenez-Conti I, Conti CJ, Slaga TJ. Changes of nucleolar organizer regions (NOR) in hamster cheek pouch chemical carcinogenesis 1990 May. (AACR).
120. Walaszek Z, Adams AK, Sherman U, Viaje A, Rotstein JB, Hanausek M, Slaga TJ. Antiproliferative effects of calcium D-glucarate (CG) and D-glucaro-1,4-lactone (GL) on rat mammary gland, colon and mouse skin 1990. p. 124. (Proc Am Assoc Cancer Res; vol. 31).
121. Slaga TJ. Cellular and molecular changes during skin tumor progression 1989 Dec. (3rd Charles Heidelberger Symposium).
122. Slaga TJ. Cellular and molecular mechanisms in skin carcinogenesis 1989 Nov. (Conference on Chemically Induced Cell Proliferation: Implications for Risk Assessment).
123. Slaga TJ, Morris RJ, Fischer SM, Gibson AC, Slaga TJ. New methods for measuring cellular proliferation in the skin 1989 Nov. (Conference on Chemically Induced Cell Proliferation: Implications for Risk Assessment).
124. Shin DM, Gimenez IB, Lee JS, Nishioka K, Lotan R, Slaga TJ, Hong WK. Sequential expression of epidermal growth factor receptor (EGFr), transglutaminase (TGase), and polyamine levels during chemical carcinogenesis in a hamster buccal pouch model (HBPM) 1989. (AACR).
125. Slaga TJ. Possible involvement of free radicals in skin tumor promotion and progression 1989. (Aspen Cancer Conference).

126. Slaga TJ. Critical events and determinants in multistage skin carcinogenesis 1988 Sep. (University of Maryland).
127. Slaga TJ. Critical events in skin tumor promotion and progression 1988 Aug. (Case Western Reserve University).
128. Aldaz CM, Conti CJ, Larcher F, Trono D, Roop DR, Chesner J, Whitehead T, Slaga TJ. Aneuploidy precedes keratin modifications and g-glutamyltransferase expression in mouse skin tumors 1988. p. 164-164. (Proc Amer Assoc Cancer Res; vol. 29).
129. Slaga TJ, O'Connell J, Aldaz M, Rotstein J, Conti C. Critical events and determinants in multistage skin carcinogenesis 1987 Dec. (U.S. Japan Cancer Program - Development of New Medium-Term Bioassays for Carcinogens).
130. Slaga TJ, Rotstein JB, O'Connell JF. The possible involvement of free radicals in skin tumor progression 1987 May. (AACR).
131. Slaga TJ, Rotstein JB. Modification of tumor progression in the mouse skin two-stage model 1987 May. (AACR).
132. Slaga TJ. Skin tumor promotion and progression 1987 Feb. (ACS Workshop Conference on Current Concepts of Tumor Promotion and Anti-Promotion).
133. Morris RJ, Slaga TJ, Potten CS. Evidence that slowly cycling epidermal basal cells from adult mice are clonogenic in vitro 1987. (Patterson Institute for Cancer Research and UTSCC Science Park-Research Division).
134. Slaga TJ, O'Connell J, Patskan G, Aldaz M, Rotstein J, Conti C. Mechanisms involved in mouse skin tumor promotion and progression 1986 Sep. (Robins Institute).
135. Slaga TJ, O'Connell J, Patskan G, Aldaz M, Rotstein J, Conti C. Critical genetic determinates and molecular events 1986 Sep. (MDA Symposium).
136. O'Connell JF, Fischer SM, Tacker KC, Patrick KE, Slaga TJ. The tumorigenic and biochemical responses of an inbred mouse strain sensitive to two-stage tumorigenesis as compared to the outbred SENCAR mice 1986 Aug. (14th International Cancer Congress).
137. O'Connell JF, Rotstein JB, Patskan GJ, Aldaz CM, Conti CJ, Klein-Szanto AJP, Slaga TJ. Evidence for possible involvement of free radicals in promotion and progression 1986 Mar. (U.S. Japan Meeting on Oxygen Radicals in Cancer).
138. Rotstein J, O'Connell J, Slaga TJ. The enhanced progression of papillomas to carcinomas by proxides in the two-stage mouse skin model 1986. (AACR).
139. Aldaz CM, Conti CJ, Fries JW, Klein-Szanto AJP, Slaga TJ. Histopathological and cytogenetic evidences of malignant conversion in mouse skin papillomas 1986. (AACR).

140. Morris RJ, Tacker KC, Fischer SM, Slaga TJ. Density gradient sedimentation of candidate epidermal stem cells from adult mice 1986. ([AACR](#)).
141. Morris RJ, Tacker KC, Baldwin JK, Fischer SM, Slaga TJ. Long-term growth, differentiation and response to phorbol esters of adult murine epidermal cells in a standard calcium medium 1986. ([AACR](#)).
142. Slaga TJ. Interspecies comparisons of tissue DNA damage, repair, fixation, and replication 1986. ([FASEB](#)).
143. Pelling JC, Patskan G, Junio M, Hixson DC, Nairn RS, Slaga TJ. Altered patterns of oncogene expression during two-stage skin carcinogenesis 1985 Nov. ([UCLA Symposia on Biochemical and Molecular Epidemiology of Cancer](#)).
144. O'Connell JF, Butler AP, Slaga TJ. Gene amplification in chemically-induced mouse skin tumors 1985 Nov. ([UCLA Symposia on Biochemical and Molecular Epidemiology of Cancer](#)).
145. Morris RJ, Slaga TJ. Evidence that a subpopulation of murine keratinocytes retains carcinogen 1985 May. ([AACR](#)).
146. Aldaz CM, Conti CJ, Fries JW, Klein-Szanto AJP, Slaga TJ. Chromosomal abnormalities in mouse skin tumors induced by two-stage carcinogenesis 1985 May. ([AACR](#)).
147. Pelling JC, Patskan G, Hixson DC, Nairn RS, Slaga TJ. Oncogene expression at various stages of tumorigenesis in SENCAR mice treated with optical enantiomers of benzo(a)pyrene-7,8-diol-9, 10-epoxide 1985 May. ([AACR](#)).
148. Aldaz CM, Conti CJ, Klein-Szanto AJP, Slaga TJ. Technical approach for cytogenetic studies of mouse skin papillomas and carcinomas 1985 Feb. ([Int Workshop on Chromosomes in Solid Tumors](#)).
149. Miller DR, Viaje A, Slaga TJ. Terminal differentiation-resistant keratinocytes in the epidermis of adult mice during two-stage carcinogenesis 1985. ([ASCB](#)).
150. Slaga TJ. Inhibition of skin tumor initiation and promotion by antioxidants and related compounds 1984 May. ([National Cancer Institute Workshop for Development of Cancer Chemopreventive Agents, Gaithersburg MD](#)).
151. Aldaz CM, Conti CJ, Gimenez IB, Slaga TJ, Klein-Szanto AJP. Regression and subsequent epidermal hypoplasia after prolonged TPA treatment 1984. ([AACR](#)).
152. Pelling JC, Hixson DC, Nairn RS, Slaga TJ. Altered gene expression during two-stage tumorigenesis in SENCAR mouse skin 1984. ([AACR](#)).
153. Chiba M, Conti CJ, Thetford D, Slaga TJ, Klein-Szanto AJP. High molecular keratins are not expressed in GGT positive areas of skin tumors 1984. ([NY Academy of](#)

Sciences).

154. Slaga TJ. Cellular mechanisms of tumor promotion and enhancement 1984. (Symposium on Tumor Promotion and Enhancement in the Etiology of Human Experimental Respiratory Tract Carcinogenesis).
155. Slaga TJ. Promotion/progression and involvement of non-DNA targets 1983 Dec. (NCI Symposium).
156. Pelling JC, Regan JD, Slaga TJ. Differential repair of benzo[a]pyrene diol epoxide (BPDE) diastereomers in human fibroblasts 1983. (AACR).
157. Pelling JC, Shah Y, Slaga TJ. Differential binding of benzo(a)pyrene-7, 8 -diol-9, 10 - epoxide diastereomers to two populations of mononucleosomes 1983. (AACR).
158. Klein-Szanto AJP, Mamrack M, Reiners Jr JJ, Slaga TJ. Alterations in epidermal filaggrin distribution during two-stage carcinogenesis 1983. (AACR).
159. Morris RJ, Fischer SM, Slaga TJ. Early response of two subpopulations of murine epidermal basal keratinocytes to treatment with TPA 1983. (Gordon Research Conference).
160. Morris RJ, Fischer SM, Slaga TJ. Tumor promoter activation of slow-cycling basal cells in mouse epidermis 1983. (AACR).
161. Alworth WL, Slaga TJ. Effects of flavones and ellipticine upon skin tumor initiation by arylhydrocarbons 1982 Mar. (Proc FASEB, Vol. 41, Abstract #3848 p.928).
162. Fischer SM, Mills GD, Slaga TJ. Modulation of skin tumor promotion by inhibitors of arachidonic acid metabolism 1982. (V International Conference Prostaglandins, Florence, Italy).
163. Klein-Szanto AJP, Chiba M, Shah Y, Slaga TJ. Histochemical localization of GGT and concanavalin A in normal, preneoplastic and neoplastic epithelia 1982. p. 82A. (Lab Invest; vol. 46).
164. Pelling JC, Slaga TJ. Comparison of levels of benzo(a)pyrene-7, 8 -diol-9, 10 - epoxide-anti (BPDE) enantiomers covalently bound in vivo to macromolecules in whole epidermis versus basal cells 1982. (Proc Amer Assoc Cancer Res, Vol. 23, Abstract #246, p.63).
165. Viaje A, Fischer SM, Slaga TJ. Effects of tumor promoters of subpopulations of keratinocytes isolated by a new density centrifugation technique 1982. (Proc 13th Intern Cancer Congress, Seattle WA, Abstract #1489, p.262).
166. Slaga TJ. Mechanisms of tumor promotion: Evidence for the multistage nature of tumor promotion 1982. (Proc 13th Intern Cancer Congress, Seattle WA, Abstract #4, p.1).
167. Fischer SM, Mills GD, Slaga TJ. Tumor promotion modulation by inhibitors of

arachidonic acid metabolism 1982. (Proc 13th Intern Cancer Congress, Seattle WA, Abstract #1367, p.241).

168. Reiners JJ, Yotti LP, Slaga TJ. Inhibition of dimethylbenz(a)anthracene induced mutagenesis by interferon 1982. (Proc UCLA Symposium on Chemistry and Biology of Interferons).
169. Fischer SM, Slaga TJ. Modulation of prostaglandin synthesis and tumor promotion 1981 Sep. (International Conference Prostaglandins and Cancer, Washington DC).
170. Weeks CE, Nelson FR, Slaga TJ. Evidence for tumor-promoter stage-specific induction of epidermal aromatic amino acid/histidine decarboxylase(s) 1981 Apr. (Amer Assoc Cancer Res, Washington DC).
171. Reiners JJ, Davidson K, Nelson K, Mamrack M, Slaga TJ. Skin tumor promotion: A comparative study of several stocks and strains of mice 1981 Mar. (Symposium of Organ and Species Specificity in Chemical Carcinogenesis, Raleigh NC).
172. Pelling JC, Slaga TJ. Binding of benzo(a)pyrene diol epoxide to mouse epidermal RNA, DNA and protein: Does selective binding of Syn and Anti diastereomers occur in epidermal proteins? 1981 Feb. (ICN-UCLA Symposia on Molecular and Cellular Biology: Mechanisms of Chemical Carcinogenesis, Keystone CO).
173. Solanki V, Slaga TJ. Specific binding of phorbol ester tumor promoters to intact primary epidermal cells from SENCAR mice 1981 Feb. (ICN-UCLA Symposia on Molecular and Cellular Biology: Mechanisms of Chemical Carcinogenesis, Keystone CO).
174. Weeks CE, Slaga TJ, Huberman E. Polyamines and human promyelocytic leukemic cell differentiation 1981 Feb. (ICN-UCLA Symposia on Molecular and Cellular Biology: Mechanisms of Chemical Carcinogenesis, Keystone CO).
175. Weeks CE, Herrmann A, Nelson F, Slaga TJ. Relationship of polyamine level alterations to tumor promotion and cellular differentiations 1981 Feb. (ICN-UCLA Symposia on Molecular and Cellular Biology: Mechanisms of Chemical Carcinogenesis, Keystone CO).
176. Slaga TJ, Fischer SM, Weeks CE, Klein-Szanto AJP, Reiners J. Studies on the mechanisms involved in multistage carcinogenesis in mouse skin 1981 Feb. (ICN-UCLA Symposia on Molecular and Cellular Biology: Mechanisms of Chemical Carcinogenesis, Keystone CO).
177. Fischer SM, Slaga TJ. Strain differences and solvent effects in mouse skin carcinogenesis experiments using carcinogens, tumor initiators and promoters 1981. (Proc Amer College of Toxicology Workshop, Arlington VA).
178. Weeks CE, Hermann A, Nelson F, Slaga TJ. Biochemical mechanisms in mouse skin tumor promotion 1980 Oct. (Symposia on Cocarcinogenesis and biological effects of tumor promoters, Elmau, Germany).

179. Fischer SM, Mills CD, Slaga TJ. Prostaglandins and tumor promotion 1980 Oct. (Symposium on Cocarcinogenesis and Biological Effects of Tumor Promoters, Elmau, Germany).
180. Slaga TJ, Fischer SM, Weeks CE, Nelson K, Mamrack M, Klein-Szanto AJP. Specificity and mechanism(s) of promoter inhibitors in multi-stage promotion 1980 Oct. (Symposium on Cocarcinogenesis and Biological Effects of Tumor Promoters, Elmau Germany).
181. Nelson KG, Slaga TJ. Tumor induced changes in mouse epidermal keratins analyzed by two-dimensional gel electrophoresis 1980 Oct. (Symposium on Cocarcinogenesis and Biological Effects of Tumor Promoters, Elmau, Germany).
182. Berry DL, Slaga TJ, Furstenberger G, Mark F. Dynamics of phorbol diester tumor promoters in epidermal cells in culture 1980 Oct. (Symposium on Cocarcinogenesis and Biological Effects of Tumor Promoters, Elmau, Germany).
183. Slaga TJ, Klein-Szanto, AJP, Major SK. Quantitative evaluation of dark keratinocytes in epidermal hyperplasia induced by TPA, mexerin, anthralin and ethylphenylpropiolate: An early morphological indicator of tumor-promoting action 1980 Oct. (Symposium on Cocarcinogenesis and Biological Effects of Tumor Promoters, Elmau, Germany).
184. Mamrack MD, Slaga TJ. The effect of tumor promoting agents on epidermal phosphoprotein kinases 1980 Oct. (Symposium on Cocarcinogenesis and Biological Effects of Tumor Promoters).
185. Weeks CE, Herrmann A, Nelson F, Slaga TJ. Alterations of polyamine metabolism and its relationship to tumor promotion 1980 Aug. (Amer Soc Pharmacol Exptl Therap Mtg, Rochester MN).
186. Weeks CE, Slaga TJ, Herrmann A, Callahan M, Huberman E. Polyamines and Differentiation 1980 Jul. (Proc Amer Soc Pharmacol Experimental Therapeutics).
187. Nelson KG, Stephenson KB, Slaga TJ. Tumor promoters induced changes in mouse epidermal acidic proteins analyzed by two dimensional gel electrophoresis 1980 May. (Proc Amer Assoc Cancer Res).
188. Moore CJ, McClusky GA, Fischer SM, Slaga TJ, Selkirk JK. Metabolism of carcinogenic 2-OH-benzo(a)pyrene in human and rodent cells 1980 May. (Proc Amer Assoc Cancer Res).
189. MacLeod MC, Kootstra A, Mansfield BK, Kenney FT, Slaga TJ, Selkirk JK. Specific interaction of metabolites of benzo(a)pyrene with nuclear proteins in cultured hamster embryo cells 1980 May. (Proc Amer Assoc Cancer Res).
190. Nesnow S, Slaga TJ, Triplett LL. Tumorigenesis of diesel exhaust, gasoline exhaust and related emission extracts on mouse skin 1980 Mar. (Proc of EPA's Meeting on the application of short-term bioassays in the fractionation and analysis of complex environmental mixtures, Williamsburg VA).

191. Mamrack MD, Slaga TJ. Studies on two-cyclic-nucleotide independent protein kinases isolated from mouse epidermis and papillomas 1980. (Proc Soc Cell Biology, Cincinnati OH).
192. Fischer SM, Mills GD, Slaga TJ. Polynuclear aromatic hydrocarbon tumor initiation: Modification by prostaglandin synthase 1980. (5th Internatl Symposium of PAH, Battelle OH).
193. Kootstra A, Slaga TJ. Implications of the binding 7, 8 7-dihydroxy 9, 10 –epoxy 7,8,9,10-tetrahydrobenzo(a)pyrene to chromosomal histone proteins 1979 Oct. (4th International Symposium on Polynuclear Aromatic Hydrocarbons, Columbus OH).
194. DiGiovanni J, Kishore GS, Slaga TJ, Boutwell RK. 2,3,7,8-tetrachlorodibenzo-p-dioxin induced alterations in oxidative and non-oxidative biotransformation of PAH in mouse skin 1979 Oct. (4th International Symposium on Polynuclear Aromatic Hydrocarbons, Columbus OH).
195. Cohen CM, Ashurst SW, Selkirk JK, Slaga TJ. Hydrocarbon-deoxyribonucleoside adducts in vivo and in vitro and their relationship to carcinogenicity 1979 Oct. (4th International Symposium on Polynuclear Aromatic Hydrocarbons, Columbus OH).
196. Slaga TJ, Iyer RP, Luga W, Secrist III A, Daub GH, Harvey RG. Comparison of the skin tumor-initiating activities of dihydrodiols, diol-epoxides, and methylated derivatives of various polycyclic aromatic hydrocarbons 1979 Oct. (4th International Symposium on Polynuclear Aromatic Hydrocarbons, Columbus OH).
197. Slaga TJ, Triplett LL, Nesnow S. Mutagenic and carcinogenic potency of extracts of diesel and related environmental emissions: Two stage carcinogenesis in skin sensitive mice 1979 Oct. (Proc of EPA's Meeting on the Health Effects of Diesel Emission, Cincinnati OH).
198. Slaga TJ, Fischer SM, Weeks CE, Klein-Szanto AJP. Multistage chemical carcinogenesis in mouse skin 1979 Jul. (Proc U.S.-Japan Joint Conference on Normal and Abnormal Epidermal Differentiations).
199. Miller DR, Slaga TJ, Fischer SM. Epidermal transformation: The production of differentiated cell lines under improved conditions of culture 1979 Jun. (Proc Tissue Culture Assoc).
200. Slaga TJ, DiGiovanni J, Bracken WM, Juchau MR. Comparative epidermal metabolism in strains of mice with differing sensitivity to skin tumorigenesis by DMBA 1979 May. (Proc Am Assoc Cancer Res).
201. Slaga TJ, Weeks CE, Bracken WM. Effect of polyamine (PA) biosynthesis inhibitors on ornithine decarboxylase (ODC) activity, PA levels and tumor promotion 1979 May. (Proc Am Assoc Cancer Res).
202. Fischer SM, Gleason GL, Bohrman JR, Slaga TJ. Prostaglandin enhancement of skin

tumor initiation and promotion 1979 May. (Proc International Prostaglandin Conference).

203. Slaga TJ. Tumor initiating activities of various derivatives of benzo(a)pyrene-benz(a)anthracene and 7,12-dimethylbenz(a)anthracene in mouse skin 1978 Oct. (Proc XII International Cancer Congress).
204. Berry DL, Slaga TJ. Metabolic conversion of 12-O-tetradecanoylphorbol-13-acetate by mouse liver microsomes, adult and newborn mouse skin and the uptake and metabolism in newborn and adult epidermal cells in culture 1978 Oct. (Proc XII International Cancer Congress).
205. Fischer SM, Slaga TJ. In vitro human and murine epidermal cell transformation with chemical carcinogens 1978 Oct. (Proc XII International Cancer Congress).
206. Kootstra A, Slaga TJ, Olins DE. Binding of benzo(a)pyrene diol-epoxide to chromosomal components 1978 Oct. (Battelle's Conference on Polynuclear Aromatic Hydrocarbons).
207. Slaga TJ, Gleason G, Huberman E, DiGiovanni J, Berry DL, Juchau MR, Selkirk JK, Harvey RG. Tumor initiating activities of various derivatives of benz(a)anthracene and 7,12-dimethylbenz(a)anthracene in mouse skin 1978 Oct. (Battelle's Conference on Polynuclear Aromatic Hydrocarbons).
208. Iyer R, Triplett LL, Slaga TJ, Papaconstantinou J. The interaction of (+) benzo(a)pyrene-7, 8 -diol-9, 10 -epoxide with fractionated mouse DNA 1978 Oct. (Battelle's Conference on Polynuclear Aromatic Hydrocarbons).
209. DiGiovanni J, Berry DL, Slaga TJ, Juchau MR. 2,3,7,8-tetrachlorodibenzo-p-dioxin: Potent anti-carcinogenic activity 1978 Oct. (Battelle's Conference on Polynuclear Aromatic Hydrocarbons).
210. Weeks CE, Slaga TJ, Huberman E. Effects of -methylornithine and putrescine on differentiation and proliferation in Friend erythroleukemic cells 1978 Sep. (Proc III International Conference Differentiation).
211. Iyer R, Triplett LL, Slaga TJ, Papaconstantinou J. Interaction of (+) benzo(a)pyrene-7,8-diol,0, 10-epoxide with fractionated eukaryotic DNA 1978 Sep. (Proc Amer Chem Soc).
212. Bohrman JS, Fischer SM, Berry DL, Viaje A, Slaga TJ. Enhanced DNA synthesis by prostaglandin F2 in the presence of 12-O-tetradecanoylphorbol-13-acetate in newborn mouse epidermal cells 1978 Jun. (Proc Tissue Culture).
213. Berry DL, Slaga TJ, DiGiovanni J, Juchau MP. Studies with chlorinated dibenzo-p-dioxins, polybrominated biphenyls and polychlorinated biphenyls in a two-stage system of mouse skin tumorigenesis 1978 Jun. (Potent anticarcinogenic effects).
214. Berry DL, Sutton TL, Viaje A, Fischer SM, Slaga TJ. Uptake and metabolic conversion

of 12-0-tetradecanoylphorbol-13-acetate by newborn and adult epidermal cells in culture 1978 May. (Proc Cold Spring Harbor Symposium on phorbol esters in Culture).

215. Slaga TJ. Phorbol ester tumor promotion 1978 May. (Proc Cold Spring Harbor Symposium on phorbol esters in Culture).
216. DiGiovanni J, Slaga TJ, Berry DL, Juchau MR. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and aroclor 1254 on 7,12-dimethylbenz(a)anthracene metabolism and tumor initiating activity in mouse skin 1978 Apr. (Proc Am Assoc Cancer Research).
217. Berry DL, Viaje A, Fischer SM, Slaga TJ. Kinetics of 12-0-tetradecanoylphorbol-13-acetate (TPA) uptake and metabolism in newborn mouse epidermal cells in culture and adult cells in culture 1978 Apr. (Proc Am Assoc Cancer Research).
218. Young JA, Rao TK, Weeks CE, Slaga TJ, Epler JL. Effects of the co-carcinogen benzo(e)pyrene on microsome mediated chemical mutagenesis in Salmonella Typhimurium 1978 Mar. (Proc Environ Mutagen Soc).
219. Kootstra A, Slaga TJ, Olins DE. Binding of benzo(a)pyrene diol epoxide to chromatin 1978 Mar. (Proc Biophyscis Soc).
220. Fischer SM, Slaga TJ, Berry DL. Regulation of cell division and differentiation in mouse and human epidermal cells in culture 1977 Oct. (XV International Congress Dermatology).
221. Slaga TJ. Tumor initiating and promoting abilities of various benzo(a)pyrene (BP) metabolites in mouse skin 1977 Sep. (Battelle's Conference on Polynuclear Aromatic Hydrocarbons).
222. Young JA, Rao TK, Slaga TJ, Epler JL. Co-mutagenic properties of tumor promoting agents in the Salmonella Typhimurium/microsomal activation system 1977 Sep. (Proc Southeastern Assoc Cancer Research).
223. Slaga TJ, Viaje A, Bracken WM, Fischer SM, Miller DR, Berry DL, Dresner S, Harris K. The effects of chemical carcinogens and tumor promoters on human foreskin epidermal cells in culture 1977 Aug. (Carcinogenesis Studies in Human Cells and Tissues Workshop, Aspen CO).
224. DiGiovanni J, Slaga TJ, Harvey RG, Viaje A, Juchau MR. The effects of 7,8-benzoflavone (7,8-BF) on skin tumor initiating activity and in vitro DNA binding of 7-bromomethyl-12methylbenz(a)anthracene (7OBRME-12-MBA) 1977 Aug. (Proc Amer Soc Pharmacology and Experimental Therapeutics).
225. DiGovanni J, Slaga TJ, Juchau MR. The effects of flavones on the metabolism and tumorigenicity of 7,12-dimethylbenz(a)anthracene (DMBA) 1977 Jul. (Lloydia, Seattle WA).
226. Fischer SM, Berry DL, Slaga TJ. Long-term growth and ability to subculture mouse

epidermal cells 1977 Jun. (Proc Tissue Culture Association).

227. Miller DR, Viaje A, Bracken WM, Slaga TJ. The effects of chemical carcinogens on newborn epidermal cells in culture 1977 Jun. (Proc Tissue Culture Association).

228. Berry DL, Fischer SM, Slaga TJ. Metabolism of TPA in adult and newborn skin and newborn epidermal cells in culture 1977 May. (Proc Am Assoc Cancer Research).

229. Lichti U, Yuspa S, Ben T, Patterson E, Slaga TJ. Polyamines as mediators of tumor promotion 1977 May. (Proc Am Assoc Cancer Research).

230. Slaga TJ. A rapid bioassay for energy-related hydrocarbons with carcinogenic, cocarcinogenic and/or promoting activities 1977 Apr. (Argonne National Laboratory Symposium and Carcinogenesis and Mutagenesis).

231. Slaga TJ, Viaje A, Bracken WM, Fischer SM, Berry DL, Miller D, LeClerc S. Inhibition of tumor promotion by anti-inflammatory agents: An approach to the biochemical mechanism 1977 Mar. (Gatlinburg Conference on Mechanisms of Tumor Promotion and Cocarcinogenesis).

232. Slaga TJ, Yuspa SH, Hennings H, Elgjo K, Schwarz JA, Viaje A. Effects of a steroidal anti-inflammatory agent on DNA synthesis in adult and newborn mouse epidermis 1976 May. (Proc Amer Assoc Cancer Research).

233. DiGiovanni J, Slaga TJ, Juchau MR, Shearer RW. The role of epidermal aryl hydrocarbon hydroxylase in 7,12-dimethylbenz(a)anthracene initiation of skin tumors 1976 May. (Proc Amer Assoc Cancer Research).

234. Berry DL, Slaga TJ, Buty SG, Santistaben G. Biotransformation of benzo(a)pyrene in mouse epidermal 1976 May. (Proc Amer Assoc Cancer Research).

235. Slaga TJ, Thompson S, Boutwell RK. Inhibition of the tumor initiating ability of the potent carcinogen, 7,12-dimethylbenz(a)anthracene (DMBA) by the weak tumor initiator, 1,2,3,4-dibenzanthracene (1,2,3,4-DBA) 1976 Apr. (Proc Amer Soc Pharmacology and Experimental Therapeutics).

236. Berry DL, Zachariah PK, Slaga TJ, Juchau MR. Transplacental stimulation of benzo(a)pyrene (BP) metabolism in extrahepatic tissues by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 1976 Apr. (Proc Amer Soc Pharmacology and Experimental Therapeutics).

237. Slaga TJ, Berry DL, Juchau MR, Thompson S. Effects of benzoflavones and trichloropropene oxide on polynuclear aromatic hydrocarbon metabolism and initiation of skin tumors 1975 Oct. (Battelle's Conference on Polynuclear Aromatic Hydrocarbons).

238. Juchau MR, Berry DL, Zachariah PK, Namkung JJ, Slaga TJ. Parental biotransformation of benzo(a)pyrene and 2-acetyl-aminofluorene 1975 Oct. (Battelle's Conference on Polynuclear Aromatic Hydrocarbons).

239. Slaga TJ, Berry DL, Juchau MR, Thompson S. Polycyclic hydrocarbon metabolism and tumor initiation in mouse skin 1975 Aug. (Proc Amer Soc Pharmacology and Experimental Therapeutics).
240. Berry DL, Zachariah PK, Namkung MH, Slaga TJ, Juchau MR. Transplacental induction of the biotransformation of chemical precarcinogens by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 1975 Aug. (Proc Amer Soc Pharmacology and Experimental Therapeutics).
241. Slaga TJ. Mouse skin tumor promotion and inhibition by steroidal anti-inflammatory agents 1975 Jul. (Fifth Conference on Biochemical Aspects of Epidermal Differentiation).
242. Slaga TJ, Thompson S, Schwarz JA. Mechanism of action of steroid anti-inflammatory agents that inhibit skin carcinogenesis 1975 May. (Proc Amer Assoc Cancer Research).
243. Berry DL, Slaga TJ, Juchau MR, Santisteban G. Effects of benzoflavones and trichloropropene oxide on aryl hydrocarbon hydroxylase and initiation of skin tumors 1975 May. (Proc Amer Assoc Cancer Res).
244. Slaga TJ, Rice JM, Das SB, Thompson S. Inhibition of intracellular binding of phorbol esters to mouse skin by dexamethasone 1974 Mar. (Proc Amer Assoc Cancer Research).
245. Slaga TJ, Bowden GT, Shapas BG, Boutwell RK. Macromolecular synthesis following a single application of initiators of mouse skin tumorigenesis 1971 Jun. (Proceedings of the American Society of Biological Chemists, San Francisco CA).
246. Slaga TJ. Chromosome analysis of the planarian worm, *Dugesia titgrinia* 1964 Oct. (Proceedings of the Ohio Academy of Science).

### **Book Chapter**

1. Junco JJ, Slaga TJ. The prevention of obesity, diabetes, and cancer with lifestyle intervention Strategies In: Carkeet C, et al.. *Phytochemicals: Health Promotion and Therapeutic Potential*. Boca Raton, FL: CRC Press; 2012. p. 113 - 152.
2. Hanausek M, Walaszek Z, Slaga TJ. Redox Modulation in Tumor Initiation, Promotion and Progression In: *Redox Genome Interactions in Health and Disease*, Editors: J Fuchs, L Packer. New York: Marcel Dekker Inc; 2003. p. 191 - 214.
3. Curtin GM, Slaga TJ. Multistage mouse skin carcinogenesis and cell cycle regulation In: *Cutaneous Oncology: Pathophysiology, Diagnosis and Treatment*, Editors: S Miller & M Maloney. Cambridge MA: Blackwell Scientific Co; 1998.
4. Skisak C, DiGiovanni J, Conti CJ, Slaga TJ, Walborg EF. Induction of short-term markers of skin tumor promotion in CD-1mice by petroleum middle distillates In:

Progress in Clinical and Biological Res. Vol. 303, Editors: M McClain, TJ Slaga, R LeBoeuf & H Pitot. New York: Wiley-Liss; 1995. p. 439 - 444.

5. Slaga TJ. Inhibition of the induction of cancer by antioxidants In: Nutrition and Biotechnology in Heart Disease and Cancer, Editors: JB Longnecker, D Kritchevsky, M Drezner. New York: M. Plenum Publishing Corp; 1995.
6. Slaga TJ, DiGiovanni J, Winberg LD, Budunova IV. Skin carcinogenesis: Characteristics, mechanisms, and prevention In: Progress in Clinical and Biological Research Series - Growth Factors and Tumor Promotion: Implications for Risk Assessment, Editors: M McClain, TJ Slaga, R LeBoeuf & H Pitot. New York: Wiley-Liss; 1995. p. 1 - 20.
7. Winberg LD, Budunova IV, Warren BS, Iyer RP, Slaga TJ. Mechanisms of skin tumor promotion and progression In: Skin Cancer: Mechanisms and human Relevance, Editor: H Mukhtar. Boca Raton FL: CRC Press; 1994. p. 113 - 120.
8. Warren BS, Slaga TJ. Mechanisms of inhibition of tumor progression In: Antimutagenesis and Anticarcinogenesis Mechanisms III, Editor: G Bronzetti. New York: Plenum Press; 1993. p. 279 - 289.
9. Gimenez-Conti IB, Slaga TJ. The hamster cheek pouch model of carcinogenesis and chemoprevention In: Advance in Experimental Medicine and Biology: The Biology and Prevention of Aerodigestive Tract Cancers, Editors: GR Newell & WK Hong. New York: Plenum Press; 1992. p. 63 - 67.
10. Morris RJ, Fischer SM, Slaga TJ. New methods for studying the proliferation and differentiation of epidermal keratinocytes from adult mice. Progress in clinical and biological research. In: Chemically Induced Cell Proliferation: Implications for Risk Assessment, Editors: B Butterworth, M McClain, W Farland & TJ Slaga. New York: Wiley-Liss Publishing Co; 1991. p. 303 - 322.
11. Slaga TJ. Critical events in skin tumor promotion and progression In: The Boundaries Between Promotion and Progression During Carcinogenesis. Plenum Publishing Corp; 1991. p. 19 - 29.
12. Slaga TJ. Mechanisms of chemical carcinogenesis In: Comprehensive Textbook of Oncology, Vol 1. Williams & Wilkins; 1991. p. 31 - 37.
13. Slaga TJ. Critical events and determinants in multistage skin carcinogenesis In: Carcinogenicity and Pesticides, ACS Symposium Series 414. 1989. p. 78 - 93.
14. Slaga TJ. Cellular and molecular mechanisms involved in multistage skin carcinogenesis In: Carcinogenesis Comprehensive Survey. 1989. p. 1 - 18.
15. Fischer SM, Reiners JJ, Pence BC, Aldaz CM, Conti CJ, Morris RJ, O'Connell JF, Rotstein JB, Slaga TJ. Mechanisms of carcinogenesis using mouse skin: The multistage assay revisited In: Tumor Promoters: Biological Approaches for Mechanistic Studies and Assay Systems; Editors: R Langenback, JC Barrett & G Elmore. New

York: Raven Press; 1988. p. 11 - 30.

16. Nesnow S, Argus M, Bergman H, Chu K, Frith C, Helmes T, McGaughy R, Ray V, Slaga TJ, Tennant R, Weisburger E. Chemical carcinogenesis: A review and analysis of the literature of selected chemicals and the establishment of the gene - tox carcinogen data base In: Mutation Research. 1987. p. 1 - 195.
17. Slaga TJ, O'Connell J, Rotstein J, Patskan G, Morris RJ, Aldaz M, Conti C. Critical genetic determinants and molecular events in multistage skin carcinogenesis In: Symposium on Fundamental Cancer Research. 1987. p. 31 - 44.
18. Klein-Szanto AJP, Morris R, Slaga TJ. Separation of cells from normal and abnormal epidermis In: Cell Separation: Methods and Selected Applications. New York: Academic Press; 1987. p. 195 - 212.
19. Slaga TJ. Interspecies comparisons of tissue DNA damage, repair, fixation and replication In: Biological Bases for Interspecies Extrapolation of Carcinogenicity Data, Editors: TA Hill, RC Wands, RW Leukroth Jr. Bethesda MD: Life Sciences Research Office (FASEB); 1986.
20. Fischer SM, Slaga TJ. Arachidonic Acid Metabolism and Tumor Promotion In: Arachidonic Acid Metabolism and Tumor Promotion. Martinus Nijhoff Publishers; 1985.
21. Chiba M, Conti CJ, Thetford D, Slaga TJ, Klein-Szanto AJP. High molecular weight keratins are not expressed in GGT positive areas of skin tumors In: Mechanisms in Carcinogenesis. An NY Acad Sci; 1985. p. 752 - 754.
22. Pelling JC, Slaga TJ. Cellular mechanisms for tumor promotion and enhancement In: Cancer of the Respiratory Tract: Predisposing Factors, Carcinol Compr Curv. 1985. p. 369 - 393.
23. Slaga TJ. Mechanisms involved in multistage skin tumorigenesis In: The Role of Chemicals and Radiation in the Etiology of Cancer; Editors: E Huberman et al.. 1985. p. 189 - 199.
24. Slaga TJ, Nesnow S. SENCAR mouse skin tumorigenesis In: Handbook of Carcinogen Testing. Noyes Publications; 1985. p. 230 - 250.
25. Slaga TJ. Mechanisms involved in two-stage carcinogenesis in mouse skin In: Mechanisms in Tumor Promotion, Vol. II; Editor: TJ Slaga. Boca Raton FL: CRC Press; 1984. p. 1 - 16.
26. Solanki V, Slaga TJ. Phorbol ester tumor promoter receptors and their down modulation In: Mechanisms in Tumor Promotion, Vol. II; Editor: TJ Slaga. Boca Raton FL: CRC Press; 1984. p. 97 - 112.
27. Weeks CE, Slaga TJ, Boutwell RK. The role of polyamines in tumor promotion In: Mechanisms in Tumor Promotion, Vol. II; Editor: TJ Slaga. Boca Raton FL: CRC Press;

1984. p. 127 - 142.

28. Slaga TJ. Multistage skin tumor promotion and specificity of inhibition In: Mechanisms in Tumor Promotion, Vol. II; Editor: TJ Slaga. Boca Raton FL: CRC Press; 1984. p. 189 - 196.
29. Nesnow S, Triplett LL, Slaga TJ. Studies on the tumor initiating, tumor promoting and tumor co-initiating properties of respiratory carcinogens In: Carcinogenesis, A Comprehensive Survey, Cancer of the Respiratory Tract: Predisposing Factors. 1984. p. 257 - 277.
30. Slaga TJ, Nelson KG. Critical protein modifications during skin tumor promotion in mice In: Mechanisms in Tumor Promotion, Vol. II; Editor: TJ Slaga. Boca Raton FL: CRC Press; 1984. p. 159 - 187.
31. Slaga TJ. Can tumor promotion be effectively inhibited? In: Models, Mechanisms and Etiology of Tumour Promotion; Editors: M Borzsonyi, NE Day, K Lapis & H Yamasaki. Lyon, France: IARC Scientific Publications No. 56; 1984. p. 497 - 506.
32. Slaga TJ. Overview of chemical carcinogenesis and anti-carcinogenesis In: Radioprotectors and Anticarcinogens; Editors: OF Nygaard & MG Simic. New York: Academic Press; 1983. p. 437 - 448.
33. Slaga TJ, Solanki V, Logani M. Studies on the mechanism of action of anti-tumor promoting agents: Importance of free radicals in promotion In: Radioprotectives and Anticarcinogens; Editors OF Nygaard & MG Simic. New York: Academic Press; 1983. p. 471 - 485.
34. Reiners J, Davidson J, Nelson K, Mamrack M, Slaga TJ. Skin tumor promotion: A comparative study of several stocks and strains of mice In: Proc Symp on Organ and Species Specificity in Chemical Carcinogenesis; Editors: S Nesnow, B Langenbach & JM Rice. New York: Plenum Press; 1983. p. 173 - 188.
35. Fischer SM, Mills GD, Slaga TJ. Modulation of skin tumor promotion by inhibitors or arachidonic acid metabolism In: Proc V Int Conf Prostaglandin. New York: Raven Press, Inc.; 1983. p. 309 - 312.
36. Slaga TJ, Nelson KG. Multistage skin tumor promotion in mouse skin: Critical protein changes during tumor promotion In: Genes and Proteins in Oncogenesis; Editors: IB Weinstein and HJ Vogel. New York: Academic Press; 1983. p. 125 - 142.
37. Nesnow S, Triplett LL, Slaga TJ. Mouse skin carcinogenesis: Application to the analysis of complex mixtures In: Short-term Bioassays in the Analysis of Complex Environmental Mixtures; Editors: Waters, Sandhu, Lewtas, Clayton, Chernoff & Nesnow. New York: Plenum Publishing Co; 1983. p. 367 - 390.
38. Slaga TJ. Mechanisms involved in multistage chemical carcinogenesis in mouse skin In: Extrahepatic Drug Metabolism and Chemical Carcinogenesis; Editor: H Rydstrom. The Netherlands: Elsevier Biomedical Press; 1983. p. 577 - 585.

39. Slaga TJ. Multistage skin carcinogenesis and specificity of inhibitors In: Modulation and Mediation of Cancer by Vitamines; Editors: FL Meyskens & KN Prasad. Karger; 1983. p. 10 - 23.
40. Slaga TJ, Fischer SM, Weeks CE, Nelson K, Mamrack M, Klein-Szanto AJP. Specificity and mechanism(s) of promoter inhibitors in multi-stage promotion In: Cocarcinogenesis and Biological Effects of Tumor Promoters; Editor: E Hecker. New York: Raven Press; 1982. p. 19 - 34.
41. Klein-Szanto AJP, Major SK, Slaga TJ. Quantitative evaluation of dark keratinocytes induced by several promoting and hyperplasiogenic agents In: Cocarcinogenesis and Biological Effects of Tumor Promoters; Editor E Hecker. New York: Raven Press; 1982. p. 19 - 34.
42. Huberman E, Weeks C, Solanki V, Callaham M, Slaga TJ. Cell differentiation, alterations in polyamine levels, and specific binding of phorbol diesters in cultured human cells In: Cocarcinogenesis and Biological Effects of Tumor Promoters; Editor: E Hecker. New York: Raven Press; 1982. p. 405 - 416.
43. Berry DL, Slaga TJ, Furstenberger G, Marks F. Dynamics of phorbol diester tumor promoters in epidermal cells in culture In: Cocarcinogenesis and Biological Effects of Tumor Promoters; Editor: E Hecker. New York: Raven Press; 1982. p. 237 - 242.
44. Mamrack M, Slaga TJ. Multistage skin tumor promotion: Involvement of a protein kinase In: Biological Carcinogenesis; Editor: M Rich. New York: Marcel Dekker Publishing Co; 1982. p. 81 - 106.
45. Slaga TJ, Fischer SM, Weeks CE, Klein-Szanto AJP, Reiners JJ. Studies on the mechanisms involved in multistage carcinogenesis in mouse skin In: Proc ICN-UCLA Symposium on Mechanisms of Chemical Carcinogenesis; Editors: C Harris & P Cerutti. A. L. Liss, Inc.; 1982. p. 207 - 227.
46. Nesnow S, Triplett LL, Slaga TJ. Comparison of the skin tumor initiating activities of emission extracts in the SENCAR mouse In: Polynuclear Aromatic Hydrocarbons: Physical and Biological Chemistry, 6th Int Symposium; Editors: M Cooke, AJ Dennis & GL Fisher. Battelle Press; 1982. p. 585 - 595.
47. DiGiovanni J, Slaga TJ. Modification of polycyclic aromatic hydrocarbon carcinogenesis In: Polycyclic Hydrocarbons and Cancer, Vol 3; Editors: HV Gelboin & POP Ts'o. New York: Academic Press, Inc.; 1981. p. 259 - 292.
48. DiGiovanni J, Slaga TJ. Effects of benzo(e)pyrene and dibenz(a,c)anthracene on the skin tumor initiating activity of polycyclic aromatic hydrocarbons In: Proc Fifth International Symposium on Polynuclear Aromatic Hydrocarbons. Columbus, Ohio: Battelle Press; 1981. p. 17 - 31.
49. Kootstra A, Slaga TJ. Differential binding of B(a)P diol-epoxide to subfractions of chromatin In: Proc Fifth International Symposium on Polynuclear Aromatic

Hydrocarbons. Columbus, Ohio: Battelle Press; 1981. p. 64 - 72.

50. Fischer SM, Slaga TJ. Modulation of prostaglandin synthesis and tumor promotion In: Proc International Conf Prostaglandins and Cancer. Alan R. Liss Inc.; 1981. p. 255 - 264.
51. Nesnow S, Triplett LL, Slaga TJ. Tumorigenesis of diesel exhaust, gasoline exhaust and related emission extracts on SENCAR mouse skin In: Proc EPA Second Symposium on Application of Short-Term Bioassays. 1981. p. 277 - 297.
52. MacLeod MC, Kootstra A, Slaga TJ, Selkirk JK. Covalent modification of nuclear and cytoplasmic proteins of hamster embryo cells during PAH metabolism In: Proc Fifth International Symposium on Polynuclear Aromatic Hydrocarbons. Columbus, Ohio: Battelle Press; 1981. p. 85 - 96.
53. Slaga TJ, Fischer SM, Weeks CE, Klein-Szanto AJP. Cellular and biochemical mechanisms of mouse skin tumor promoters In: Reviews in Biochemical Toxicology, Vol. 3; Editors: E Hodgson, JR Bend & RM Philpot. 1980.
54. Slaga TJ. Food additives and contaminants as modifying factors in cancer induction In: Nutrition and Cancer, Edited by G.R. Newell and N.M. Ellison. New York: Raven Press; 1980. p. 279 - 290.
55. Slaga TJ. Etiology, mechanisms and prevention - A summary. In: Carcinogenesis, A Comprehensive Study; Editor: TJ Slaga. New York: Raven Press; 1980. p. 243 - 262.
56. Slaga TJ. Potent inhibitors of tumor promotion In: Carcinogenesis, A Comprehensive Study. New York: Raven Press; 1980. p. 111 - 126.
57. DiGiovanni J, Slaga TJ, Berry DL, Juchau MR. Inhibitory effects of environmental chemicals on polycyclic aromatic hydrocarbon carcinogenesis In: Carcinogenesis, A Comprehensive Survey. New York: Raven Press; 1980. p. 145 - 168.
58. Fischer SM, Gleason GL, Bohrman JS, Slaga TJ. Prostaglandin enhancement of skin tumor initiation and promotion In: Advances in Prostaglandin and Thromboxane Research; Editors: B Samuelson, PW Ranswell & R Paoletti. New York: Raven Press; 1980. p. 517 - 522.
59. Slaga TJ, Fischer SM, Weeks CE, Klein-Szanto AJP. Multistage chemical carcinogenesis in mouse skin In: Biochemistry of Normal and Abnormal Epidermal Differentiation; Editors: M Seije & IA Bernstein. Tokyo: University of Tokyo Press; 1980. p. 193 - 218.
60. Kootstra A, Cronen NC, Slaga TJ. Binding of B(a)P-diol-epoxide to chromosomal histone proteins In: Proc Fourth International Symposium on Polynuclear Aromatic Hydrocarbons. Columbus, Ohio: Battelle Press; 1980. p. 633 - 644.
61. DiGiovanni J, Kishore GS, Slaga TJ, Boutwell RK. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced alterations in oxidative and non-oxidative biotransformation of PAH in

- mouse skin. Role in anti-carcinogenesis by TCDD. In: Proc Fourth International Symposium on Polynuclear Aromatic Hydrocarbons. Columbus, Ohio: Battelle Press; 1980.
62. Cohen GM, Ashurst W, Selkirk JK, Slaga TJ. Hydrocarbon-deoxyribonucleoside adducts in vivo and in vitro and their relationship to carcinogenicity In: Proc Fourth International Symposium on Polynuclear Aromatic Hydrocarbons. Columbus, Ohio: Battelle Press; 1980. p. 503 - 519.
63. Slaga TJ, Iyer RP, Lyga W, Secrist A, Daub GH, Harvey RG. Comparison of the skin tumor-initiating activities of dihydrodiols, diolepoxides, and methylated derivatives of various polycyclic aromatic hydrocarbon In: Proc Fourth International Symposium on Polynuclear Aromatic Hydrocarbons. Columbus, Ohio: Battelle Press; 1980. p. 753 - 769.
64. Slaga TJ, Iyer R, Triplett LL, Papaconstantinou J. Interaction of ( ) benzo(a)pyrene-7, 8-diol-9, 10-epoxide with fractionated eukaryotic DNA In: Proc III International Battelle Conference on Polycyclic Aromatic Hydrocarbons. 1979. p. 805 - 818.
65. Berry DL, Slaga TJ, DiGovanni J, Juchau MR. Studies with chlorinated dibenzo-p-dioxins, polybrominated biphenyls and polychlorinated biphenyls in a two-stage system of mouse skin tumorigenesis. Potent anticarcinogenic effects. In: Chlorinated Hydrocarbons, annals NY Acad Sci. 1979. p. 405 - 414.
66. Slaga TJ, Gleason GL, DiGiovanni J, Berry D, Juchau MR, Harvey RG. Tumor initiating activities of various derivatives of benz(a)anthracene and 7,12-dimethylbenz(a)anthracene in mouse skin In: Proc III International Battelle Conference on Polycyclic Aromatic Hydrocarbons. Ann Arbor Press; 1979. p. 753 - 764.
67. DiGiovanni J, Berry DL, Slaga TJ, Juchau MR. Studies on the relationships between induction of biotransformation and tumor-initiating activity of 7m12-dimethylbenz(a)anthracene in mouse skin In: Proc III International Battelle Conference on Polycyclic Aromatic Hydrocarbons. Ann Arbor Press; 1979. p. 553 - 568.
68. Kootstra A, Slaga TJ, Olins DE. Studies on the binding of B(a)P diol-epoxide to DNA and chromatin In: Proc III International Battelle Conference on Polycyclic Aromatic Hydrocarbons. 1979. p. 819 - 834.
69. Fischer SM, Viaje A, Mills GD, Slaga TJ. Explant methods for epidermal cell cultures In: Methods and Perspectives in Cell Biology; Editor: D Prescott. Academic Press; 1979. p. 207 - 227.
70. Yuspa SH, Lichti U, Hennings H, Ben T, Patterson E, Slaga TJ. Tumor promoter stimulated proliferation in mouse epidermis in vivo and in vitro. Mediation by polyamines and inhibition by the anti-promoter steroid flucinolone acetonide. In: Mechanisms of Tumor Promotion and Carcinogenesis; Editors: TJ Slaga, RK Boutwell & A Sivak. New York: Raven Press; 1978.
71. Slaga TJ, Fischer SM, Viaje A, Berry DL, Bracken WM, LeClerc S, Miller DR. Inhibition

of tumor promotion by anti-inflammatory agents: An approach to the biochemical mechanism of promotion In: Mechanisms of Tumor Promotion and Carcinogenesis, Vol. II; Editors: TJ Slaga, RK Boutwell & A Sivak. New York: Raven Press; 1978. p. 173 - 195.

72. Slaga TJ, Bracken WM, Viaje A, Berry DL, Fischer SM, Miller DR, Levin W, Conney AH, Yagi H, Jerina DM. Tumor initiating and promoting activities of various benzo(a)pyrene metabolites in mouse skin In: Carcinogenesis, A Comprehensive Survey; Editors: RI Freudenthal & PW Jones. New York: Raven Press; 1978. p. 371 - 382.
73. Slaga TJ, Berry DL, Jucau MR, Thompson S, Buty SC, Viaje A. Effects of benzoflavones and trichloropropene oxide on polynuclear aromatic hydrocarbon metabolism and initiation of skin tumors In: Carcinogenesis, A Comprehensive Survey; Editors: RI Freudenthal & PW Jones. New York: Raven Press; 1976. p. 127 - 137.
74. Juchau MR, Berry DL, Zachariah PK, Namkung MJ, Slaga TJ. Prenatal biotransformation of benz(a)pyrene and 2-acetylfluorene in human and sub-human primates In: Carcinogenesis, A Comprehensive Survey; Editors: RI Freudenthal & PW Jones. New York: Raven Press; 1976. p. 23 - 34.

### ***Book/Monograph***

1. Slaga TJ, Keuneke R. The Detox Revolution: A Powerful New Program for Boosting Your Body's Ability to Achieve Optimal Health and Fight Disease New York: Contemporary Books, Div of McGraw-Hill; 2003.
2. Slaga TJ, Quilici-Timmcke J. A New Breakthrough in Cancer Research: D-Glucarate Helps Remove Toxins and Carcinogens from the Body New York, NY: Keats Publishing; 1999.
3. Walker C, Groopman J, Slaga TJ, Klein-Szanto. Progress in Clinical and Biological Research - Genetics and Cancer Susceptibility: Implications for Risk Assessment New York, NY: Wiley-Liss; 1996.
4. Crombrughe B, Slaga TJ. Genetics Mechanisms of Cancer Houston, TX: 48th Annual Symposium on Fundamental Cancer Research; 1995.
5. McClain M, Slaga TJ, LeBoeuf R, Pitot H. Progress in Clinical and Biological Research Series - Growth Factors and Tumor Promotions: Implications for Risk Assessment New York, NY: Wiley-Liss; 1995.
6. Spitzer HL, Slaga TJ, Greenlee WF, McClain M. Progress in Clinical and Biological Research Series - Receptor-Mediated Biological Processes: Implications for Evaluating Carcinogenesis New York, NY: Wiley-Liss; 1994.
7. Klein-Szanto AJP, Anderson A, Barrett JC, Slaga TJ. Progress in Clinical and Biological Research Series - Comparative Molecular Carcinogenesis New York, NY: Wiley-Liss; 1992.

8. D'Amato R, Slaga TJ, Farland WH, Henry C. Progress in Clinical and Biological Research Series - Relevance of Animals Studies to Evaluate Human Cancer Risk New York, NY: Wiley-Liss; 1992.
9. Butterworth BE, Slaga TJ, Farland W, McClain M. Progress in Clinical and Biological Research Series - Chemically Induced Cell Proliferation: Implications for Risk Assessment New York, NY: Wiley-Liss; 1991.
10. Slaga TJ, Stevenson D, Klein-Szanto AJP, Boutwell RK, D'Amato R, Spitzer HL. Progress in Clinical and Biological Research Series - Mouse Liver Carcinogenesis: Mechanisms and Species Comparisons New York, NY: Alan R. Liss, Inc.; 1990.
11. Slaga TJ, Stevenson D, Klein-Szanto AJP, Boutwell RK, D'Amato R, Spitzer HL. Progress in Clinical and Biological Research Series - Skin Carcinogenesis: Mechanisms and Human Relevance New York, NY: Alan R. Liss, Inc.; 1989.
12. Slaga TJ, Conti CJ, Klein-Szanto AJP. Skin Tumors: Experimental and Clinical Aspects Raven Press; 1988.
13. Butterworth BE, Slaga TJ. Banbury Reports 25 - Nongenotoxic Mechanisms in Carcinogenesis New York, NY: Cold Spring Harbor Laboratory; 1987.
14. Becker FF, Slaga TJ. Critical Molecular Determinants of Carcinogenesis - M.D. Anderson Symposium on Fundamental Cancer Research Austin, TX: University of Texas Press; 1987.
15. Slaga TJ, DiGiovanni J. Inhibition of chemical carcinogenesis Washington DC: American Chemical Society; 1984.
16. Slaga TJ. Mechanisms of Tumor Promotion: Volume IV: Cellular Responses to Tumor Promoters Boca Raton FL: CRC Press; 1984.
17. Slaga TJ. Mechanisms of Tumor Promotion: Volume III: Tumor Promotion and Skin Carcinogenesis In Vitro Boca Raton, FL: CRC Press; 1984.
18. Slaga TJ, Fischer SM. Arachidonic Acid Metabolism and Tumor Promotion: Volume III Hingham, MA: Martinus Nijhoff Publishers; 1984.
19. Slaga TJ. Mechanisms of Tumor Promotion: Volume II: Tumor Promotion and Skin Carcinogenesis Boca Raton, FL: CRC Press; 1984.
20. Slaga TJ. Mechanisms of Tumor Promotion: Volume I: Tumor Promotion in Internal Organs Boca Raton, FL: CRC Press; 1983.
21. Slaga TJ. Carcinogenesis - A Comprehensive Survey: Modifiers of Chemical Carcinogenesis: An Approach to the Biochemical Mechanism and Cancer Prevention New York, NY: Raven Press; 1980.

22. Slaga TJ, Boutwell RK, Sivak A. Carcinogenesis - A Comprehensive Survey: Mechanisms of Tumor Promotion and Carcinogenesis New York, NY: Raven Press; 1978.

### **Editorial**

1. Slaga TJ. Epidermal cell proliferation and promoting ability of phorbol esters Letter to the Editor, J Natl Cancer Inst 1977;59:299-300.

### **Electronic/Web Publication**

- \* 1. Kowalczyk P, Kowalczyk M, Junco JJ, Tolstykh O, Kinjo T, Truong H, Walaszek Z, Hanausek M, Slaga TJ. The possible separation of 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation and hyperplasia by compound A 2012 Available from: doi: 10.1002/mc.21883
- 2. Slaga TJ. Cellular and molecular mechanisms of tumor promotion 1983

### **Journal Article**

- \* 1. Hyunseung L, Morales LD, Slaga TJ, Kim DJ. Activation of T-cell protein-tyrosine phosphatase suppresses keratinocyte survival and proliferation following UVB irradiation J Biological Chemistry 2015;290:13-24.
- \* 2. Cho J, Tremmel L, Rho O, Camelio AM, Siegel D, Slaga TJ, DiGiovanni J. Evaluation of pentacyclic triterpenes found in *Perilla frutescens* for inhibition of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate Oncotarget 2015
- \* 3. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of pentaerythrityl tetraesters as used in cosmetics Int J Toxicol 2015;34(2 S):99S-112S.
- \* 4. Fiume MM, Heldreth BA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of ethanolamine and ethanolamine salts as used in cosmetics Int J Toxicol 2015;34(2S):84S-98S.
- \* 5. Johnson W Jr., Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of alkyl PEG sulfosuccinates as used in cosmetics Int J Toxicol 2015;34(2S):70S-83S.
- \* 6. Fiume MM, Heldreth BA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of alkyl esters as used in cosmetics Int J Toxicol 2015;34(2S):5S-69S.
- \* 7. Fiume MM, Boyer I, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of talc as used in cosmetics Int J Toxicol 2015;34(1S):66S-129S.
- \* 8. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr.,

Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of dialkyl malates as used in cosmetics Int J Toxicol 2015;34(1S):5S-17S.

- \* 9. Johnson W Jr., Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of galactomannans as used in cosmetics Int J Toxicol 2015;34(1S):35S-65S.
- \* 10. Fiume MM, Heldreth BA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of ethanalamides as used in cosmetics Int J Toxicol 2015;34(1S):18S-34S.
- \* 11. Cho J, Rho O, Junco J, Carbajal S, Siegel D, Slaga TJ, DiGiovanni J. Effect of combined treatment with ursolic acid and reserctrlol on skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate Cancer Prev Res 2015;8(9):817-825.
- \* 12. Junco JJ, Mancha-Ramirez A, Malik G, Wei S, Kim DJ, Liang H, Slaga TJ. Ursolic acid and resveratrol synergize with chloroquine to reduce melanoma cell viability Melanoma Res 2015;25(2):103-112.
- \* 13. Liang H, Kowalczyk P, Junco JJ, Klug-De Santiago HL, Malik G, Wei S, Slaga TJ. Differential effects on lung cancer cell proliferation by agonists of glucocorticoid and PPAR[alpha] receptors Molecular Carcinogenesis 2014;53(9):753-763.
- \* 14. Kowalczyk P, Junco JJ, Kowalczyk M, Sosnowska R, Tolstykh O, Walaszek Z, Hanausek M, Slaga TJ. The effects of dissociated glucocorticoids RU24858 and RU24782 on TPA-induced skin tumor promotion biomarkers in SENCAR mice Molecular Carcinogenesis 2014;53(6):488-497.
- \* 15. Junco JJ, Mancha A, Malik G, Wei S, Kim DJ, Liang H, Slaga TJ. Resveratrol and ursolic acid synergize with chloroquine to inhibit B16F10 melanoma cell viability (IN PRESS) Melanoma Research 2014
- \* 16. Slaga TJ. The anti-skin cancer effects of ursolic acid in vitro are partially mediated by AMPK and PPARx (IN PRESS) Hormones and Cancer 2014
- \* 17. Zhang Y, Chang FM, Huang J, Junco JJ, Maffi SK, Pridgen HI, Castano G, Dang H, Ding X, Yang F, Kim DJ, Slaga TJ, He R, Wei S. DSSylation, a novel protein modification targets proteins induced by oxidative stress, and facilitates their degradation in cells Protein and Cell 2014;5(2):124-140.
- \* 18. Lu M, Villarreal R, Bai J, Yang X, Hu D, Zhang C, Liang H, Slaga TJ, Blennis J, Scherer PE, Dong LQ, Liu F. Grb10 promotes lipolysis and thermogenesis by phosphorylation-dependent feedback inhibition of mTORC1 Cell Metabolism 2014;19(6):967-980.
- \* 19. Burnett C, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of nylon as used in cosmetics Int J Toxicol 2014;33 4S:47S-60S.

- \* 20. Burnett C, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of animal- and plant-derived amino acids as used in cosmetics Int J Toxicol 2014;33(4S):5S-12S.
- \* 21. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Amended safety assessment of Hypericum perforatum-derived ingredients as used in cosmetics Int J Toxicol 2014;33(3 S):5S-23S.
- \* 22. Fiume MM, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of Vitis vinifera (grape)-derived ingredients as used in cosmetics Int J Toxicol 2014;33(3S):48S-83S.
- \* 23. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of modified terephthalae polymers as used in cosmetics Int J Toxicol 2014;33(3S):36S-47S.
- \* 24. Burnett CL, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of 6-hydroxyindole as used in cosmetics Int J Toxicol 2014;33(3S):24S-35S.
- \* 25. Burnett CL, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of PEGylated oils as used in cosmetics Int J Toxicol 2014;33(4S):13S-39S.
- \* 26. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of Dimethicone crosspolymers as used in cosmetics Int J Toxicol 2014;33(2 S):65S-115S.
- \* 27. Johnson W Jr., Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of chlorphenesin as used in cosmetics Int J Toxicol 2014;33(2 S):5S-15S.
- \* 28. Fiume MM, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of Cucumis sativus (cucumber)-derived ingredients as used in cosmetics Int J Toxicol 2014;33(2 S):47S-64S.
- \* 29. Fiume MM, Heldreth BA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of citric acid, inorganic citrate salts, and alkyl citrate esters as used in cosmetics Int J Toxicol 2014;33(2 S):16S-46S.
- \* 30. Ma Y-Y, Lin H, Chang F-M, Chang T-C, Trieu T, Pridgen H.I., Zhang Y, Huang J, Patino-Guzman K, Diab N, Slaga TJ, Wei S. Identification of the deleted in split hand/split foot 1 protein as a novel biomarker for human cervical cancer. Carcinogenesis 2013;34(1):68-78.

- \* 31. Junco JJ, Mancha A, Malik G, Wei S, Kim DJ, Liang H, Slaga TJ. Resveratrol and P-cycloprotein inhibitors enhance the anti-skin cancer effects of ursolic acid Mol Cancer Res 2013;11(12):1521-1529.
- \* 32. Kowalczyk M, Junco JJ, Kowal, Tolstykh O, Hanausek M, Slaga TJ, Walaszek Z. Effects of combined phytochemicals on skin tumorigenesis in SENCAR mice Int J Oncol 2013;43(3):911-918.
- \* 33. Boyer IJ, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Amended safety assessment of formaldehyde and methylene glycol as used in cosmetics Int J Toxicol 2013;32(6 S):5S-32S.
- \* 34. Burnett CL, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of alpha-amino acids as used in cosmetics Int J Toxicol 2013;32(6 S):41S-64S.
- \* 35. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of ammonium hectorites as used in cosmetics Int J Toxicol 2013;32(6 S):33S-40S.
- \* 36. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of borosilicate glasses as used in cosmetics Int J Toxicol 2013;32(5 S):65S-72S.
- \* 37. Johnson W Jr., Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of alkyl glyceryl ethers as used in cosmetics Int J Toxicol 2013;32(5S):5S-21S.
- \* 38. Burnett CL, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of lauriminodipropionic acid, sodium lauriminodipropionate, and disodium lauriminodipropionate as used in cosmetics Int J Toxicol 2013;32(5S):49S-55S.
- \* 39. Fiume MM, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of decyl glucoside and other alkyl glucosides as used in cosmetics Int J Toxicol 2013;32(5S):22S-48S.
- \* 40. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of silylates and surface-modified siloxysilicates Int J Toxicol 2013;32(3S):5S-24S.
- \* 41. Fiume MM, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of triethanolamine and triethanolamine-containing ingredients as used in cosmetics Int J Toxicol 2013;32(3S):59S-83S.
- \* 42. Fiume MM, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC,

Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of diethanolamides as used in cosmetics Int J Toxicol 2013;32(3S):36S-58S.

- \* 43. Burnett CL, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of 2-amino-4-hydroxyethylaminoanisole and 2-amino-4-hydroxyethylaminoanisole sulfate as used in cosmetics Int J Toxicol 2013;32(3S):25S-35S.
- \* 44. Chang FM, Reyna SM, Granados JC, Wei S, Innis-Whitehouse W, Maffi SK, Rodriguez E, Slaga TJ, Short JD. Inhibition of neddylation represses LPS-induced proinflammatory cytokine production in macrophage cells J Biol Chem 2012;287(42):35756-35767.
- \* 45. Fiume MM, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of stearyl heptanoate and related stearyl alkanoates as used in cosmetics Int J Toxicol 2012;31(S2):141S-146S.
- \* 46. Johnson W Jr., Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of 1,2-glycols as used in cosmetics Int J Toxicol 2012;31(S2):147S-168S.
- \* 47. Fiume MM, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of alkyl PEG ethers as used in cosmetics Int J Toxicol 2012;31(S2):169S-244S.
- \* 48. Fiume MM, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of propylene glycol, tripropylene glycol, and PPGs as used in cosmetics Int J Toxicol 2012;31(S2):245S-260S.
- \* 49. Fiume MM, Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG Jr., Shanks RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the cosmetic ingredient review expert panel on the safety assessment of dicarboxylic acids, salts, and esters Int J Toxicol 2012;31(S1):5S-76S.
- \* 50. Burnett CL, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the cosmetic ingredient review expert panel on the safety assessment of cocamidopropyl betaine (CAPB) Int J Toxicol 2012;31(S1):77S-111S.
- \* 51. Heldreth B, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler D, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the cosmetic ingredient review expert panel on the safety assessment of methyl acetate Int J Toxicol 2012;31(S1):112S-136S.
- \* 52. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of alkyl benzoates as used in cosmetics Int J Toxicol 2012;31(6S):342S-372S.

- \* 53. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of trimoniums as used in cosmetics Int J Toxicol 2012;31(6S):296S-341S.
- \* 54. Johnson W Jr., Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of isoparaffins used in cosmetics Int J Toxicol 2012;31(6S):269S-295S.
- 55. Bergfeld WF, Belsito DV, Klaassen CD, Hill R, Liebler D, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of xylene sulfonic acid, toluene sulfonic acid, and alkyl aryl sulfonate hydrotropes as used in cosmetics. Int J Toxicol 2011 Dec;30(6 Sup):270-283.
- 56. Johnson W, Heldreth B, Bergfeld WF, Belsito DV, Klaassen CD, Hill R, Liebler D, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the Cosmetic Ingredient Review Expert Panel on the safety assessment of pelargonic acid (nonanoic acid) and nonanoate esters. Int J Toxicol 2011 Dec;30(6 Sup):228-269.
- 57. Johnson W, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of cyclomethicone, cyclotetrasiloxane, cyclopentasiloxane, cyclohexasiloxane, and cycloheptasiloxane. Int J Toxicol 2011 Dec;30(6 Sup):149-227.
- 58. Burnett CL, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the Amended Safety Assessment of PVM/MA copolymer and its related salts and esters as used in cosmetics. Int J Toxicol 2011 Oct;30(5 Sup):128-144.
- \* 59. Kowalczyk M, Spears E, Narog M, Zoltaszek R, Kowalczyk P, Hanausek M, Yoshimi N, Slaga TJ, Walaszek Z. Modulation of biomarkers related to tumor initiation and promotion in mouse skin by a natural  $\beta$ -glucuronidase inhibitor and its precursors Oncol Rep 2011 Sep;26(3):551-556.
- 60. Johnson W, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Amended safety assessment of Sesamum indicum (sesame) seed oil, hydrogenated sesame seed oil, Sesamum indicum (sesame) oil unsaponifiables, and sodium sesameseedate. Int J Toxicol 2011 May;30(3 Sup):40-53.
- 61. Andersen FA, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG, Shank RC, Slaga TJ, Snyder PW. Final report of the safety assessment of cosmetic ingredients derived from Zea mays (corn). Int J Toxicol 2011 May;30(3 Sup):17-39.
- 62. Burnett CL, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report on the safety assessment of Cocos nucifera (coconut) oil and related ingredients. Int J Toxicol 2011 May;30(3 Sup):5-16.
- \* 63. Wang A, Liu M, Liu X, Dong LQ, Glickman RD, Slaga TJ, Zhou Z, Liu F. Up-regulation

of adiponectin by resveratrol: The essential roles of the Akt/FOXO1 and AMPK signaling pathways and DsbA-L. J Biol Chem 2011 Jan;286(1):60-66.

64. Hanausek M, Spears E, Walaszek Z, Kowalczyk MC, Kowalczyk P, Wendel C, Slaga TJ. Inhibition of murine skin carcinogenesis by freeze-dried grape powder and other grape-derived major antioxidants. Nutr Cancer 2011 Jan;63(1):28-38.
- \* 65. Zoltaszek R, Kowalczyk P, Kowalczyk M, Hanausek M, Kilianska ZM, Slaga TJ, Walaszek Z. Dietary D-glucarate effects on the biomarkers of inflammation during early post-initiation stages of benzo[a] pyrene-induced lung tumorigenesis in A/J mice Oncol Lett 2011 Jan;2(1):145-154.
66. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Amended safety assessment of dodecylbenzenesulfonate, decylbenzenesulfonate, and tridecylbenzenesulfonate salts as used in cosmetics. Int J Toxicol 2010 Nov;29(6 Sup):288-305.
67. Andersen FA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW. Final amended safety assessment of hydroquinone as used in cosmetics. Int J Toxicol 2010 Nov;29(6 Sup):274-287.
68. Burnett CL, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the safety assessment of Kojic acid as used in cosmetics. Int J Toxicol 2010 Nov;29(6 Sup):244-273.
69. Andersen FA, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW. Final report of the Cosmetic Ingredient Review Expert Panel amended safety assessment of Calendula officinalis-derived cosmetic ingredients. Int J Toxicol 2010 Nov;29(6 Sup):221-243.
70. Burnett CL, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG, Shank RC, Slaga TJ, Snyder PW, Alan Andersen F. Final report of the safety assessment of methylisothiazolinone. Int J Toxicol 2010 Jul;29(4 Sup):187-213.
71. Robinson VC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Marks JG, Shank RC, Slaga TJ, Snyder PW, Alan Andersen F. Final report of the amended safety assessment of sodium laureth sulfate and related salts of sulfated ethoxylated alcohols. Int J Toxicol 2010 Jul;29(4 Sup):151-161.
72. Diamante C, Fiume MZ, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG, Shank RC, Slaga TJ, Snyder PW, Alan Andersen F. Final safety assessment of thiodipropionic acid and its dialkyl esters as used in cosmetics. Int J Toxicol 2010 Jul;29(4 Sup):137-150.
73. Kinjo T, Kowalczyk P, Kowalczyk M, Walaszek Z, Slaga TJ, Hanausek M. Effects of desipramine on the cell cycle and apoptosis in Ca3/7 mouse skin squamous carcinoma cells. Int J Mol Med 2010 Jun;25(6):861-867.
74. Becker LC, Bergfeld WF, Belsito DV, Klaassen CD, Hill R, Leibler D, Marks JG, Shank

RC, Slaga TJ, Snyder PW, Alan Andersen F. Final report of the amended safety assessment of Quaternium-15 as used in cosmetics. Int J Toxicol 2010 May;29(3 Sup):98-114.

75. Becker LC, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG, Shank RC, Slaga TJ, Snyder PW, Alan Andersen F. Final report of the safety assessment of allantoin and its related complexes. Int J Toxicol 2010 May;29(3 Sup):84-97.
- \* 76. Kowalczyk MC, Kowalczyk P, Tolstykh O, Hanausek M, Walaszek Z, Slaga TJ. Synergistic effects of combined phytochemicals and skin cancer prevention in SENCAR mice. Cancer Prev Res (Phila Pa) 2010 Feb;3(2):170-178.
- \* 77. Kinjo T, Kowalczyk P, Kowalczyk M, Walaszek Z, Slaga TJ, Hanausek M. Effects of desipramine on the cell cycle and apoptosis in Ca3/7 mouse skin squamous carcinoma cells Int J Mol Med 2010;25:861-867.
- \* 78. Robinson VC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Final report of the amended safety assessment of sodium laureth sulfate and related salts of sulfated ethoxylated alcohols Int J Toxicol 2010;29:1515-1675.
- \* 79. Sander M, Slaga TJ, Harris CC. Mechanisms of toxicity, carcinogenesis, cancer prevention and cancer therapy Mol Carcinog 2010;49:410-428.
- \* 80. Burnett CL, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Final report of the safety assessment of methylisothiazolinone Int J Toxicol 2010;29:187S-213S.
- \* 81. Becker LC, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Final report of the amended safety assessment of myristic acid and its salts and esters as used in cosmetics Int J Toxicol 2010;29:162S-186S.
- \* 82. Diamante C, Fiume MZ, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Final safety assessment of thiodipropionic acid and its dialkyl esters as used in cosmetics Int J Toxicol 2010;29:137S-150S.
- \* 83. Fiume M, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Final report on the safety assessment of sodium cetearyl sulfate and related alkyl sulfates as used in cosmetics Int J Toxicol 2010;29:115S-132S.
- \* 84. Becker LC, Bergfeld WF, Belsito DV, Klaassen CD, Hill R, Liebler D, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Final report of the amended safety assessment of Quaternium-15 as used in cosmetics Int J Toxicol 2010;29:98S-114S.
- \* 85. Becker LC, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Final report of the safety assessment of allantoin and its

related complexes Int J Toxicol 2010;29:84S-97S.

- \* 86. Burnett CL, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Final amended report of the safety assessment of toluene-2,5-diamine, toluene-2,5-diamine sulfate, and toluene-3,4-diamine as used in cosmetics Int J Toxicol 2010;29:61S-83S.
- \* 87. Kinjo T, Kowalczyk P, Kowalczyk M, Walaszek Z, Nishimaki T, Slaga TJ, Hanausek M. Desipramine inhibits the growth of a mouse skin squamous cell carcinoma cell line and affects glucocorticoid receptor-mediated transcription. Mol Carcinog 2009 Dec;48(12):1123-1130.
- \* 88. Kowalczyk M, Walaszek Z, Kowalczyk P, Kinjo T, Hanausek M, Slaga TJ. Differential effects of several phytochemicals and their derivatives on murine keratinocytes in vitro and in vivo: implications for skin cancer prevention Carcinogenesis 2009 Jun;30(6):1008-1015.
- \* 89. Kowalczyk P, Kinjo T, Kowalczyk M, Walaszek Z, Hanausek M, Slaga TJ. Effect of phosphodiesterase antagonists on glucocorticoid mediated growth inhibition in murine skin cell lines Eur J Pharmacol 2009 May;610(1-3):29-36.
- \* 90. Hanausek M, Spears E, Walaszek Z, Wendel C, Zoltaszek R, Slaga TJ. Inhibition of different stages of skin carcinogenesis by freeze-dried grape powder and other grape-derived major antioxidants Int J Oncol 2009
- \* 91. Robinson V, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Amended safety assessment of tall oil acid, sodium tallate, potassium tallate, and ammonium tallate Int J Toxicol 2009;28:252S-258S.
- \* 92. Becker LC, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen A. Final report on the safety assessment of amino nitrophenols as used in hair dyes Int J Toxicol 2009 Jan;28:217S-251S.
- \* 93. Becker LC, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Amended safety assessment of sodium picramate and picramic acid Int J Toxicol 2009;28:205S-216S.
- \* 94. Diamante C, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen A. Final report on the safety assessment of Basic Violet 1, Basic Violet 3, and Basic Violet 4 Int J Toxicol 2009;28:193S-204S.
- \* 95. Robinson V, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report on the safety assessment of Piper methysticum leaf/root/stem extract and Piper methysticum root extract Int J Toxicol 2009;28:175S-188S.
- \* 96. Robinson V, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report on the safety assessment of PPG-2 methyl ether, PPG-3 methyl ether, and PPG-2 methyl ether acetate Int J Toxicol

2009;28:162S-174S.

- \* 97. Burnett CL, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final amended report on safety assessment on aminomethyl propanol and aminomethyl propanediol Int J Toxicol 2009;28:141S-161S.
- \* 98. Burnett CL, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final amended report on the safety assessment of Ammonium Thioglycolate, Butyl Thioglycolate, Calcium Thioglycolate, Ethanolamine Thioglycolate, Ethyl Thioglycolate, Glyceryl Thioglycolate, Isooctyl Thioglycolate, Isopropyl Thioglycolate, Magnesium Thiog Int J Toxicol 2009 Jan;28:68-133.
- \* 99. Becker LC, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Final report of the safety assessment of hyaluronic acid, potassium hyaluronate, and sodium hyaluronate Int J Toxicol 2009;28:5-67.
- \* 100. Sander M, Slaga TJ, Trump BF, Harris CC. The twenty-second Aspen Cancer Conference: Mechanisms of Toxicity, Carcinogenesis, Cancer Prevention, and Cancer Therapy, 2007. Mol Carcinog 2008 Jul;47(7):554-571.
- \* 101. Morita N, Walaszek Z, Kinjo T, Nishimaki T, Hanausek M, Slaga TJ, Mori H, Yoshimi N.. Effects of synthetic and natural in vitro inhibitors of beta-glucuronidase on azoxymethane-induced colon carcinogenesis in rats Mol Med Rep 2008 Jan;1:741-746.
- \* 102. Sander M, Slaga TJ, Trump BF, Harris CC. Mechanisms of toxicity, carcinogenesis, cancer prevention, and cancer therapy Mol Carcinog 2008;47:554-571.
- \* 103. Sander M, Slaga TJ, Trump BF, Harris CC. The twenty-second aspen cancer conference: Mechanisms of toxicity, carcinogenesis, cancer prevention, and cancer therapy, 2007. Mol Carcinog 2007 Dec
- \* 104. Walaszek Z, Hanausek M, Slaga TJ. The role of skin painting in predicting lung cancer. Int J Toxicol 2007 Jul;26(4):345-351.
- \* 105. Curtin GM, Hanausek M, Walaszek Z, Zoltaszek R, Swauger JE, Mosberg AT, Slaga TJ. Short-term biomarkers of cigarette smoke condensate tumor promoting potential in mouse skin. Toxicol Sci 2006 Jan;89(1):66-74.
- \* 106. Garcia GE, Wisniewski HG, Lucia MS, Arevalo N, Slaga TJ, Kraft SL, Strange R, Kumar AP. 2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res 2006;12(3 Pt):980-988.
- \* 107. Ghosh R, Nadiminty L, Fitzpatrick JE, Alworth WL, Slaga TJ, Kumar AP. Eugenol causes melanoma growth suppression through inhibition of E2F1 transcriptional activity JBC 2005;280:5812-5819.
- \* 108. Curtin GM, Hanausek M, Walaszek Z, Mosberg AT, Slaga TJ. Short-term in vitro and in

vivo analyses for assessing the tumor-promoting potentials of cigarette smoke condensates. Toxicol Sci 2004 Sep;81(1):14-25.

- \* 109. Hanausek M, Walaszek Z, Szemraj J, Zoltaszek R, Slaga TJ. Modulation of biomarkers during chemoprevention of mouse lung tumorigenesis by D-glucarate. Chest 2004 May;125(5 Sup):149-149.
- \* 110. Walaszek Z, Hanausek M, Narog M, Raich PC, Slaga TJ. Mechanisms of lung cancer chemoprevention by D-glucarate. Chest 2004 May;125(5 Sup):149-150.
- \* 111. Walaszek Z, Hanausek M, Slaga TJ, Hanausek ME. Mechanisms of chemoprevention. Chest 2004 May;125(5 Sup):128-133.
- \* 112. Hanausek M, Walaszek Z, Viaje A, LaBate M, Spears E, Farrell D, Henrich R, Tveit A, Walborg EF, Slaga TJ. Exposure of mouse skin to organic peroxides: subchronic effects related to carcinogenic potential. Carcinogenesis 2004 Mar;25(3):431-437.
- \* 113. Ghosh R, Addanki P, Kumar, Garcia GE, Rajnarayanan RV, Alworth WL, Slaga TJ.. Curcumin Derivatives: Potential for prostate cancer management Toxicologic Pathology 2004;32:132-167.
- \* 114. Curtin GM, Hanausek M, Walaszek Z, Zoltaszek R, Swauger JE, Slaga TJ, Ayres PJ. Physiological and toxicological consequences of mainstream tobacco smoke exposure in A/J mice TSRC 2004
- \* 115. Hanausek M, Walaszek Z, Slaga TJ. Detoxifying cancer causing agents to prevent cancer. Integr Cancer Ther 2003 Jun;2(2):139-144.
- \* 116. Budunova IV, Kowalczyk D, Pérez P, Yao YJ, Jorcano JL, Slaga TJ. Glucocorticoid receptor functions as a potent suppressor of mouse skin carcinogenesis. Oncogene 2003 May;22(21):3279-3287.
- \* 117. Cascallana JL, Bravo A, Page A, Budunova I, Slaga TJ, Jorcano JL, Pérez P. Disruption of eyelid and cornea development by targeted overexpression of the glucocorticoid receptor. Int J Dev Biol 2003 Feb;47(1):59-64.
- \* 118. Ghosh R, Ott AM, Seetharam D, Slaga TJ, Kumar AP. Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2-methoxyoestradiol: therapeutic implications? Melanoma Res 2003;13(2):119-127.
- \* 119. Kumar AP, Garcia GE, Ghosh R, Rajnarayanan RV, Alworth WL, Slaga TJ. 4-hydroxy-3-methoxybenzoic acid methyl ester (HMBME): A curcumin derivative targets Akt/NFkB cell survival signaling pathway: Potential for prostate cancer management Neoplasia 2003;5(3):255-266.
- \* 120. Kumar P, Garcia GE, Orsborn J, Levin VA, Slaga TJ. 2-Methoxyestradiol interferes with NF kappa B transcriptional activity in primitive neuroectodermal brain tumors: Implications for management Carcinogenesis 2003;24:209-216.

- \* 121. Gasparian AV, Yao YJ, Lü J, Yemelyanov AY, Lyakh LA, Slaga TJ, Budunova IV. Selenium compounds inhibit I kappa B kinase (IKK) and nuclear factor-kappa B (NF-kappa B) in prostate cancer cells. Mol Cancer Ther 2002 Oct;1(12):1079-1087.
- \* 122. Spiegelman VS, Tang W, Chan AM, Igarashi M, Aaronson SA, Sassoon DA, Katoh M, Slaga TJ, Fuchs SY. Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. J Biol Chem 2002 Sep;277(39):36624-36630.
- \* 123. Bhatia N, Herter JR, Slaga TJ, Fuchs SY, Spiegelman VS. Mouse homologue of HOS (mHOS) is overexpressed in skin tumors and implicated in constitutive activation of NF-kappaB. Oncogene 2002 Feb;21(10):1501-1509.
- \* 124. Spiegelman VS, Tang W, Katoh M, Slaga TJ, Fuchs SY. Inhibition of HOS expression and activities by Wnt pathway. Oncogene 2002 Jan;21(5):856-860.
- \* 125. Gasparian AV, Yao YJ, Kowalczyk D, Lyakh LA, Karseladze A, Slaga TJ, Budunova IV. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci 2002 Jan;115(Pt 1):141-151.
- \* 126. Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova IV, Martínez J, Larcher F, Slaga TJ, Gutkind JS, Jorcano JL, Paramio JM. Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 2002 Jan;21(1):53-64.
- \* 127. Hanausek M, Ganesh P, Walaszek Z, Arntzen CJ, Slaga TJ, Gutterman JU, Hanausek ME. Avicins, a family of triterpenoid saponins from *Acacia victoriae* (Benth), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model. Proc Natl Acad Sci U S A 2001 Sep;98(20):11551-11556.
- \* 128. Pérez P, Page A, Bravo A, Del Río M, Giménez-Conti I, Budunova I, Slaga TJ, Jorcano JL. Altered skin development and impaired proliferative and inflammatory responses in transgenic mice overexpressing the glucocorticoid receptor. FASEB J 2001 Sep;15(11):2030-2032.
- \* 129. Spiegelman VS, Stavropoulos P, Latres E, Pagano M, Ronai Z, Slaga TJ, Fuchs SY. Induction of beta-transducin repeat-containing protein by JNK signaling and its role in the activation of NF-kappaB. J Biol Chem 2001 Jul;276(29):27152-27158.
- \* 130. Kumar AP, Garcia GE, Slaga TJ. 2-Methoxyestradiol blocks cell-cycle progression at G2/M phase and inhibits growth of human prostate cancer cells Molecular Care Carcin 2001;31:111-124.
- \* 131. Johnson W Jr., Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr., Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety assessment of TinIV oxide as used in cosmetics Int J Toxicol 2001;33(4S):40S-60S.
- \* 132. Tang MS, Vulimiri SV, Viaje A, Chen JX, Bilolikar DS, Morris RJ, Harvey RG, Slaga TJ, DiGiovanni J. Both (+/-)-syn- and (+/-)-anti-7,12-dimethylbenz[a]anthracene-3,4-diol-1,2-epoxides initiate tumors in mouse skin that possess -CAA- to -CTA- mutations at Codon 61 of c-H-ras. Cancer Res 2000 Oct;60(20):5688-5695.

- \* 133. Spiegelman VS, Slaga TJ, Pagano M, Minamoto T, Ronai Z, Fuchs SY. Wnt/beta-catenin signaling induces the expression and activity of betaTrCP ubiquitin ligase receptor. Mol Cell 2000 May;5(5):877-882.
- \* 134. Coghlan LG, Gimenez-Conti I, Kleiner HE, Fischer SM, Rundhaug JE, Conti CJ, Slaga TJ, DiGiovanni J. Development and initial characterization of several new inbred strains of SENCAR mice for studies of multistage skin carcinogenesis. Carcinogenesis 2000 Apr;21(4):641-646.
- \* 135. Yoshimi N, Walaszek Z, Mori H, Hanausek M, Szemraj J, Slaga TJ. Inhibition of azoxymethane-induced rat colon carcinogenesis by potassium hydrogen D-glucarate. Int J Oncol 2000 Jan;16(1):43-48.
- \* 136. Cline MJ, Dungworth DL, Fischer TH, Gardner DE, Pryor WA, Rennard SI, Slaga TJ, Wagner BM. A safer cigarette: A comparative study. A consensus report Inhalation Toxicology 2000
- \* 137. Budunova IV, Perez P, Vaden VR, Spiegelman VS, Slaga TJ, Jorcano JL. Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene 1999 Dec;18(52):7423-7431.
- \* 138. Gopalakrishna R, Gundimeda U, Anderson WB, Colburn NH, Slaga TJ. Tumor promoter benzoyl peroxide induces sulfhydryl oxidation in protein kinase C: its reversibility is related to the cellular resistance to peroxide-induced cytotoxicity. Arch Biochem Biophys 1999 Mar;363(2):246-258.
- \* 139. Hursting SD, Slaga TJ, Fischer SM, DiGiovanni J, Phang JM. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. J Natl Cancer Inst 1999 Feb;91(3):215-225.
- \* 140. Nesnow S, Cavanee W, Gilmer TM, Kaufman DG, Slaga TJ, Hohman R, Bishop JM, Poirier MC, Harris CC, Trump BF, Yuspa SH, Pfeifer AM, Sherman MI, Tennant R. Thirteenth Aspen Cancer Conference: Workshop on mechanisms of toxicity and carcinogenesis Mol Carcinog 1999;25:99-106.
- \* 141. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Final report on the safety assessment of Cetech-1, -2, -3, -4, -5, -6, -10, -12, -14, -15, -16, -20, -23, -25, -30, -40, -44 and -50 Int J Toxicology 1999;18(2)
- \* 142. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Final report on the safety assessment of Cocamide MEA Int J Toxicol 1999;18(2)
- \* 143. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Final report on the safety assessment of Oleth-2, -3, -4, -5, -6, -8, -9, -10, -11, -12, -15, -16, -20, -23, -25, -30, -40, -44, and -50 Int J Toxicol 1999;18(2)
- \* 144. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Final safety assessment for PCA and sodium PCA Int J Toxicol 1999;18(2)

- \* 145. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Final report on the safety assessment of Propylene Glycol (PG) Dicaprylate, PG Dicaprylate/Dicaprate, PG Dicocoate, PG Dipelargonate, PG Isostearate, PG Laurate, PG Myristate, PG Oleate, PG Oleate SE, PG Dioleate, PG Dicaprate, PG Disostearate, and PG Di Int J Toxicol 1999;18(2)
- \* 146. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Special report: Reproductive and developmental toxicity of ethylene glycol and its ethers Int J Toxicol 1999;18(2)
- \* 147. Bergeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Note regarding the safety assessment of Chlorhexidine, Chlorhexidine Diacetate, Chlorhexidine Digluconate, and Chlorhexidine Dihydrochloride Int J Toxicol 1999;18(2)
- \* 148. Walborg EF, DiGiovanni J, Conti CJ, Slaga TJ, Freeman JJ, Steup DR, Skisak CM. Short-term biomarkers of tumor promotion in mouse skin treated with petroleum middle distillates. Toxicol Sci 1998 Oct;45(2):137-145.
- \* 149. Gimenez-Conti IB, Binder RL, Johnston D, Slaga TJ. Comparison of the skin tumor-promoting potential of different organic peroxides in SENCAR mice. Toxicol Appl Pharmacol 1998 Mar;149(1):73-79.
- \* 150. Stern MC, Gimenez-Conti IB, Budunova I, Coghlan L, Fischer SM, DiGiovanni J, Slaga TJ, Conti CJ. Analysis of two inbred strains of mice derived from the SENCAR stock with different susceptibility to skin tumor progression. Carcinogenesis 1998 Jan;19(1):125-132.
- \* 151. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Amended final report on the safety assessment of dioctyl sodium sulfocuccinate Int J Toxicol 1998;17(4)
- \* 152. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Final report on the safety assessment of HC Orange No. 1. Int J Toxicol 1998;17(4)
- \* 153. Bergeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Final report on the safety assessment of mink oil Int J Toxicol 1998;17(4)
- \* 154. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Final report on the safety assessment of pentaerthryl Rosinate Int J Toxicol 1998;17(4)
- \* 155. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Final report on the safety assessment of polyvinylpyrrolidone (PVP) Int J Toxicol 1998;17(4)
- \* 156. Bergfeld WF, Belsito DV, Carlton WW, Klaassen CD, Schroeter AL, Shank RC, Slaga TJ. Final report on the safety assessment of Glycolic Acid, Ammonium, Calcium, Potassium, and Sodium Glycolates, Methyl, Ethyl, Propyl, and Butyl Glycolates and

Lactic Acid, Ammonium, Calcium, Potassium, Sodium, and TEA-Lactates, Methyl, Ethyl, Isopropyl and Int J Toxicol 1998;17(1)

- \* 157. Bednarek AK, Chu Y, Slaga TJ, Aldaz CM. Telomerase and cell proliferation in mouse skin papillomas. Mol Carcinog 1997 Dec;20(4):329-331.
- \* 158. Rundhaug JE, Gimenez-Conti I, Stern MC, Budunova IV, Kiguchi K, Bol DK, Coghlan LG, Conti CJ, DiGiovanni J, Fischer SM, Winberg LD, Slaga TJ. Changes in protein expression during multistage mouse skin carcinogenesis. Mol Carcinog 1997 Sep;20(1):125-136.
- \* 159. Spiegelman VS, Budunova IV, Carbajal S, Slaga TJ. Resistance of transformed mouse keratinocytes to growth inhibition by glucocorticoids. Mol Carcinog 1997 Sep;20(1):99-107.
- \* 160. Budunova IV, Carbajal S, Kang H, Viaje A, Slaga TJ. Altered glucocorticoid receptor expression and function during mouse skin carcinogenesis. Mol Carcinog 1997 Mar;18(3):177-185.
- \* 161. Qing WG, Conti CJ, LaBate M, Johnston D, Slaga TJ, MacLeod MC. Induction of mammary cancer and lymphoma by multiple, low oral doses of 7,12-dimethylbenz[a]anthracene in SENCAR mice. Carcinogenesis 1997 Mar;18(3):553-559.
- \* 162. Kang H, Budunova IV, Carbajal S, Slaga TJ. Inhibition of glucocorticoid receptor by diverse tumor promoters in SENCAR mouse epidermis Int J Oncology 1997;10:241-246.
- \* 163. Curtin GM, Fischer SM, Slaga TJ. Identification of an autocrine mechanism for regulating cell-cycle progression in murine keratinocytes. J Cancer Res Clin Oncol 1997 Jan;123(2):71-81.
- \* 164. Volpe JP, Conti CJ, Slaga TJ. Characterization of mutant HA-ras gene expression in transformed murine keratinocyte lines grown under in vitro and in vivo conditions. Mol Carcinog 1996 Dec;17(4):202-206.
- \* 165. Chen JX, Kisleyou AS, Harvey RG, Slaga TJ, Morris RJ, Tang M. Using UvrABC nuclease to detect 7,12-dimethylbenz[a]anthracene anti-diol epoxide-DNA binding specificity in the mouse H-ras gene. Chem Res Toxicol 1996 Dec;9(8):1350-1354.
- \* 166. Chen JX, Pao A, Zheng Y, Ye X, Kisleyou AS, Morris R, Slaga TJ, Harvey RG, Tang MS. Sequence preference of 7,12-dimethylbenz[a]anthracene-syn-diol epoxide-DNA binding in the mouse H-ras gene detected by UvrABC nucleases. Biochemistry 1996 Jul;35(29):9594-9602.
- \* 167. Battalora MS, Conti CJ, Aldaz CM, Slaga TJ, Johnston DA, DiGiovanni J. Regression and progression characteristics of papillomas induced by chrysarobin in SENCAR mice. Carcinogenesis 1996 May;17(5):955-960.

- \* 168. Slaga TJ, Budunova IV, Gimenez-Conti IB, Aldaz CM. The mouse skin carcinogenesis model. J Investig Dermatol Symp Proc 1996 Apr;1(2):151-156.
- \* 169. Budunova IV, Carbajal S, Slaga TJ. Effect of diverse tumor promoters on the expression of gap-junctional proteins connexin (Cx)26, Cx31.1, and Cx43 in SENCAR mouse epidermis. Mol Carcinog 1996 Mar;15(3):202-214.
- \* 170. Budunova IV, Carbajal S, Viaje A, Slaga TJ. Connexin expression in epidermal cell lines from SENCAR mouse skin tumors. Mol Carcinog 1996 Mar;15(3):190-201.
- \* 171. Budunova IV, Carbajal S, Slaga TJ. The expression of gap junctional proteins during different stages of mouse skin carcinogenesis. Carcinogenesis 1995 Nov;16(11):2717-2724.
- \* 172. Bednarek A, Budunova I, Slaga TJ, Aldaz CM. Increased telomerase activity in mouse skin premalignant progression. Cancer Res 1995 Oct;55(20):4566-4569.
- \* 173. Slaga TJ. Inhibition of skin tumor initiation, promotion, and progression by antioxidants and related compounds. Crit Rev Food Sci Nutr 1995 Jan;35(1-2):51-57.
- \* 174. O'Driscoll KR, Madden PV, Christiansen KM, Viage A, Slaga TJ, Fabbro D, Powell CT, Weinstein IB. Overexpression of protein kinase C beta I in a murine keratinocyte cell line produces effects on cellular growth, morphology and differentiation. Cancer Lett 1994 Aug;83(1-2):249-259.
- \* 175. Rannug A, Holmberg B, Ekström T, Mild KH, Gimenez-Conti I, Slaga TJ. Intermittent 50 Hz magnetic field and skin tumor promotion in SENCAR mice. Carcinogenesis 1994 Feb;15(2):153-157.
- \* 176. Budunova IV, Slaga TJ. Alteration of gap junctional intercellular communications during carcinogenesis Cancer Journal 1994;7(6):228-237.
- \* 177. Tennant RW, Prescott DM, Puck TT, Slaga TJ, Saffiotti U, Wogan GN, Nesnow S, McClain RM. Eighth Aspen Cancer Conference: Molecular mechanisms of toxicity in relation to the genetics of animal and human neoplasia Mol Carcinog 1994;10:117-124.
- \* 178. Nesnow S, Gold A, Sangaiah R, Slaga TJ. Mouse skin tumor-initiating activity of benz[*a*]aceanthrylene in SENCAR mice. Cancer Lett 1993 Sep;73(2-3):73-76.
- \* 179. DiGiovanni J, Walker SE, Aldaz CM, Slaga TJ, Conti CJ. Further studies on the influence of initiation dose on papilloma growth and progression during two-stage carcinogenesis in SENCAR mice. Carcinogenesis 1993 Sep;14(9):1831-1836.
- \* 180. Rannug A, Ekström T, Mild KH, Holmberg B, Gimenez-Conti I, Slaga TJ. A study on skin tumour formation in mice with 50 Hz magnetic field exposure. Carcinogenesis 1993 Apr;14(4):573-578.
- \* 181. Yoshimi N, Gimenez-Conti IB, Slaga TJ. Morphological changes of the nucleolar organizer regions induced by 7,12-dimethylbenz[*a*]anthracene in the hamster cheek

pouch. J Oral Pathol Med 1993 Mar;22(3):97-100.

- \* 182. Warren BS, Naylor MF, Winberg LD, Yoshimi N, Volpe JP, Gimenez-Conti I, Slaga TJ. Induction and inhibition of tumor progression. Proc Soc Exp Biol Med 1993 Jan;202(1):9-15.
- \* 183. Robles AI, Gimenez-Conti IB, Roop D, Slaga TJ, Conti CL. Low frequency of codon 61 Ha-ras mutations and lack of keratin 13 expression in 7,12-dimethylbenz[a]-anthracene-induced hamster skin tumors Molecular Carcinogenesis 1993;7:94-98.
- \* 184. Gimenez-Conti IB, Slaga TJ. The hamster cheek pouch carcinogenesis model J Cell Biochem Suppl 1993;17F:83-90.
- \* 185. Warren BS, Slaga TJ. Mechanisms of inhibition of tumor progression Basic Life Sci 1993;61:279-289.
- \* 186. Tennant RW, Harris CC, Kaufman DG, Nesnow S, Slaga TJ, Stevenson DE, Trump BF. Sixth Aspen Cancer Conference: Molecular mechanisms of genetic deregulation in toxicity and carcinogenesis Mol Carcinog 1993;7:67-72.
- \* 187. Likhachev AJ, Warren BS, Slaga TJ. O6-alkylguanine-DNA alkyltransferase activity in epidermal tumor and normal epidermal cells of mice of various stocks and strains. Carcinogenesis 1992 Jul;13(7):1265-1268.
- \* 188. Gimenez-Conti IB, Bianchi AB, Fischer SM, Reiners JJ, Conti CJ, Slaga TJ. Dissociation of sensitivities to tumor promotion and progression in outbred and inbred SENCAR mice. Cancer Res 1992 Jun;52(12):3432-3435.
- \* 189. Ruggeri B, Caamano J, Slaga TJ, Conti CJ, Nelson WJ, Klein-Szanto AJ. Alterations in the expression of uvomorulin and Na<sup>+</sup>,K<sup>+</sup>-adenosine triphosphatase during mouse skin tumor progression. Am J Pathol 1992 May;140(5):1179-1185.
- \* 190. Fischer SM, Leyton J, Lee ML, Locniskar M, Belury MA, Maldve RE, Slaga TJ, Bechtel DH. Differential effects of dietary linoleic acid on mouse skin-tumor promotion and mammary carcinogenesis. Cancer Res 1992 Apr;52(7 Sup):2049-2054.
- \* 191. Fischer SM, Conti CJ, Locniskar M, Belury MA, Maldve RE, Lee ML, Leyton J, Slaga TJ, Bechtel DH. The effect of dietary fat on the rapid development of mammary tumors induced by 7,12-dimethylbenz(a)anthracene in SENCAR mice. Cancer Res 1992 Feb;52(3):662-666.
- \* 192. Mirowski M, Hanausek M, Sherman U, Adams AK, Walaszek Z, Slaga TJ. An enzyme-linked immunosorbent assay for p65 oncofetal protein and its potential as a new marker for cancer risk assessment in rodents and humans. Prog Clin Biol Res 1992;374:281-294.
- \* 193. Gimenez-Conti IB, Bianchi AB, Stockman SL, Conti CJ, Slaga TJ. Activating mutation of the Ha-ras gene in chemically induced tumors of the hamster cheek pouch Molecular Carcinogenesis 1992;5:259-263.

- \* 194. Slaga TJ, Gimenez-Conti IB. An animal model for oral cancer JNCI 1992;13:55-60.
- \* 195. Gimenez-Conti IB, Slaga TJ. The hamster cheek pouch model of carcinogenesis and chemoprevention Adv Exp Med Biol 1992;320:63-67.
- \* 196. Morris RJ, Haynes AC, Fischer SM, Slaga TJ. Concomitant proliferation and formation of a stratified epithelial sheet by explant outgrowth of epidermal keratinocytes from adult mice. In Vitro Cell Dev Biol 1991 Nov;27A(11):886-895.
- \* 197. Vo TK, Fischer SM, Slaga TJ. Effects of N-acyl dehydroalanines on phorbol ester-elicited tumor development and other events in mouse skin. Cancer Lett 1991 Oct;60(1):25-32.
- \* 198. Jongen WM, Fitzgerald DJ, Asamoto M, Piccoli C, Slaga TJ, Gros D, Takeichi M, Yamasaki H. Regulation of connexin 43-mediated gap junctional intercellular communication by Ca<sup>2+</sup> in mouse epidermal cells is controlled by E-cadherin. J Cell Biol 1991 Aug;114(3):545-555.
- \* 199. Alworth WL, Viaje A, Sandoval A, Warren BS, Slaga TJ. Potent inhibitory effects of suicide inhibitors of P450 isozymes on 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene initiated skin tumors. Carcinogenesis 1991 Jul;12(7):1209-1215.
- \* 200. Gimenez-Conti I, Viaje A, Chesner J, Conti C, Slaga TJ. Induction of short-term markers of tumor promotion by organic peroxides. Carcinogenesis 1991 Apr;12(4):563-569.
- \* 201. Miller DR, Allison DP, Rorvik MC, Slaga TJ. Inhibited morphological terminal differentiation and enhanced proliferation of cultured mouse epidermal cells at different concentrations of dimethyl sulphoxide. Cell Prolif 1991 Mar;24(2):191-201.
- \* 202. Leyton J, Lee ML, Locniskar M, Belury MA, Slaga TJ, Bechtel D, Fischer SM. Effects of type of dietary fat on phorbol ester-elicited tumor promotion and other events in mouse skin. Cancer Res 1991 Feb;51(3):907-915.
- \* 203. Finch J, Andrews K, Krieg P, Slaga TJ, Furstenberger G, Ootsuyama A, Tanooka J, Bowden GT. Identification of a cloned sequence activated during multi-stage carcinogenesis in mouse skin Carcinogenesis 1991;12(8):1519-1522.
- \* 204. Morris RJ, Fischer SM, Slaga TJ. New methods for studying the proliferation and differentiation of epidermal keratinocytes from adult mice Prog Clin Biol Res 1991;369:303-322.
- \* 205. Slaga TJ. Fifty years of the University of Texas M.D. Anderson Cancer Center and the study of carcinogenesis Mol Carcinog 1991;4:417-418.
- \* 206. Morris RJ, Fischer SM, Klein-Szanto AJ, Slaga TJ. Subpopulations of primary adult murine epidermal basal cells sedimented on density gradients. Cell Tissue Kinet 1990 Nov;23(6):587-602.

- \* 207. Gimenez-Conti I, Aldaz CM, Bianchi AB, Roop DR, Slaga TJ, Conti CJ. Early expression of type I K13 keratin in the progression of mouse skin papillomas. Carcinogenesis 1990 Nov;11(11):1995-1999.
- \* 208. Gimenez-Conti IB, Shin DM, Bianchi AB, Roop DR, Hong WK, Conti CJ, Slaga TJ. Changes in keratin expression during 7,12-dimethylbenz[a]anthracene-induced hamster cheek pouch carcinogenesis. Cancer Res 1990 Jul;50(14):4441-4445.
- \* 209. Viaje A, Lu JY, Hopkins NE, Nettikumara AN, DiGiovanni J, Alworth WL, Slaga TJ. Inhibition of the binding of 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene to DNA in mouse skin epidermis by 1-ethynylpyrene. Carcinogenesis 1990 Jul;11(7):1139-1143.
- \* 210. Fischer SM, Patrick KE, Patamalai B, Slaga TJ. Effects of antihistamines on phorbol ester tumor promotion and vascular permeability changes. Carcinogenesis 1990 Jun;11(6):991-996.
- \* 211. Shin DM, Gimenez IB, Lee JS, Nishioka K, Wargovich MJ, Thacher S, Lotan R, Slaga TJ, Hong WK. Expression of epidermal growth factor receptor, polyamine levels, ornithine decarboxylase activity, micronuclei, and transglutaminase I in a 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch carcinogenesis model. Cancer Res 1990 Apr;50(8):2505-2510.
- \* 212. Ewing MW, Conti CJ, Phillips JL, Slaga TJ, DiGiovanni J. Further characterization of skin tumor promotion and progression by mezerein in SENCAR mice. J Natl Cancer Inst 1989 May;81(9):676-682.
- \* 213. Klann RC, Fitzgerald DJ, Piccoli C, Slaga TJ, Yamasaki H. Gap-junctional intercellular communication in epidermal cell lines from selected stages of SENCAR mouse skin carcinogenesis. Cancer Res 1989 Feb;49(3):699-705.
- \* 214. Miller DR, Viaje A, Rotstein J, Aldaz CM, Conti CJ, Slaga TJ. Induction of terminal differentiation-resistant epidermal cells in mouse skin and in papillomas by different initiators during two-stage carcinogenesis. Cancer Res 1989 Jan;49(2):410-414.
- \* 215. Aldaz CM, Trono D, Larcher F, Slaga TJ, Conti CJ. Sequential trisomization of chromosomes 6 and 7 in mouse skin premalignant lesions Molec Carcinogenesis 1989;2:22-26.
- \* 216. O'Connell JF, Miller DR, Morris RJ, Patskan GP, Viaje AV, Slaga TJ. Investigations of multistage carcinogenesis - applications of in vitro - in vivo studies Carcinogenesis Comprehensive Survey 1989;11:339-348.
- \* 217. Ewing MW, Conti CJ, Kruszewski FH, Slaga TJ, DiGiovanni J. Tumor progression in Sencar mouse skin as a function of initiator dose and promoter dose, duration, and type. Cancer Res 1988 Dec;48(24 Pt):7048-7054.
- \* 218. Rotstein JB, Slaga TJ. Anticarcinogenesis mechanisms, as evaluated in the multistage

mouse skin model. Mutat Res 1988 Dec;202(2):421-427.

- \* 219. Morris RJ, Tacker KC, Fischer SM, Slaga TJ. Quantitation of primary in vitro clonogenic keratinocytes from normal adult murine epidermis, following initiation, and during promotion of epidermal tumors. Cancer Res 1988 Nov;48(22):6285-6290.
- \* 220. Rotstein JB, Slaga TJ. Effect of exogenous glutathione on tumor progression in the murine skin multistage carcinogenesis model. Carcinogenesis 1988 Sep;9(9):1547-1551.
- \* 221. Aldaz CM, Conti CJ, Yuspa SH, Slaga TJ. Cytogenetic profile of mouse skin tumors induced by the viral Harvey-ras gene. Carcinogenesis 1988 Aug;9(8):1503-1505.
- \* 222. Aldaz CM, Conti CJ, Larcher F, Trono D, Roop DR, Chesner J, Whitehead T, Slaga TJ. Sequential development of aneuploidy, keratin modifications, and gamma-glutamyltransferase expression in mouse skin papillomas. Cancer Res 1988 Jun;48(11):3253-3257.
- \* 223. Slaga TJ. Interspecies comparisons of tissue DNA damage, repair, fixation, and replication. Environ Health Perspect 1988 Apr;77:73-82.
- \* 224. Ewing MW, Crysup SE, Phillips JL, Slaga TJ, DiGiovanni J. Enhancement of mezerein-promoted papilloma formation by treatment with 12-O-tetradecanoylphorbol-13-acetate or mezerein prior to initiation. Carcinogenesis 1988 Mar;9(3):405-410.
- \* 225. Conti CJ, Fries JW, Viaje A, Miller DR, Morris R, Slaga TJ. In vivo behavior of murine epidermal cell lines derived from initiated and non-initiated skin Cancer Research 1988;48:435-439.
- \* 226. Dotto P, O'Connell J, Patskan J, Conti CJ, Ariza A, Slaga TJ. Malignant progression of papilloma-derived keratinocytes. Differential affect of the ras, neu and p53 oncogenes. Molec Carcinog 1988;1(3):171-179.
- \* 227. Rotstein JB, Slaga TJ. Acetic acid, a potent agent of tumor progression in the multistage mouse skin model for chemical carcinogenesis Cancer Letters 1988;42:87-90.
- \* 228. Ostrowski LE, Finch J, Krieg P, Matrisan L, Patskan G, O'Connell JF, Phillips J, Slaga TJ, Breathnach R, Bowden GT. Expression pattern of a gene for a secreted metalloproteinase during late stages of tumor progression Molecular Carcinogenesis 1988;1(1):13-19.
- \* 229. O'Connell JF, Nesnow S, Slaga TJ. Initiation, promotion and complete carcinogenesis by N-methyl-N'-nitro-N-nitrosoguanidine or ethylnitrosourea in the Sencar mouse skin tumorigenesis model. Cancer Lett 1987 Nov;37(3):301-310.
- \* 230. Colburn NH, Farber E, Weinstein EB, Diamond L, Slaga TJ. American Cancer Society workshop on tumor promotion and antipromotion. Cancer Res 1987 Oct;47(20):5509-5513.

- \* 231. Fischer SM, Fürstenberger G, Marks F, Slaga TJ. Events associated with mouse skin tumor promotion with respect to arachidonic acid metabolism: a comparison between SENCAR and NMRI mice. Cancer Res 1987 Jun;47(12):3174-3179.
- \* 232. Miller DR, Viaje A, Aldaz CM, Conti CJ, Slaga TJ. Terminal differentiation-resistant epidermal cells in mice undergoing two-stage carcinogenesis. Cancer Res 1987 Apr;47(7):1935-1940.
- \* 233. Aldaz CM, Conti CJ, Klein-Szanto AJ, Slaga TJ. Progressive dysplasia and aneuploidy are hallmarks of mouse skin papillomas: relevance to malignancy. Proc Natl Acad Sci U S A 1987 Apr;84(7):2029-2032.
- \* 234. Morris RJ, Tacker KC, Baldwin JK, Fischer SM, Slaga TJ. A new medium for primary cultures of adult murine epidermal cells: application to experimental carcinogenesis. Cancer Lett 1987 Mar;34(3):297-304.
- \* 235. Fischer SM, O'Connell JF, Conti CJ, Tacker KC, Fries JW, Patrick KE, Adams LM, Slaga TJ. Characterization of an inbred strain of the SENCAR mouse that is highly sensitive to phorbol esters. Carcinogenesis 1987 Mar;8(3):421-424.
- \* 236. Patskan GJ, Klein-Szanto AJ, Phillips JL, Slaga TJ. Metastasis from squamous cell carcinomas of SENCAR mouse skin produced by complete carcinogenesis. Cancer Lett 1987 Feb;34(2):121-127.
- \* 237. Nesnow S, Argus M, Bergman H, Chu K, Frith C, Helmes T, McGaughey R, Ray V, Slaga TJ, Tennant R, Weisburger E. Chemical carcinogens: A review and analysis of the literature of selected chemicals and the establishment of the gene-tox carcinogen data base Mutation Res 1987;185:1-196.
- \* 238. O'Connell JF, Rotstein JB, Slaga TJ. Tumor promotion and progression in the mouse skin model Banbury Report 25: Nongenotoxic Mechanisms in Carcinogenesis 1987:11-24.
- \* 239. Conti CJ, Aldaz CM, O'Connell J, Klein-Szanto AJ, Slaga TJ. Aneuploidy, an early event in mouse skin tumor development. Carcinogenesis 1986 Nov;7(11):1845-1848.
- \* 240. Klein-Szanto AJ, Conti CJ, Aldaz CM, Clapp N, Nesnow S, Slaga TJ. Effects of chronic topical application of 12-O-tetradecanoylphorbol-13-acetate on the skin and internal organs of SENCAR mice. Environ Health Perspect 1986 Sep;68:75-80.
- \* 241. Nesnow S, Bergman H, Slaga TJ. Comparison of the tumorigenic response of SENCAR and C57BL/6 mice to benzo(a)pyrene and the inter-experimental variability over a three-year period. Environ Health Perspect 1986 Sep;68:19-25.
- \* 242. Conti CJ, Fries JW, Aldaz CM, Klein-Szanto AJ, Slaga TJ. Allogeneic transplantation of normal epidermal cells and squamous cell carcinomas in SENCAR mice. Environ Health Perspect 1986 Sep;68:125-129.

- \* 243. Slaga TJ. SENCAR mouse skin tumorigenesis model versus other strains and stocks of mice. Environ Health Perspect 1986 Sep;68:27-32.
- \* 244. Pelling JC, Ernst SM, Strawhecker JM, Johnson JA, Nairn RS, Slaga TJ. Elevated expression of Ha-ras is an early event in two-stage skin carcinogenesis in SENCAR mice. Carcinogenesis 1986 Sep;7(9):1599-1602.
- \* 245. Butler AP, Byus CV, Slaga TJ. Phosphorylation of histones is stimulated by phorbol esters in quiescent Reuber H35 hepatoma cells. J Biol Chem 1986 Jul;261(20):9421-9425.
- \* 246. Aldaz CM, Conti CJ, O'Connell J, Yuspa SH, Klein-Szanto AJ, Slaga TJ. Cytogenetic evidence for gene amplification in mouse skin carcinogenesis. Cancer Res 1986 Jul;46(7):3565-3568.
- \* 247. Morris RJ, Fischer SM, Slaga TJ. Evidence that a slowly cycling subpopulation of adult murine epidermal cells retains carcinogen. Cancer Res 1986 Jun;46(6):3061-3066.
- \* 248. O'Connell JF, Klein-Szanto AJ, DiGiovanni DM, Fries JW, Slaga TJ. Enhanced malignant progression of mouse skin tumors by the free-radical generator benzoyl peroxide. Cancer Res 1986 Jun;46(6):2863-2865.
- \* 249. O'Connell JF, Klein-Szanto AJ, DiGiovanni DM, Fries JW, Slaga TJ. Malignant progression of mouse skin papillomas treated with ethylnitrosourea, N-methyl-N'-nitro-N-nitrosoguanidine, or 12-O-tetradecanoylphorbol-13-acetate. Cancer Lett 1986 Mar;30(3):269-274.
- \* 250. Rorvik MC, Pelling JC, Allison DP, Slaga TJ. The intracellular fate of [3H]benzo[a]pyrene diol epoxide diastereomers localized in vivo in SENCAR mouse epidermis: a quantitative electron microscopic study. Carcinogenesis 1986 Mar;7(3):345-352.
- \* 251. Aldaz CM, Conti CJ, Klein-Szanto AJ, Slaga TJ. A direct cytogenetic technique for mouse skin carcinomas and papillomas. Cancer Genet Cytogenet 1986 Feb;20(3-4):223-229.
- \* 252. Nesnow S, Triplett LL, Slaga TJ. Studies on the tumor initiating, tumor promoting and tumor co-initiating properties of respiratory carcinogens Carcinogenesis 1986;7:257-277.
- \* 253. Conti CJ, Clapp N, Klein-Szanto AJ, Nesnow S, Slaga TJ. Survival curves and incidence of neoplastic and non-neoplastic disease in SENCAR mice. Carcinogenesis 1985 Nov;6(11):1649-1652.
- \* 254. Fischer SM, Hardin L, Klein-Szanto A, Slaga TJ. Retinoyl-phorbol-acetate is a complete skin tumor promoter in SENCAR mice. Cancer Lett 1985 Jul;27(3):323-327.
- \* 255. Aldaz CM, Conti CJ, Gimenez IB, Slaga TJ, Klein-Szanto AJ. Cutaneous changes during prolonged application of 12-O-tetradecanoylphorbol-13-acetate on mouse skin

and residual effects after cessation of treatment. Cancer Res 1985 Jun;45(6):2753-2759.

- \* 256. Morris RJ, Fischer SM, Slaga TJ. Evidence that the centrally and peripherally located cells in the murine epidermal proliferative unit are two distinct cell populations. J Invest Dermatol 1985 Apr;84(4):277-281.
- \* 257. Alworth WL, Slaga TJ. Effects of ellipticine, flavone, and 7,8-benzoflavone upon 7,12-dimethylbenz[a]anthracene, 7,14-dimethyldibenzo[a,h]anthracene and dibenzo[a,h]anthracene initiated skin tumors in mice. Carcinogenesis 1985 Apr;6(4):487-493.
- \* 258. Fischer SM, Klein-Szanto AJ, Adams LM, Slaga TJ. The first stage and complete promoting activity of retinoic acid but not the analog RO-10-9359. Carcinogenesis 1985 Apr;6(4):575-578.
- \* 259. Mamrack MD, Klein-Szanto AJ, Reiners JJ, Slaga TJ. Alteration in the distribution of the epidermal protein filaggrin during two-stage chemical carcinogenesis in the SENCAR mouse skin. Cancer Res 1984 Jun;44(6):2634-2641.
- \* 260. Chiba M, Slaga TJ, Klein-Szanto AJ. A morphometric study of dedifferentiated and involutinal dark keratinocytes in 12-O-tetradecanoylphorbol-13-acetate-treated mouse epidermis. Cancer Res 1984 Jun;44(6):2711-2717.
- \* 261. Nesnow S, Triplett LL, Slaga TJ. Tumor initiating activities of 1-nitropyrene and its nitrated products in SENCAR mice. Cancer Lett 1984 May;23(1):1-8.
- \* 262. Davidson KA, Ewald L, Herrmann A, Ogle SP, Slaga TJ. Effects of the antiandrogen, cyproterone acetate, on the induction of papillomas, DNA synthesis and ornithine decarboxylase activity in mouse skin. Carcinogenesis 1984 May;5(5):609-614.
- \* 263. Nesnow S, Gold A, Sangaiah R, Triplett LL, Slaga TJ. Mouse skin tumor-initiating activity of benz[e]aceanthrylene and benz[l]aceanthrylene in SENCAR mice. Cancer Lett 1984 Apr;22(3):263-268.
- \* 264. Reiners JJ, Nesnow S, Slaga TJ. Murine susceptibility to two-stage skin carcinogenesis is influenced by the agent used for promotion. Carcinogenesis 1984 Mar;5(3):301-307.
- \* 265. Pelling JC, Slaga TJ, DiGiovanni J. Formation and persistence of DNA, RNA, and protein adducts in mouse skin exposed to pure optical enantiomers of 7 beta,8 alpha-dihydroxy-9 alpha,10 alpha-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene in vivo. Cancer Res 1984 Mar;44(3):1081-1086.
- \* 266. Fischer SM, Viaje A, Mills GD, Wong EW, Weeks CE, Slaga TJ. The growth of cultured human foreskin keratinocytes is not stimulated by a tumor promoter. Carcinogenesis 1984 Jan;5(1):109-112.
- \* 267. Solanki V, Yotti L, Logani MK, Slaga TJ. The reduction of tumor initiating activity and

cell mediated mutagenicity of dimethylbenz[a]anthracene by a copper coordination compound. Carcinogenesis 1984 Jan;5(1):129-131.

- \* 268. Slaga TJ. Multistage skin carcinogenesis: A useful model for the study of the chemoprevention of cancer Acta Pharmacologica et Toxicologica 1984;V.55(2)
- \* 269. Slaga TJ. Potential for preventing cancer by chemical inhibitors Cancer Bulletin 1984;36(1):61-64.
- \* 270. Slaga TJ, Butler AP. Cellular and biochemical changes during multistage skin tumor promotion Japan Sci Soc Press, Tokyo/VNU Science Press, Utrecht 1984:291-301.
- \* 271. Davidson KA, Slaga TJ. Glucocorticoid receptor levels in mouse skin after repetitive applications of 12-O-tetradecanoylphorbol-13-acetate and mezerein. Cancer Res 1983 Aug;43(8):3847-3851.
- \* 272. Fischer SM, Hardin LG, Slaga TJ. Diazepam inhibition of phorbol ester tumor promotion. Cancer Lett 1983 Jun;19(2):181-187.
- \* 273. Fischer SM, Ogle S, Marnett LJ, Nesnow S, Slaga TJ. The lack of initiating and/or promoting activity of sodium malondialdehyde on SENCAR mouse skin. Cancer Lett 1983 May;19(1):61-66.
- \* 274. Buhler DR, Unlü F, Thakker DR, Slaga TJ, Conney AH, Wood AW, Chang RL, Levin W, Jerina DM. Effect of a 6-fluoro substituent on the metabolism and biological activity of benzo(a)pyrene. Cancer Res 1983 Apr;43(4):1541-1549.
- \* 275. Ashurst SW, Cohen GM, Nesnow S, DiGiovanni J, Slaga TJ. Formation of benzo(a)pyrene/DNA adducts and their relationship to tumor initiation in mouse epidermis. Cancer Res 1983 Mar;43(3):1024-1029.
- \* 276. Nesnow S, Triplett LL, Slaga TJ. Mouse skin tumor initiation-promotion and complete carcinogenesis bioassays: mechanisms and biological activities of emission samples. Environ Health Perspect 1983 Jan;47:255-268.
- \* 277. Reiners JJ, Slaga TJ. Effects of tumor promoters on the rate and commitment to terminal differentiation of subpopulations of murine keratinocytes. Cell 1983 Jan;32(1):247-255.
- \* 278. Klein-Szanto AJ, Nelson KG, Shah Y, Slaga TJ. Simultaneous appearance of keratin modifications and gamma-glutamyltransferase activity as indicators of tumor progression in mouse skin papillomas. J Natl Cancer Inst 1983 Jan;70(1):161-168.
- \* 279. Reiners JJ, Yotti LP, McKeown CK, Newnow S, Slaga TJ. Keratinocyte cell-mediated mutagenesis assay: Correlation with in vivo tumor studies Carcinogenesis 1983;4:321-326.
- \* 280. DiGiovanni J, Diamond L, Harvey RG, Slaga TJ. Enhancement of the skin-initiating activity of polycyclic aromatic hydrocarbons by methylsubstitution at nonbenzo "bay-

region" positions Adv Prostaglandin Thromboxane Leukot Res 1983;4:403-407.

- \* 281. Slaga TJ, Klein-Szanto AJP. Initiation-promotion versus complete skin carcinogenesis in mice: Importance of dark basal keratinocytes (stem cells) Cancer Investigation 1983;1(5):425-436.
- \* 282. MacLeod MC, Pelling JC, Slaga TJ, Nikbakht-Noghrei PA, Mansfield BK, Selkirk JK. Specificity of interaction between carcinogens Polynuclear aromatic hydrocarbon and nuclear proteins. Widespread occurrence of a restricted pattern of histone-binding in intact cells. Prog Nucleic Acid Res and Mol Biol 1983;29:111-115.
- \* 283. Slaga TJ, Fischer SM. Strain differences and solvent effects in mouse skin carcinogenesis experiments using carcinogens tumor initiators and promoters Prog Exp Tumor Res 1983;26:85-109.
- 284. Slaga TJ. Cellular and molecular mechanisms of tumor promotion So Cancer Surveys 1983;2
- 285. Slaga TJ. Initiation and promotion in carcinogenesis - an appraisal So Cancer Surveys 1983;2
- \* 286. Davidson KA, Slaga TJ. Effects of phorbol ester tumor promoters and hyperplasiogenic agents on cytoplasmic glucocorticoid receptors in epidermis. J Invest Dermatol 1982 Dec;79(6):378-382.
- \* 287. Buhler DR, Unlu F, Thakker DR, Slaga TJ, Newman MS, Levin W, Conney AH, Jerina DM. Metabolism and tumorigenicity of 7-, 8-, 9-, and 10-fluorobenzo(a)pyrenes. Cancer Res 1982 Nov;42(11):4779-4783.
- \* 288. Weeks CE, Herrmann AL, Nelson FR, Slaga TJ. alpha-Difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits tumor promoter-induced polyamine accumulation and carcinogenesis in mouse skin. Proc Natl Acad Sci U S A 1982 Oct;79(19):6028-6032.
- \* 289. Nelson KG, Slaga TJ. Keratin modifications in epidermis, papillomas, and carcinomas during two-stage carcinogenesis in the SENCAR mouse. Cancer Res 1982 Oct;42(10):4176-4181.
- \* 290. Nelson KG, Stephenson KB, Slaga TJ. Protein modifications induced in mouse epidermis by potent and weak tumor-promoting hyperplasiogenic agents. Cancer Res 1982 Oct;42(10):4164-4175.
- \* 291. Wood AW, Levin W, Chang RL, Conney AH, Slaga TJ, O'Malley RF, Newman MS, Buhler DR, Jerina DM. Mouse skin tumor-initiating activity of 5-, 7-, and 12-methyl- and fluorine-substituted benz[a]anthracenes. J Natl Cancer Inst 1982 Sep;69(3):725-728.
- \* 292. Solanki V, Logani MK, Slaga TJ. Effect of tunicamycin on receptors for tumor promoters. Cancer Lett 1982 Sep;16(3):319-325.

- \* 293. Miller DR, Hamby KM, Slaga TJ. Contact-stimulated proliferation of cultured mouse epidermal cells by 3T3 feeder layers: inhibition of proliferation by 12-O-tetradecanoylphorbol-13-acetate (TPA). J Cell Physiol 1982 Jul;112(1):76-82.
- \* 294. Klein-Szanto AJ, Slaga TJ. Effects of peroxides on rodent skin: epidermal hyperplasia and tumor promotion. J Invest Dermatol 1982 Jul;79(1):30-34.
- \* 295. DiGiovanni J, Miller DR, Singer JM, Viaje A, Slaga TJ. Benzo(a)pyrene metabolism in primary cultures of mouse epidermal cells and untransformed and transformed epidermal cell lines. Cancer Res 1982 Jul;42(7):2579-2586.
- \* 296. Nesnow S, Triplett LL, Slaga TJ. Comparative tumor-initiating activity of complex mixtures from environmental particulate emissions on SENCAR mouse skin. J Natl Cancer Inst 1982 May;68(5):829-834.
- \* 297. Fischer SM, Nelson KD, Reiners JJ, Viaje A, Pelling JC, Slaga TJ. Separation of epidermal cells by density centrifugation: a new technique for studies on normal and pathological differentiation. J Cutan Pathol 1982 Feb;9(1):43-49.
- \* 298. Slaga TJ, Fischer SM, Triplett LL, Nesnow S. Comparison of complete carcinogenesis and tumor initiation and promotion in mouse skin: The induction of papillomas by tumor initiation-promotion. A reliable short term assay. J Am College Toxicol 1982;1:83-99.
- \* 299. Kootstra A, MacLeod MC, Iyer R, Selkirk JD, Slaga JT. Selective modification of nuclear proteins by polycyclic aromatic hydrocarbons and by benzo(a)pyrene diol-epoxides Carcinogenesis 1982;3:821-824.
- \* 300. DiGiovanni J, Rymer J, Slaga TJ, Boutwell RK. Anticarcinogenic and cocarcinogenic effects of benzo(a)pyrene and dibenz(a,c)anthracene on skin tumor initiation by polycyclic hydrocarbons Carcinogenesis 1982:371-375.
- \* 301. Nelson KG, Slaga TJ. Effects of inhibitors of tumor promotion on 12-O-tetradecanoyl-phorbol-13-acetate induced keratin modification in mouse epidermis Carcinogenesis 1982;3:1311-1315.
- \* 302. DiGiovanni J, Diamond L, Singer JM, Daniel FB, Witiak DT, Slaga JT. Tumor-initiating activity of 4-fluoro-7, 12-dimethylbenz(a)anthracene and 1,2,3,4-tetrahydro-7,12-dimethylbenz(a)anthracene in female Sencar mice Carcinogenesis 1982;3:651-655.
- \* 303. Slaga TJ, Fischer SM, Weeks CE, Klein-Szanto AJP, Reiners JJ. Studies on the mechanisms involved in multistage carcinogenesis in mouse skin J Cellular Biochem 1982;18:99-119.
- \* 304. Raveh D, Slaga TJ, Huberman E. Cell-mediated mutagenesis and tumor initiating activity of the ubiquitous polycyclic hydrocarbon, cyclopenta (c,d) pyrene Carcinogenesis 1982;3:763-766.
- \* 305. Logani MK, Solanki V, Slaga TJ. Effect of tumor promoters on lipid peroxidation in mouse skin Carcinogenesis 1982;3(11):1303-1306.

- \* 306. Slaga TJ. Multistage chemical carcinogenesis in mouse skin: A rational approach to the mechanisms involved and cancer prevention Gann 1982;9:1715-1719.
- \* 307. Iyer RP, Slaga TJ, Pal BC. Preparation of enantiomers of ( ) - trans 7,8-dihydroxy-9, 10 epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene Indian J Chem 1982;21B:275-278.
- \* 308. Pelling JC, Slaga TJ. Comparison of levels of benzo(a)pyrene diol epoxide diastereomers covalently bound in vivo to macromolecular components of the whole epidermis versus the basal cell layer Carcinogenesis 1982;3(10):1135-1141.
- \* 309. Nesnow S, Evans C, Slaga TJ. Skin carcinogenesis studies of emission extracts Dev Toxicol Environ Sci 1982;10:320
- \* 310. Fischer SM, Mills GD, Slaga TJ. Inhibition of mouse skin tumor promotion by several inhibitors of arachidonic acid metabolism Carcinogenesis 1982;3:1243-1245.
- \* 311. Solanki V, Slaga TJ. The down-modulation of receptors for phorbol ester tumor promoter in primary epidermal cells Carcinogenesis 1982;3:993-998.
- \* 312. Argyris TS, Slaga TJ. Promotion of carcinomas by repeated abrasion in initiated skin of mice. Cancer Res 1981 Dec;41(12 Pt):5193-5195.
- \* 313. Klein-Szanto AJ, Slaga TJ. Numerical variation of dark cells in normal and chemically induced hyperplastic epidermis with age of animal and efficiency of tumor promoter. Cancer Res 1981 Nov;41(11 Pt):4437-4440.
- \* 314. MacLeod MC, Kootstra A, Mansfield BK, Slaga TJ, Selkirk JK. Binding of benzo(a)pyrene derivatives to specific proteins in nuclei of intact hamster embryo cells. Cancer Res 1981 Oct;41(10):4080-4086.
- \* 315. Slaga TJ, Klein-Szanto AJ, Triplett LL, Yotti LP, Trosko KE. Skin tumor-promoting activity of benzoyl peroxide, a widely used free radical-generating compound. Science 1981 Aug;213(4511):1023-1025.
- \* 316. Solanki V, Slaga TJ. Specific binding of phorbol ester tumor promoters to intact primary epidermal cells from Sencar mice. Proc Natl Acad Sci U S A 1981 Apr;78(4):2549-2553.
- \* 317. Solanki V, Slaga TJ, Callahan M, Huberman E. Down regulation of specific binding of [20-3H]phorbol 12,13-dibutyrate and phorbol ester-induced differentiation of human promyelocytic leukemia cells. Proc Natl Acad Sci U S A 1981 Mar;78(3):1722-1725.
- \* 318. Hennings H, Devor D, Wenk ML, Slaga TJ, Former B, Colburn NH, Bowden GT, Eljjo K, Yuspa SH. Comparison of two-stage epidermal carcinogenesis initiated by 7,12-dimethylbenz(a)anthracene or N-methyl-N'-nitro-N-nitrosoguanidine in newborn and adult SENCAR and BALB/c mice. Cancer Res 1981 Mar;41(3):773-779.
- \* 319. Slaga TJ, Triplett L, Nesnow S. Mutagenic and carcinogenic potency of extracts of

diesel and related environmental emissions: Two stage carcinogenesis in skin tumor sensitive mice Environ Intl 1981;5:417-423.

- \* 320. Huberman E, Weeks C, Herrmann A, Callaham M, Slaga TJ. Alterations in polyamine levels induced by phorbol diesters and other agents that promote differentiation in human promyelocytic leukemia cells Proc Natl Acad Sci USA 1981;78:1062-1066.
- \* 321. Solanki V, Rana RS, Slaga TJ. Diminution of mouse epidermal superoxide dismutase and catalase activity by tumor promoters Carcinogenesis 1981;2:1141-1146.
- \* 322. Weeks CE, Slaga TJ, Herrmann AL, McKeown CK, Huberman E. Involvement of the polyamines in cell growth and differentiation in cultured Friend Erythroleukemia cells Carcinogenesis 1981;2:612-733.
- \* 323. Slaga TJ. Studies on the mechanisms of action of modifiers of skin carcinogenesis Proc US-Polish Conference on Carcinogenesis and Mutagenesis, Postepz Mikrobiologii 1981;20:113-129.
- \* 324. MacLeod MC, Kootstra A, Mansfield BK, Slaga TJ, Selkirk JK. Specificity in interaction of benzo[a]pyrene with nuclear macromolecules: implication of derivatives of two dihydrodiols in protein binding. Proc Natl Acad Sci U S A 1980 Nov;77(11):6396-6400.
- \* 325. Levin W, Buening MK, Wood AW, Chang RL, Kedzierski B, Thakker DR, Boyd DR, Gadaginamath GS, Armstrong RN, Yagi H, Karle JM, Slaga TJ, Jerina DM, Conney AH. An enantiomeric interaction in the metabolism and tumorigenicity of (+)- and (-)-benzo[a]pyrene 7,8-oxide. J Biol Chem 1980 Oct;255(19):9067-9074.
- \* 326. Fischer SM, Gleason GL, Mills GD, Slaga TJ. Indomethacin enhancement of TPA tumor promotion in mice. Cancer Lett 1980 Oct;10(4):343-350.
- \* 327. Miller DR, Hamby KM, Allison DP, Fischer SM, Slaga TJ. The maintenance of a differentiated state in cultured mouse epidermal cells. Exp Cell Res 1980 Sep;129(1):63-71.
- \* 328. Kootstra A, Shah YB, Slaga TJ. Binding of B[a]P diol-epoxide (anti) to nucleosomes containing high mobility group proteins. FEBS Lett 1980 Jul;116(1):62-66.
- \* 329. Verma AK, Slaga TJ, Wertz PW, Mueller GC, Boutwell RK. Inhibition of skin tumor promotion by retinoic acid and its metabolite 5,6-epoxyretinoic acid. Cancer Res 1980 Jul;40(7):2367-2371.
- \* 330. Kootstra A, Haas BL, Slaga TJ. Reactions of benzo[pa]pyrene diol-epoxides with DNA and nucleosomes in aqueous solutions. Biochem Biophys Res Commun 1980 Jun;94(4):1432-1438.
- \* 331. Slaga TJ, Gleason GL, Mills G, Ewald L, Fu PP, Lee HM, Harvey RG. Comparison of the skin tumor-initiating activities of dihydrodiols and diol-epoxides of various polycyclic aromatic hydrocarbons. Cancer Res 1980 Jun;40(6):1981-1984.

- \* 332. Slaga TJ, Fischer SM, Nelson K, Gleason GL. Studies on the mechanism of skin tumor promotion: evidence for several stages in promotion. Proc Natl Acad Sci U S A 1980 Jun;77(6):3659-3663.
- \* 333. DiGiovanni J, Berry DL, Gleason GL, Kishore GS, Slaga TJ. Time-dependent inhibition by 2,3,7,8-tetrachlorodibenzo-p-dioxin of skin tumorigenesis with polycyclic hydrocarbons. Cancer Res 1980 May;40(5):1580-1587.
- \* 334. DiGiovanni J, Slaga TJ, Boutwell RK. Comparison of the tumor-initiating activity of 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene in female SENCAR and CS-1 mice. Carcinogenesis 1980 May;1(5):381-389.
- \* 335. Klein-Szanto AJ, Major SK, Slaga TJ. Induction of dark keratinocytes by 12-O-tetradecanoylphorbol-13-acetate and mezerein as an indicator of tumor-promoting efficiency. Carcinogenesis 1980 May;1(5):399-406.
- \* 336. Kootstra A, Slaga TJ. Binding of isomers of benzo[a]pyrene diol-epoxide to chromatin. Biochem Biophys Res Commun 1980 Apr;93(3):954-959.
- \* 337. Iyer RP, Lyga JW, Secrist JA, Daub GH, Slaga TJ. Comparative tumor-initiating activity of methylated benzo(a)pyrene derivatives in mouse skin. Cancer Res 1980 Apr;40(4):1073-1076.
- \* 338. Slaga TJ, Klein-Szanto AJ, Fischer SM, Weeks CE, Nelson K, Major S. Studies on mechanism of action of anti-tumor-promoting agents: their specificity in two-stage promotion. Proc Natl Acad Sci U S A 1980 Apr;77(4):2251-2254.
- \* 339. Fischer SM, Viaje A, Harris KL, Miller DR, Bohrman JS, Slaga TJ. Improved conditions for murine epidermal cell culture. In Vitro 1980 Feb;16(2):180-188.
- \* 340. Fischer SM, Gleason GL, Slaga TJ. Prostaglandin enhancement of skin tumor initiation and promotion Adv Prostaglandin Thromboxane Res 1980;6:517-522.
- \* 341. Fischer SM, Viaje A, Slaga TJ. Explant methods for epidermal cell culture Methods Cell Biol 1980:207-227.
- \* 342. DiGiovanni J, Viaje A, Fischer S, Slaga TJ, Boutwell RK. Biotransformation of 7,12-dimethylbenz(a)anthracene by mouse epidermal cells in culture Carcinogenesis 1980;1:41-49.
- \* 343. Fischer SM, Gleason GL, Hardin LG, Bohrman JS, Slaga TJ. Prostaglandin modulation of phorbol ester skin tumor promotion Carcinogenesis 1980;1:242-248.
- \* 344. Slaga TJ, Fischer SM. Multistage chemical carcinogenesis in mouse skin Curr Probl Dermatol 1980;10:218
- \* 345. Moore CJ, McClusky GA, Fischer SM, MacLeod MC, Slaga TJ, Selkirk JK. Metabolism of carcinogenic 2-hydroxybenzo(a)pyrene in rodent and human cells Carcinogenesis 1980;1:979-987.

- \* 346. Weeks CE, Slaga TJ. Inhibition of phorbol ester-induced polyamine accumulation in mouse epidermis by anti-inflammatory steroid. Biochem Biophys Res Commun 1979 Dec;91(4):1488-1496.
- \* 347. Kootstra A, Slaga TJ. Differential accessibility of (+/-) trans-7 beta, 8 alpha-dihydroxy-9 alpha, 10 alpha-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene to histone proteins. FEBS Lett 1979 Dec;108(2):321-325.
- \* 348. Mufson RA, Fischer SM, Verma AK, Gleason GL, Slaga TJ, Boutwell RK. Effects of 12-O-tetradecanoylphorbol-13-acetate and mezerein on epidermal ornithine decarboxylase activity, isoproterenol-stimulated levels of cyclic adenosine 3':5'-monophosphate, and induction of mouse skin tumors in vivo. Cancer Res 1979 Dec;39(12):4791-4795.
- \* 349. Kootstra A, Slaga TJ, Olins DE. Interaction of benzo[alpha]pyrene diol-epoxide with nuclei and isolated chromatin. Chem Biol Interact 1979 Dec;28(2-3):225-236.
- \* 350. Weeks CE, Rao TK, Young JA, Slaga TJ, Epler JL. Effect of weak-, non-, and co-carcinogenic chemicals on 2-acetylaminofluorene-induced mutation in Salmonella typhimurium. Toxicology 1979 Nov;14(3):255-262.
- \* 351. Cohen GM, Bracken WM, Iyer RP, Berry DL, Selkirk JK, Slaga TJ. Anticarcinogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on benzo(a)pyrene and 7,12-dimethylbenz(a)anthracene tumor initiation and its relationship to DNA binding. Cancer Res 1979 Oct;39(10):4027-4033.
- \* 352. DiGiovanni J, Berry DL, Slaga TJ, Jones AH, Juchau MR. Effects of pretreatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin on the capacity of hepatic and extrahepatic mouse tissues to convert procarcinogens to mutagens for Salmonella typhimurium auxotrophs. Toxicol Appl Pharmacol 1979 Sep;50(2):229-239.
- \* 353. Weeks CE, Slaga TJ, Hennings H, Gleason GL, Bracken WM. Inhibition of phorbol ester-induced tumor promotion in mice by vitamin A analog and anti-inflammatory steroid. J Natl Cancer Inst 1979 Aug;63(2):401-406.
- \* 354. Slaga TJ, Gleason GL, Hardin L. Comparison of the skin tumor initiating activity of 3-methylcholanthrene and 3,11-dimethylcholanthrene in mice. Cancer Lett 1979 Jul;7(2-3):97-102.
- \* 355. Slaga TJ, Jecker L, Bracken WM, Weeks CE. The effects of weak or non-carcinogenic polycyclic hydrocarbons on 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene skin tumor-initiation. Cancer Lett 1979 Jun;7(1):51-59.
- \* 356. DiGiovanni J, Romson JR, Linville D, Juchau MR, Slaga TJ. Covalent binding of polycyclic aromatic hydrocarbons to adenine correlates with tumorigenesis in mouse skin. Cancer Lett 1979 Jun;7(1):39-43.
- \* 357. Slaga TJ, Gleason GL, DiGiovanni J, Sukumaran KB, Harvey RG. Potent tumor-

initiating activity of the 3,4-dihydrodiol of 7,12-dimethylbenz(a)anthracene in mouse skin. Cancer Res 1979 Jun;39(6 Pt):1934-1936.

- \* 358. Berry DL, Slaga TJ, DiGiovanni J, Juchau MR. Studies with chlorinated dibenzo-p-dioxins, polybrominated biphenyls, and polychlorinated biphenyls in a two-stage system of mouse skin tumorigenesis: potent anticarcinogenic effects. Ann N Y Acad Sci 1979 May;320:405-414.
- \* 359. Slaga TJ, Huberman E, DiGiovanni J, Gleason G, Harvey RG. The importance of the "bay region" diol-epoxide in 7,12-dimethylbenz[a]anthracene skin tumor initiation and mutagenesis. Cancer Lett 1979 Apr;6(4-5):213-220.
- \* 360. DiGiovanni J, Berry DL, Juchau MR, Slaga TJ. 2,3,7,8-Tetrachlorodibenzo-P-dioxin: potent anticarcinogenic activity in CD-1 mice. Biochem Biophys Res Commun 1979 Feb;86(3):577-584.
- \* 361. Huberman E, Slaga TJ. Mutagenicity and tumor-initiating activity of fluorinated derivatives of 7,12-dimethylbenz(a)anthracene. Cancer Res 1979 Feb;39(2 Pt):411-414.
- \* 362. Slaga TJ, Bracken WJ, Gleason G, Levin W, Yagi H, Jerina DM, Conney AH. Marked differences in the skin tumor-initiating activities of the optical enantiomers of the diastereomeric benzo(a)pyrene 7,8-diol-9,10-epoxides. Cancer Res 1979 Jan;39(1):67-71.
- \* 363. Rao TK, Young JA, Weeks CE, Slaga TJ, Epler JL. Effect of the cocarcinogen benzo(e)pyrene on microsome-mediated chemical mutagenesis in *Salmonella typhimurium* Environmental Mutagenesis 1979;1:105-112.
- \* 364. Berry DL, Bracken WM, Fischer SM, Viaje A, Slaga TJ. Metabolic conversion of 12-O-tetradecanoylphorbol-13-acetate in adult and newborn mouse skin and mouse liver microsomes. Cancer Res 1978 Aug;38(8):2301-2306.
- \* 365. Slaga TJ, Viaje A, Bracken WM, Buty SG, Miller DR, Fischer SM, Richter CK, Dumont JN. In vitro transformation of epidermal cells from newborn mice. Cancer Res 1978 Aug;38(8):2246-2252.
- \* 366. Slaga TJ, Bracken WM, Viaje A, Berry DL, Fischer SM, Miller DR. Lack of involvement of 6-hydroxymethylation in benzo[a]pyrene skin tumor initiation in mice. J Natl Cancer Inst 1978 Aug;61(2):451-455.
- \* 367. DiGiovanni J, Slaga TJ, Viaje A, Berry DL, Harvey RG, Juchau MR. Effects of 7, 8-benzoflavone on skin tumor-initiating activities of various 7- and 12-substituted derivatives of 7, 12-dimethylbenz[a]anthracene in mice. J Natl Cancer Inst 1978 Jul;61(1):135-140.
- \* 368. Slaga TJ, Huberman E, Selkirk JK, Harvey RG, Bracken WM. Carcinogenicity and mutagenicity of benz(a)anthracene diols and diol-epoxides. Cancer Res 1978 Jun;38(6):1699-1704.

- \* 369. Berry DL, DiGiovanni J, Juchau MR, Bracken WM, Gleason GL, Slaga TJ. Lack of tumor-promoting ability of certain environmental chemicals in a two-stage mouse skin tumorigenesis assay. Res Commun Chem Pathol Pharmacol 1978 Apr;20(1):101-108.
- \* 370. Slaga TJ, Bracken WM, Dresner S, Levin W, Yagi H, Jerina DM, Conney AH. Skin tumor-initiating activities of the twelve isomeric phenols of benzo(a)pyrene. Cancer Res 1978 Mar;38(3):678-681.
- \* 371. Slaga TJ, Viaje A, Buty SG, Bracken WM. Dibenz[a,c]anthracene: a potent inhibitor of skin-tumor initiation by 7,12-dimethylbenz[a]anthracene. Res Commun Chem Pathol Pharmacol 1978 Mar;19(3):477-483.
- \* 372. Slaga TJ, Lichti U, Hennings H, Elgjo K, Yuspa SH. Effects of tumor promoters and steroidal anti-inflammatory agents on skin of newborn mice in vivo and in vitro. J Natl Cancer Inst 1978 Feb;60(2):425-431.
- \* 373. Slaga TJ, Bracken WM, Viaje A, Levin W, Yagi H, Jerina DM, Conney AH. Comparison of the tumor-initiating activities of benzo(a)pyrene arene oxides and diol-epoxides. Cancer Res 1977 Nov;37(11):4130-4133.
- \* 374. DiGiovanni J, Viaje A, Berry DL, Slaga TJ, Juchau MR. Tumor-initiating ability of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and Arochlor 1254 in the two-stage system of mouse skin carcinogenesis. Bull Environ Contam Toxicol 1977 Nov;18(5):552-557.
- \* 375. Berry DL, Lieber MR, Fischer SM, Slaga TJ. Qualitative and quantitative separation of a series of phorbol-ester tumor promoters by high-pressure liquid chromatography. Cancer Lett 1977 Sep;3(3-4):125-132.
- \* 376. Lichti U, Slaga TJ, Ben T, Patterson E, Hennings H, Yuspa SH. Dissociation of tumor promoter-stimulated ornithine decarboxylase activity and DNA synthesis in mouse epidermis in vivo and in vitro by fluocinolone acetonide, a tumor-promotion inhibitor. Proc Natl Acad Sci U S A 1977 Sep;74(9):3908-3912.
- \* 377. Slaga TJ, Buty SG, Thompson S, Bracken WM, Viaje A. A kinetic study on the in vitro covalent binding of polycyclic hydrocarbons to nucleic acids using epidermal homogenates as the activating system. Cancer Res 1977 Sep;37(9):3126-3131.
- \* 378. Berry DL, Slaga TJ, Wilson NM, Zachariah PK, Namkung MJ, Bracken WM, Juchau MR. Transplacental induction of mixed-function oxygenases in extra-hepatic tissues by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Pharmacol 1977 Aug;26(15):1383-1388.
- \* 379. Berry DL, Bracken WR, Slaga TJ, Wilson NM, Butty SG, Juchau MR. Benzo(a)pyrene metabolism in mouse epidermis. Analysis by high pressure liquid chromatography and DNA binding. Chem Biol Interact 1977 Aug;18(2):129-142.
- \* 380. Levin W, Wood AW, Chang RL, Slaga TJ, Yagi H, Jerina DM, Conney AH. Marked differences in the tumor-initiating activity of optically pure (+)- and (-)-trans-7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene on mouse skin. Cancer Res 1977 Aug;37(8

Pt):2721-2725.

- \* 381. Slaga TJ, Viaje A, Bracken WM, Berry DL, Fischer SM, Miller DR, Leclerc SM. Skin-tumor-initiating ability of benzo(a)pyrene-7,8-diol-9,10-epoxide (anti) when applied topically in tetrahydrofuran. Cancer Lett 1977 Jul;3(1-2):23-30.
- \* 382. Berry DL, Zachariah PK, Slaga TJ, Juchau MR. Analysis of the biotransformation of benzo [a] pyrene in human fetal and placental tissues with high-pressure liquid chromatography. Eur J Cancer 1977 Jul;13(7):667-675.
- \* 383. Zachariah PK, Slaga TJ, Berry DL, Bracken WM, Buty SG, Martinsen CM, Juchau MR. The ability of enteric bacteria to catalyze the covalent binding of bile acids and cholesterol to DNA and their in ability to metabolize benzo(a)pyrene to a binding product and to known metabolites. Cancer Lett 1977 Jul;3(1-2):99-105.
- \* 384. Schwarz JA, Viaje A, Slaga TJ. Fluocinolone acetonide: a potent inhibitor of mouse skin tumor promotion and epidermal DNA synthesis. Chem Biol Interact 1977 Jun;17(3):331-347.
- \* 385. Slaga TJ, Thompson S, Berry DL, Digiovanni J, Juchau MR, Viaje A. The effects of benzoflavones on polycyclic hydrocarbon metabolism and skin tumor initiation. Chem Biol Interact 1977 Jun;17(3):297-312.
- \* 386. Slaga TJ, Bracken WM. The effects of antioxidants on skin tumor initiation and aryl hydrocarbon hydroxylase. Cancer Res 1977 Jun;37(6):1631-1635.
- \* 387. Slaga TJ, Thompson S, Schwarz JA. Binding of dexamethasone by the subcellular fractions of mouse epidermis and dermis. J Invest Dermatol 1977 May;68(5):307-309.
- \* 388. Viaje A, Slaga TJ, Wigler M, Weinstein IB. Effects of antiinflammatory agents on mouse skin tumor promotion, epidermal DNA synthesis, phorbol ester-induced cellular proliferation, and production of plasminogen activator. Cancer Res 1977 May;37(5):1530-1536.
- \* 389. Berry DL, Slaga TJ, Viaje A, Wilson NM, DiGiovanni J, Juchau MR, Selkirk JK. Effect of trichloropropene oxide on the ability of polyaromatic hydrocarbons and their "K-region" oxides to initiate skin tumors in mice and to bind to DNA in vitro. J Natl Cancer Inst 1977 Apr;58(4):1051-1055.
- \* 390. Slaga TJ, Viaje A, Bracken W. The effects of anti-inflammatory agents on skin tumor initiation and aryl hydrocarbon hydroxylase. Res Commun Chem Pathol Pharmacol 1977 Feb;16(2):337-350.
- \* 391. Slaga TJ, Boutwell RK. Inhibition of the tumor-initiating ability of the potent carcinogen 7,12-dimethylbenz(a)anthracene by the weak tumor initiator 1,2,3,4-dibenzanthracene. Cancer Res 1977 Jan;37(1):128-133.
- \* 392. DiGiovanni J, Slaga TJ, Berry DL, Jachau MR. Metabolism of 7,12-dimethylbenz(a)anthracene in mouse skin homogenates analyzed with high pressure

liquid chromatography Drug Metabolism and Disposition 1977;5:295-301.

- \* 393. Slaga TJ, Viaje A, Betty DL, Brachen W, Buty SG, Scribner JD. Skin tumor initiating ability of benzo(a)pyrene 4,5- 7,5- and 7,8-diol-9,10-epoxides and 7,8-diol. Cancer Lett 1976 Nov;2(2):115-121.
- \* 394. Slaga TJ, Scribner JD, Viaje A. Epidermal cell proliferation and promoting ability of phorbol esters. J Natl Cancer Inst 1976 Nov;57(5):1145-1149.
- \* 395. Slaga TJ, Krum AA. The influence of prolonged ACTH treatment on rat adrenal steroidogenesis. Res Commun Chem Pathol Pharmacol 1976 Oct;15(2):279-290.
- \* 396. Yuspa SH, Lichti U, Ben T, Patterson E, Hennings H, Slaga TJ, Colburn N, Kelsey W. Phorbol esters stimulate DNA synthesis and ornithine decarboxylase activity in mouse epidermal cell cultures. Nature 1976 Jul;262(5567):402-404.
- \* 397. Buty SG, Thompson S, Slaga TJ. The role of epidermal aryl hydrocarbon hydroxylase in the covalent binding of polycyclic hydrocarbon to DNA and its relationship to tumor initiation. Biochem Biophys Res Commun 1976 Jun;70(4):1102-1108.
- \* 398. Thompson S, Slaga TJ. The effects of dexamethasone on mouse skin initiation and aryl hydrocarbon hydroxylase. Eur J Cancer 1976 May;12(5):363-370.
- \* 399. Thompson S, Slaga TJ. Mouse epidermal aryl hydrocarbon hydroxylase. J Invest Dermatol 1976 Feb;66(02):108-111.
- \* 400. Slaga TJ, Bowden GT, Boutwell RK. Acetic acid, a potent stimulator of mouse epidermal macromolecular synthesis and hyperplasia but with weak tumor-promoting ability. J Natl Cancer Inst 1975 Oct;55(4):983-987.
- \* 401. Slaga TJ, Thompson S, Smuckler EA. Prolonged inhibition of mouse epidermal DNA synthesis by dexamethasone. J Natl Cancer Inst 1975 Apr;54(4):931-936.
- \* 402. Scribner JD, Slaga TJ. Tumor initiation by N-acyloxy derivatives of piperidine and N-arylacetamides. J Natl Cancer Inst 1975 Feb;54(2):491-493.
- \* 403. Slaga TJ, Bowden GT, Scribner JD, Boutwell RK. Dose-response studies on the ability of 7,12-dimethylbenz(alpha)anthracene and benz(alpha)anthracene to initiate skin tumors. J Natl Cancer Inst 1974 Nov;53(5):1337-1340.
- \* 404. Slaga TJ, Das SB, Rice JM, Thompson S. Fractionation of mouse epidermal chromatin components. J Invest Dermatol 1974 Oct;63(4):343-349.
- \* 405. Bowden GT, Slaga TJ, Shapas BG, Boutwell RK. The role of aryl hydrocarbon hydroxylase in skin tumor initiation by 7,12-dimethylbenz(a)anthracene and 1,2,5,6-dibenzanthracene using DNA binding and thymidine-3H incorporation into DNA as criteria. Cancer Res 1974 Oct;34(10):2634-2642.

- \* 406. Scribner JD, Slaga TJ. Influence of nonsteroid anti-inflammatory agents on protein synthesis and hyperplasia caused by a tumor promoter. J Natl Cancer Inst 1974 Jun;52(6):1865-1868.
- \* 407. Slaga TJ, Scribner JD, Rice JM, Das SB, Thompson S. Inhibition by dexamethasone of intracellular binding of phorbol esters to mouse skin. J Natl Cancer Inst 1974 May;52(5):1611-1618.
- \* 408. Slaga TJ, Bowden GT, Shapas BG, Boutwell RK. Macromolecular synthesis following a single application of polycyclic hydrocarbons used as initiators of mouse skin tumorigenesis. Cancer Res 1974 Apr;34(4):771-777.
- \* 409. Slaga TJ, Scribner JD. Inhibition of tumor initiation and promotion by anti-inflammatory agents. J Natl Cancer Inst 1973 Nov;51(5):1723-1725.
- \* 410. Slaga TJ, Krum AA. Aldosterone biosynthesis from 4-14C-pregnenolone and 4-14C-progesterone, in the rat and rabbit. Proc Soc Exp Biol Med 1973 Sep;143(4):1201-1206.
- \* 411. Slaga TJ, Krum AA. Modification of rabbit adrenal steroid biosynthesis by prolonged ACTH administration. Endocrinology 1973 Sep;93(3):517-526.
- \* 412. Slaga TJ, Scribner JD, Rice JM. In vitro binding of labeled 20-methylcholanthrene to a specific cytosol-protein. Chem Biol Interact 1973 Jul;7(1):51-62.
- \* 413. Slaga TJ, Scribner JD, Rice JM. Physical binding of labeled 20-methylcholanthrene to mouse epidermal subcellular fractions. Cancer Res 1973 May;33(5):1032-1037.
- \* 414. Slaga TJ, Bowden GT, Shapas BG, Boutwell RK. Macromolecular synthesis following a single application of alkylating agents used as initiators of mouse skin tumorigenesis. Cancer Res 1973 Apr;33(4):769-776.
- \* 415. Scribner JD, Slaga TJ. Multiple effects of dexamethasone on protein synthesis and hyperplasia caused by a tumor promoter. Cancer Res 1973 Mar;33(3):542-546.
- \* 416. Stokely PS, Slaga TJ, Brown TC, Kuchan F. The distribution of fresh water triclad planarians in Jefferson County, Ohio The Ohio Journal of Science 1965;65:305
- \* 417. Johnson W, Slaga TJ. Final report on the safety assessment of Elaeis Guineensis (palm) oil, Elaeis Guineensis (palm) kernal oil, hydrogenated palm oil and hydrogenated palmm kernal oil Int J Toxicol

### **Review Article**

- \* 1. Walaszek Z, Hanausek M, Slaga TJ. Combined natural source inhibitors in skin cancer prevention Cellscience Reviews 2005;1(3)
- \* 2. Slaga TJ, Barrett JC, DiGiovanni J. Introducing emerging technologies Molecular Carcinogenesis 1999;25(2)-85.

- \* 3. Slaga TJ. Tumor promotion and/or enhancement models Int J Toxicol 1998;17(3):109-127.
- \* 4. Slaga TJ, Hanausek M, Morizot D, Walaszek Z. The importance of animal models in understanding human carcinogenesis and its chemoprevention Cancer Bull 1995;47:438-444.
- \* 5. DiGiovanni J, Slaga TJ. Carcinogenesis Cancer Bulletin 1995;47:432-433.
- \* 6. Slaga TJ. Inhibition of the induction of cancer by antioxidants Adv Exp Med Biol 1995;369:167-174.
- \* 7. Slaga TJ. Inhibition of skin tumor initiation, promotion, and progression by antioxidants and related compounds Crit Rev Food Sci Nutr 1995;35(1-2):51-57.
- \* 8. Slaga TJ. Fifty years of the University of Texas MD Anderson Cancer Center and the study of carcinogenesis Molecular Carcinogenesis 1991;4:417-418.
- \* 9. Slaga TJ. Critical events in skin tumor promotion and progression Basic Life Sci 1991;57:19-29.
- \* 10. Slaga TJ. Overview of tumor promotion in animals. Environ Health Perspect 1983 Apr;50:3-14.
- \* 11. Slaga TJ. Host factors in the susceptibility of mice to tumor initiating and promoting agents IARC Sci Publ 1983;51:257-273.
- \* 12. Montesano R, Slaga TJ. Initiation and promotion in carcinogenesis: An appraisal. Cancer Surveys, Vol. 2 1983;4:613-621.
- \* 13. Fischer SM, Mills GD, Slaga TJ. Modulation of skin tumor promotion by inhibitors of arachidonic-acid metabolism Advances in Prostaglandin Thromboxane and Leukotriene Research 1983;12
- \* 14. Slaga TJ. Anti-inflammatory steroids: Potent inhibitors of tumor promotion Carcinog Compr Surv 1980;5:111-126.

#### **PRESENTATIONS:**

- 10/2015 Phytonutrients related to the prevention of obesity, diabetes and cancer, Thailand Congress of Nutrition, Bangkok, Thailand (Keynote Speaker)
- 01/2015 In pursuit of an effective anti-inflammatory and anti-cancer agent, Distinguished Lecture Series, Texas Tech University School of Medicine, El Paso, TX (Invited Speaker)
- 10/2013 In pursuit of an effective anti-inflammatory and anti-cancer agent, Distinguished Lecture

Series, University of Texas Pan American, Edinburg, TX (Invited Speaker)

09/2010 Phytonutrients Related to Cancer Prevention, Thailand Congress of Nutrition, Bangkok, Thailand (Keynote Speaker)

09/2010 Prevention of Obesity, Diabetes and Cancer, FDA, Thailand (Invited Speaker)

**Details:** *Invited to present Special Lecture*

09/2010 Cancer Prevention, Chulalongkorn Research Institute, Bangkok, Thailand (Invited Speaker)

**Details:** *Special Lecture*

04/2009 Can We Really Prevent Cancer with Diet and Physical Activity?, Cellular Energy Metabolism and Cancer Symposium, UT MD Anderson Cancer Center, Houston, TX (Invited Speaker)

**Details:** *Organizer and speaker*

10/2008 Phytonutrients and Cancer Prevention, 7th International Conference on Phytochemicals, Health Promotion and Therapeutic Potential, Nutriline Health Institute, Buena Park, CA (Invited Speaker)

07/2007 Chronic Inflammation and Cancer, Aspen Cancer Conference, Aspen, CO (Invited Speaker)

**Details:** *Invited Chair*

07/2006 Hormones and Cancer, Aspen Cancer Conference, Aspen, CO (Invited Speaker)

05/2005 Mechanisms Involved in Cancer Prevention, ISCAP Symposium in Cancer Prevention, Kyoto, Japan (Invited Speaker)

05/2005 Glucocorticoids and Cancer Prevention, University of Ryukyuo, Okinawa, Japan (Invited Speaker)

02/2005 Glucocorticoids and Cancer Prevention, SACI, University of Texas Health Science Center at San Antonio, San Antonio, TX (Invited Speaker)

02/2004 Glucocorticoids and Cancer Prevention, Nutrition Department, The University of Texas at Austin, Austin, TX (Invited Speaker)

06/2003 Lung Cancer: Early Events, Early Interventions, Thomas L. Petty Aspen Lung Conference, 46th Annual Meeting, Aspen, CO (Invited Speaker)

08/2001 Nutrients and Gene Expression in Cancer, American Chemical Society Annual Meeting, Chicago, IL (Invited Speaker)

- 07/2000 Glucocorticoids are Potent Inhibitors of Skin Cancer, Fifteenth Aspen Cancer Conference, Workshop: Mechanisms of Toxicity, Carinogenesis and Cancer Prevention, Aspen, CO (Invited Speaker)
- 11/1998 Glucocorticoids are Potent Inhibitors of Skin Cancer, University of Colorado Comprehensive Cancer Center, CO (Invited Speaker)
- 11/1998 Glucocorticoids are Potent Inhibitors of Skin Cancer, School of Veterinary Medicine, Colorado State University, CO (Invited Speaker)
- 10/1998 Cancer Causation and Prevention, School of Pharmacy, University of Colorado Health Science Center, CO (Invited Speaker)
- 07/1998 Rational Approach to Cancer Prevention, Thirteenth Aspen Cancer Conference Workshop: Mechanisms of Toxicity and Carcinogenesis, Aspen, CO (Sole Presenter)
- 05/1997 Potent Inhibitors of Carcinogenesis, Faculty Retreat, College of Pharmacy, University of Texas at Austin, Austin, TX (Invited Speaker)
- 01/1997 Diet, Nutrition, and Cancer, 7th Charles Heidelberger Conference, Los Angeles, CA (Sole Presenter)
- 11/1996 Cancer Causation and Prevention, Rotary Club, Giddings, TX (Invited Speaker)
- 10/1996 Seminar Presentation, National Institute of Environmental Health Sciences, Research Triangle Park, NC (Invited Speaker)
- 10/1996 Cancer Prevention: Importance of Vitamins, Minerals, Antioxidants, and Other Phytochemicals, National Association of Retail Druggists 98th Annual Convention, New Orleans, LA (Sole Presenter)
- 06/1996 Cancer Prevention: Issues of Food vs. Supplements, Dietitian Oncology and Nutrition Education Program, "New Directions in Nutrition and Cancer, Houston, TX (Sole Presenter)
- 06/1996 Cellular and Molecular Changes during Multistage Skin Carcinogenesis, Registry of Comparative Pathology Symposium, "Oncogenes and Other Molecular Aspects of Cancers", St. Louis, MO (Sole Presenter)
- 04/1996 Cancer Causation and Prevention, Donor Appreciation Breakfast, American Cancer Society, Austin, TX (Invited Speaker)

- 10/1995 Cancer Causation and Prevention, Smithville High School, Smithville, TX (Invited Speaker)
- 10/1995 Critical Events in Skin Carcinogenesis, Argonne National Laboratory, Chicago, IL (Invited Speaker)
- 10/1995 Seminar Presentation, HESI Programs: Present and Future, Washington, DC (Sole Presenter)
- 09/1995 Multistage Skin Carcinogenesis, Tulane University, New Orleans, LA (Invited Speaker)
- 07/1995 Glucocorticoids are Potent Inhibitors of Skin Cancer, 44th Annual Symposium on the Biology of Skin, Snowmass, CO (Sole Presenter)
- 04/1995 Antioxidants are Potent Inhibitors of Skin Carcinogenesis, Phytochemical Conference, Research and Development, Nutrilite Products, Inc., Buena Park, CA (Sole Presenter)
- 02/1995 Peroxides as Tumor Promoters, 1995 Annual Winter Toxicology Forum, Washington, DC (Sole Presenter)
- 11/1994 Seminar Presentation, Meeting of Experts on the Effects of Low Frequency Magnetic Fields on Carcinogenesis, Cologne, Germany (Sole Presenter)
- 10/1994 Diet, Nutrition, and Cancer, Sports Nutrition Workshop, Amway World Headquarters, Ada, MI (Sole Presenter)
- 09/1994 Seminar Presentation, Drug Safety Subsection Workshop, Washington, DC (Sole Presenter)
- 05/1994 Seminar Presentation, Centre for International Meetings on Biology Workshop on Human Experimental Skin Carcinogenesis, Madrid, Spain (Sole Presenter)
- 02/1994 Seminar Presentation, Fifth Heidelberg Conference on Targets for Cancer Research: Prevention, Differentiation, Selective Therapy, Honolulu, HI (Sole Presenter)
- 01/1994 Glucocorticoids are Potent Inhibitors of Skin Cancer, Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA (Invited Speaker)
- 01/1994 Potent Inhibitors of Skin Carcinogenesis, American Health Foundation, White Plains, NY (Invited Speaker)
- 12/1993 Glucocorticoids and Skin Cancer, Department of Pathology, Baylor College of Medicine, Houston, TX (Invited Speaker)

- 12/1993 Growth Factors and Tumor Promotion, 7th International Conference on Carcinogenesis and Risk Assessment, Austin, TX (Sole Presenter)
- 12/1993 Nutrition and Biotechnology in Heart Disease and Cancer, Institute of Nutrition, University of North Carolina, Chapel Hill, NC (Sole Presenter)
- 11/1993 Oxidative Processes and Antioxidants: Their Relation to Nutrition and Health Outcomes, Thirteenth Ross Conference on Medical Research, Charleston, SC (Sole Presenter)
- 10/1993 Cellular and Molecular Mechanisms in Skin Carcinogenesis, Department of Cellular and Structural Biology, The University of Texas Health Science Center at San Antonio, San Antonio, TX (Invited Speaker)
- 08/1993 Cancer and Antioxidants: Biochemical Aspects, ILSI Workshop on Substantiation of the Impact of Nutrient and Nonnutrient Antioxidants on Health, Washington, DC (Sole Presenter)
- 07/1993 Cellular and Molecular Progression of Neoplasia, Eight Aspen Cancer Conference Workshop, Aspen, CO (Sole Presenter)
- 02/1993 Hamster Buccal Pouch, Chemoprevention of Premalignant Lesions of the Upper Aerodigestive Tract Workshop, NCI, Amelia Island, FL (Sole Presenter)
- 10/1992 Cellular and Molecular Mechanisms Involved in Skin Tumor Promotion and Progression, Environmental Skin Cancer: Models, Mechanisms and Human Relevance Conference, Cleveland, OH (Sole Presenter)
- 09/1992 Polycyclic Aromatic Hydrocarbon Carcinogenesis, 1992 Environmental Issues Conference, Exxon Corporation, Seabrook, TX (Sole Presenter)
- 07/1992 Benzoyl Peroxide Promotion Studies in Rodents, Toxicology Forum, Aspen, CO (Sole Presenter)
- 07/1992 Genetic Susceptibility to Carcinogenesis, Seventh Aspen Cancer Conference Workshop, Aspen, CO (Sole Presenter)
- 04/1992 Progressor Agents in Multistage Epidermal Carcinogenesis, FASEB, Anaheim, CA (Sole Presenter)
- 01/1992 Cell Proliferation and Chemical Carcinogenesis, ILSI Risk Science Institute, NIEHS, Research Triangle Park, NC (Sole Presenter)
- 11/1991 Chemical Carcinogenesis, M.D. Anderson Associates Steering Committee, University of Texas M.D. Anderson Cancer Center, Houston, TX (Invited Speaker)

- 11/1991 Skin Carcinogenesis, M.D. Anderson Public Affairs, University of Texas M.D. Anderson Cancer Center, Houston, TX (Invited Speaker)
- 09/1991 Molecular Mechanisms of Carcinogenesis in Humans and Rodents, International Symposium, NIEHS, Research Triangle Park, NC (Sole Presenter)
- 07/1991 Mechanisms Involved in Multistage Skin Carcinogenesis, PanAmerican Society for Pigment Cell Research 3rd Meeting, Edmonton, Canada (Sole Presenter)
- 07/1991 Molecular Mechanisms of Genetic Deregulation in Toxicity and Carcinogenesis, Sixth Aspen Cancer Conference, Aspen, CO (Sole Presenter)
- 06/1991 Cancer Causation and Prevention, Cancer Research Center, Tbilisi, Russia (Invited Speaker)
- 05/1991 Cancer Causation and Prevention, All-Union Cancer Research Centre, Moscow, Russia (Invited Speaker)
- 05/1991 Tumor Promotion and Progression II, American Association for Cancer Research 82nd Annual Meeting, Houston, TX (Sole Presenter)
- 04/1991 Cancers of the Aerodigestive Tract, Keystone Symposia on Molecular and Cellular Biology, Steamboat Springs, CO (Sole Presenter)
- 02/1991 Causation and Prevention of Head and Neck Cancer, Division of Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX (Invited Speaker)
- 02/1991 The Biology and Prevention of Aerodigestive Tract Cancers, Golden Jubilee Cancer Prevention Conference, University of Texas M.D. Anderson Cancer Center, Houston, TX (Sole Presenter)
- 10/1990 Critical Determinants in Skin Carcinogenesis, Argonne National Laboratory, Chicago, IL (Invited Speaker)
- 09/1990 The Molecular and Cellular Basis of Disease: Epithelial Differentiation and Neoplasia, First Annual Schweppe Colloquium, Northwestern University Cancer Center, Chicago, IL (Sole Presenter)
- 08/1990 Radiation and Skin Cancer, National Institute of Occupational Health, Stockholm, Sweden (Invited Speaker)
- 08/1990 Cancer Causation and Prevention, National Institute of Occupational Health, Helsinki, Finland

(Invited Speaker)

- 08/1990 Cancer Causation and Prevention, N. N. Petrov Research Institute of Oncology, Leningrad, Russia (Invited Speaker)
- 08/1990 Critical Determinants in Skin Tumor Promotion and Progression, 15th International Cancer Congress, Hamburg, Germany (Sole Presenter)
- 07/1990 Recent Advances in Genetic Deregulation, Toxicology, and Carcinogenesis, Fifth Aspen Cancer Conference, Aspen, CO (Sole Presenter)
- 06/1990 Seminar Presentation, Second FDA Cytokine/Growth Factor Workshop: Long-term Assessment, FDA, Bethesda, MD (Sole Presenter)
- 05/1990 The Role of Increased Cell Proliferation in Carcinogenesis, Genotoxicity and Environmental Mutagen (GEMS) Spring Symposium, Greensboro, NC (Sole Presenter)
- 02/1990 Cellular and Molecular Mechanisms in Skin Carcinogenesis, Department of Cell Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX (Invited Speaker)
- 02/1990 New Approach to the Inhibition of Tumor Progression, California Biotechnology, Inc., Mountain View, CA (Invited Speaker)
- 12/1989 Understanding the Mechanisms Involved in Carcinogenesis, Cancer Prevention Division, National Cancer Center, Tokyo, Japan (Invited Speaker)
- 12/1989 Cancer Causation and Prevention, Department of Oncological Pathology, Nara Medical College Cancer Center, Nara, Japan (Invited Speaker)
- 12/1989 Prevention of Environmentally Induced Cancer, Division of Toxicology, National Institute of Hygienic Science Biological Safety Research Center, Tokyo, Japan (Invited Speaker)
- 12/1989 Skin Carcinogenesis, First Department of Pathology, Gifu University School of Medicine, Gifu City, Japan (Invited Speaker)
- 12/1989 Mechanisms Induced in Tumor Promotion, Department of Pathology, Nagoya City University Medical School, Nagoya, Japan (Invited Speaker)
- 12/1989 Carcinogenesis and Chemotherapy - Cancer's Continuing Core Challenges, The Third Charles Heidelberger Symposium, Kyoto, Japan (Sole Presenter)
- 11/1989 Rational Approach to Cancer Prevention, M.D. Anderson Cancer Prevention Meeting,

University of Texas M.D. Anderson Cancer Center, Houston, TX (Invited Speaker)

- 11/1989 Cellular and Molecular Mechanisms of Skin Carcinogenesis, Department of Botany, University of Texas at Austin, Austin, TX (Invited Speaker)
- 11/1989 Prevention and Treatment of Cancer, Center for Biotechnology, Baylor College of Medicine, The Woodlands, TX (Invited Speaker)
- 11/1989 Chemically Induced Cell Proliferation: Implications for Risk Assessment, Barton Creek Conference, Austin, TX (Sole Presenter)
- 10/1989 Cellular and Molecular Mechanisms Involved in the Induction of Cancer, University of Arkansas for Medical Sciences, Little Rock, AK (Invited Speaker)
- 10/1989 Cellular and Molecular Aspects of Skin Carcinogenesis, Washington State University, Pullman, WA (Invited Speaker)
- 10/1989 Mechanisms Involved in Skin Tumor Promotion and Progression, Medical College of Ohio, Toledo, OH (Invited Speaker)
- 10/1989 Prostaglandins and Skin Cancer, First International Conference on Eicosanoids and Bioactive Lipids in Cancer and Radiation Injury, Detroit, MI (Sole Presenter)
- 09/1989 Molecular Mechanisms in Skin Carcinogenesis, NEIHS International Conference on Critical Target Genes in Chemical Carcinogenesis, Research Triangle Park, NC (Invited Speaker)
- 08/1989 Cancer Causation and Prevention, Michigan Cancer Foundation, Detroit, MI (Invited Speaker)
- 07/1989 Carcinogenesis: From Molecular Mechanisms to Molecular Epidemiology, The Fourth Aspen Cancer Conference, Aspen, CO (Sole Presenter)
- 05/1989 Seminar Presentation, NIH Consensus Development Conference on Sunlight, Ultraviolet Radiation, and the Skin, National Institutes of Health, Bethesda, MD (Sole Presenter)
- 05/1989 Importance of Free Radicals in Skin Tumor Promotion and Progression, AACR, San Francisco, CA (Sole Presenter)
- 03/1989 Mouse Skin Model Multistage Carcinogenesis and Chemoprevention, Chemoprevention of Upper Aerodigestive Tract Cancers, Washington, DC (Sole Presenter)
- 03/1989 Chemoprevention of Upper Aerodigestive Tract Cancers, NCI Upper Aerodigestive Cancer Working Group of the Organ Systems Program, Washington, DC (Sole Presenter)

- 02/1989 Mechanism Involved in Skin Carcinogenesis, Lilly Research Laboratories, Greenfield, IN (Invited Speaker)
- 10/1988 Introduction to Multistage Carcinogenesis-Biomedical Measures of Promotion, EPRI Tutorial on Cancer Biology and Electric and Magnetic Fields Research, Phoenix, AZ (Sole Presenter)
- 09/1988 Promotion and Progression During Carcinogenesis, Program in Continuing Medical Education, Case Western Reserve University, Cleveland, OH (Invited Speaker)
- 09/1988 Critical Events and Determinants in Multistage Skin Carcinogenesis, American Chemical Society's Symposium on Pesticides and Carcinogenicity, Los Angeles, CA (Sole Presenter)
- 09/1988 Critical Events and Determinants in Multistage Skin Carcinogenesis, Carcinogenicity and Pesticides, College Park, MD (Sole Presenter)
- 08/1988 Cancer Causes and Prevention, Argonne National Laboratory, Chicago, IL (Invited Speaker)
- 07/1988 Cancer Causes and Prevention: The Role of Diet and Nutrition, Nutrition Department, Pennsylvania State University, University Park, PA (Invited Speaker)
- 07/1988 Electronic Fields and Skin Cancer, Electromagnetic Fields and Cancer Workshop, Electric Power Research Institute, Monterey, CA (Sole Presenter)
- 06/1988 Skin Cancer Causation and Prevention, Institute of Pathology, Case Western Reserve University, Cleveland (Invited Speaker)
- 05/1988 Rational Approaches to Cancer Prevention, 31st Annual Nutrition and Food Service Management Meeting, Department of Home Economics, University of Texas at Austin, Austin, TX (Invited Speaker)
- 04/1988 Chemical Agents as a Cause of Cancer, New Frontiers in Cancer Research: A Search for Causes, Tenton, NJ (Sole Presenter)
- 03/1988 Diet and Nutrition, Texas Physicians Advisory Committee, Houston, TX (Sole Presenter)
- 02/1988 Promotion and Progression Mechanism Involved in Skin Tumors, Environmental Health Center, University of Cincinnati, Cincinnati, OH (Invited Speaker)
- 02/1988 Progression Mechanism of Tumor Promotion, Second Charles Heidelberger Memorial Symposium, Honolulu, HI (Sole Presenter)

- 01/1988 Cancer Prevention, School of Pharmacology, University of Connecticut, Storris, CT (Invited Speaker)
- 01/1988 Cancer Causation and Prevention, Coriell Institute for Medical Research, Capewood, NJ (Invited Speaker)
- 12/1987 Biochemical and Molecular Aspects of Promotion and Progression, Dermal Carcinogenesis Conference, Austin, TX (Sole Presenter)
- 12/1987 Critical Events and Determinants in Multistage Skin Carcinogenesis, USA-Japan Seminar, Honolulu, HI (Sole Presenter)
- 10/1987 Cancer Causation and Prevention, Symposium on Immunotoxicology, Cornell University, Ithaca, NY (Invited Speaker)
- 10/1987 Multistage Carcinogenesis:Initiation-Promotion-and Progression, Department of Physiology and Biophysics, University of Illinois, Urbana, IL (Invited Speaker)
- 10/1987 Mechanisms Involved in Skin Tumor Initiation, Promotion and Progression, Department of Physiology and Biophysics, University of Illinois, Urbana, IL (Invited Speaker)
- 07/1987 Cellular Mechanisms of Tumor Promotion and Enhancement, Aspen Cancer Conference, Aspen, CO (Sole Presenter)
- 03/1987 The Possible Involvement of Free Radicals in Skin Tumor Progression, 2nd International Conference on Anticarcinogenesis and Radiation Protection, Gaithersburg, MD (Sole Presenter)
- 03/1987 Mechanisms Involved in Tumor Promotion, Tissue Culture Association Workshop, Houston, TX (Sole Presenter)
- 02/1987 Mechanisms Involved in Tumor Promotion, EPA Workshop on Risk Assessment Methodologies for Tumor Promoters, Bethesda, MD (Sole Presenter)
- 02/1987 Skin Tumor Promotion and Progression, ACS Workshop Conference on Current Concepts of Tumor Promotion and Anti-Promotion, Research Key Biscayne, FL (Sole Presenter)
- 01/1987 Mechanisms Involved in Skin Tumors: Initiation, Promotion and Progression, Great Lakes Regional Discussion Group Meeting, Cincinnati, OH (Sole Presenter)
- 12/1986 Cancer Causation and Prevention, UTSCC, Kleburg Foundation, Houston, TX (Invited Speaker)

- 09/1986 Mechanisms Involved in Skin Tumor Initiation, Promotion and Progression, University Catholique de Louvain, Brussels, Belgium (Invited Speaker)
- 09/1986 Mechanisms Involved in Skin Tumor Promotion and Progression, Department of Pharmacology, University of London, London, United Kingdom (Invited Speaker)
- 09/1986 Non-Mutagenic Carcinogens: How Much Risk to Man?, The Robins Institute, Guildford, United Kingdom (Sole Presenter)
- 09/1986 Critical Genetic Determinants and Molecular Events in Multistage Carcinogenesis, 39th Annual Symposium on Fundamental Cancer Research, Houston, TX (Sole Presenter)
- 09/1986 Diet and Cancer - Public Health Messages in Product Advertising, AICR Symposium, Washington, DC (Sole Presenter)
- 08/1986 Mechanisms Involved in Tumor Promotion, Wolfson Laboratory for Molecular Pathology, The Beatson Institute for Cancer Research, Glasgow, United Kingdom (Invited Speaker)
- 08/1986 Cellular and Molecular Mechanisms of Skin Tumor Promotion and Progression, Gordon Conference on Cancer, London, United Kingdom (Sole Presenter)
- 08/1986 Tumor Promoters, 14th International Cancer Congress, Budapest, Hungary (Sole Presenter)
- 07/1986 Cancer Causation and Prevention, Annual Summer Toxicology Forum, Aspen, CO (Sole Presenter)
- 06/1986 Cancer Causation and Prevention, The Howard Hughes Foundation, Dallas, TX (Invited Speaker)
- 06/1986 Seminar Presentation, Annual Meeting, The American Cancer Society, Phoenix, AZ (Invited Speaker)
- 05/1986 Skin Carcinogenesis, The Proctor & Gamble Company, Cincinnati, OH (Invited Speaker)
- 05/1986 Skin Tumor Promotion, Toxicology Department, Rohm & Haas Company, Philadelphia, PA (Invited Speaker)
- 04/1986 Tumor Promotion, Conference on Nongenotoxic Mechanisms in Carcinogenesis, Banbury Center, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (Sole Presenter)
- 02/1986 Cell Proliferation and Tumor Promotion, Department of Pathology, University of Maryland

School of Medicine, Baltimore, MD (Invited Speaker)

- 01/1986 Cell Proliferation and Carcinogenesis, Department of Hematology; Cytometry Section, UTSCC M.D. Anderson Hospital and Tumor Institute, Houston, TX (Invited Speaker)
- 01/1986 Biological Bases for Interspecies Extrapolation of Carcinogenicity Data, The Federation of American Society for Experimental Biology Symposium, Bethesda, MD (Sole Presenter)
- 01/1986 Interspecies Comparisons of Tissue DNA Damage, Repair, Fixation and Replication, The Federation of American Society for Experimental Biology Workshop, Bethesda, MD (Sole Presenter)
- 12/1985 EMF and Skin Cancer, Health Effects Institute, Bethesda, MD (Sole Presenter)
- 11/1985 Skin Tumor Promotion, Division of Biology and Medical Research, Argonne National Laboratory, Argonne, IL (Invited Speaker)
- 10/1985 Mechanisms Involved in Carcinogenesis, University of Cagliari, Cagliari, Italy (Invited Speaker)
- 10/1985 Cancer Causation and Prevention, Rotary Club of Houston, American Cancer Society, Houston, TX (Invited Speaker)
- 09/1985 Cancer Can Be Prevented, Crusade Kick-Off, American Cancer Society, Lockhart, TX (Invited Speaker)
- 09/1985 PAH Carcinogenesis, Purdue University, West Lafayette, IN (Invited Speaker)
- 09/1985 Seminar Presentation, Media Effectiveness Workshop, UTSCC, Kleburg Foundation, Houston, TX (Sole Presenter)
- 08/1985 Cancer Can Be Prevented, District Meeting, American Cancer Society, Austin, TX (Invited Speaker)
- 07/1985 Inflammation and Skin Tumor Promotion, Winter Toxicology Forum, Aspen, CO (Sole Presenter)
- 06/1985 Diet, Nutrition, and Cancer: Issues in Causation and Prevention, Clinical Nutrition Workshop, Houston, TX (Sole Presenter)
- 05/1985 SENCAR Mouse in Toxicological Testing, EPA Workshop, OH (Sole Presenter)

- 04/1985 Cancer Causation and Prevention, Crusade Kick-Off, American Cancer Society, Smithville, TX (Invited Speaker)
- 04/1985 Growth Factors and Mechanisms of Tumor Promotion and Progressions, UCLA Symposium, University of California, Steamboat Springs, CO (Sole Presenter)
- 04/1985 Experimental Animal Studies on the mechanisms Involved in Skin Tumor Promotion and Progression, UCLA Symposium, University of California, Steamboat Springs, CO (Sole Presenter)
- 03/1985 Mechanisms of Skin Tumor Promotion, Division of Chemical Oncology, Wisconsin Clinical Cancer Center, Madison, WI (Invited Speaker)
- 03/1985 PAH Carcinogenesis, Exxon Corporation, East Millstone, NJ (Invited Speaker)
- 02/1985 Mechanisms Involved in Carcinogenesis, Lineberger Cancer Research, Chapel Hill, NC (Invited Speaker)
- 02/1985 A Progress Report of Skin Tumor Initiation and Promotion, NIEHS, Research Triangle Park, NC (Sole Presenter)
- 02/1985 In Vivo Models - Skin, Winter Toxicology Forum, Washington, DC (Sole Presenter)
- 11/1984 Mechanisms Involved in Multistage Skin Carcinogenesis, The University Cancer Foundation, Houston, TX (Sole Presenter)
- 08/1984 Studies on the Mechanisms Involved in Multistage Skin Carcinogenesis, Argonne National Laboratory, Oak Brook, IL (Sole Presenter)
- 08/1984 Role of Chemical and Radiation in the Etiology of Cancer, Argonne National Laboratory, Oak Brook, IL (Sole Presenter)
- 07/1984 PAH Carcinogenesis, University College of London, London, United Kingdom (Invited Speaker)
- 07/1984 Skin Tumor Promotion, Swiss Institute, Luasanne, Switzerland (Invited Speaker)
- 06/1984 Skin Tumor Promotion, EPA Symposium on Tumor Promotion and Enhancement, Williamsburg, VA (Sole Presenter)
- 05/1984 Cellular and Molecular Mechanisms in Carcinogenesis, Department of Biochemistry, School of Medicine, Vanderbilt University, Nashville, TN (Invited Speaker)

- 05/1984 Inflammation and Skin Tumor Promotion, AACR Conference, Toronto, Canada (Sole Presenter)
- 05/1984 Development of Cancer Chemopreventive Agents, NIH Workshop, National Institutes of Health, Bethesda, MD (Sole Presenter)
- 05/1984 Studies on the Mechanisms Involved in Multistage Chemical Carcinogenesis, Vanderbilt University, Nashville, TN (Sole Presenter)
- 04/1984 Cancer Causation and Prevention, Department of Biology, Trinity University, San Antonio, TX (Invited Speaker)
- 04/1984 Cell Proliferation and Tumor Promotion, Swiss Institute, Luusanne, Switzerland (Invited Speaker)
- 04/1984 Multistage Carcinogenesis, IARC Fellowship Selection Committee, Lyon, France (Sole Presenter)
- 03/1984 PAH Carcinogenesis, Hoffman-LaRoche, Inc., Newark, NJ (Invited Speaker)
- 02/1984 Mechanisms of Skin Tumor Promoters, National Institute of Environmental Health Sciences, Chapel Hill, NC (Invited Speaker)
- 02/1984 Cancer Causation and Prevention, UICC Fellowship Committee, Geneva, Switzerland (Sole Presenter)
- 01/1984 PAH Carcinogenesis, Toxicology Committee Roundtable Discussion, American Petroleum Institute, San Diego, CA (Sole Presenter)
- 12/1983 PAH Carcinogenesis, Symposium on the Comparison of Mechanisms of Carcinogenesis by Radiation and Chemical Agents, NCI, Gaithersburg, MD (Sole Presenter)
- 11/1983 Critical Events in Skin Tumor Promotion, University of Tokyo, Tokyo, Japan (Invited Speaker)
- 11/1983 Cancer Causation and Prevention, Kurumi University, Kurumi, Japan (Invited Speaker)
- 11/1983 Paper Presentation, Tumor Promotion Meeting, Japan (Sole Presenter)
- 11/1983 Skin Tumor Development, Workshop on Biological Adaptation and the Development of Cancer, Department of Pathology, University of Toronto, Toronto, Canada (Sole Presenter)

- 11/1983 Inflammation and Tumor Promotion, 14th International Symposium, The National Cancer Center Research Institute, Tokyo, Japan (Sole Presenter)
- 09/1983 Paper Presentation, Modifiers of Chemical Carcinogenesis meeting, Copenhagen, Denmark (Sole Presenter)
- 08/1983 PAH Carcinogenesis, Shell Toxicology Laboratory, Houston, TX (Invited Speaker)
- 07/1983 Paper Presentation, Carcinogenesis Meeting, Menton, France (Sole Presenter)
- 05/1983 Mechanisms of Skin Tumor Promotion, Tumor Promotion Meeting, Budapest, Hungary (Sole Presenter)
- 04/1983 Mechanisms of Skin Carcinogenesis, Department of Dermatology, University of Pennsylvania, PA (Invited Speaker)
- 03/1983 Mechanisms of Skin Tumor Promotion, Frederick Cancer Center, Frederick, MD (Invited Speaker)
- 02/1983 Critical Events in Skin Carcinogenesis, Riverside Symposium on Cellular and Molecular Aspects of Hormones, University of California (Sole Presenter)
- 01/1983 Role of Inflammation in Skin Tumor Promotion, Department of Pharmacology, Baylor College of Medicine, Houston, TX (Invited Speaker)
- 12/1982 Mechanisms Involved in Carcinogenesis, Department of Zoology, University of Texas at Austin, Austin, TX (Invited Speaker)
- 11/1982 PAH Carcinogenesis, Department of Chemistry, University of Texas at Austin, Austin, TX (Invited Speaker)
- 10/1982 Prevention of Skin Tumor Promotion by Antioxidants, NCI Workshop on the Role of Free Radicals in Tumor Promotion, Washington, DC (Sole Presenter)
- 09/1982 PAH Carcinogenesis, 13th International Cancer Congress Symposium on Chemical Carcinogenesis, Seattle, WA (Sole Presenter)
- 06/1982 Critical Events in Skin Carcinogenesis, P&S Biomedical Sciences Symposia on Genes and Proteins in Oncogenesis, New York, NY (Sole Presenter)
- 06/1982 Role of Free Radicals in Skin Tumor Promotion, First Conference on Radioprotectors and Anticarcinogenesis, Washington, DC (Sole Presenter)

- 06/1982 Inflammation and Skin Carcinogenesis, International Conference on the Role of Host Factors in Experimental Carcinogenesis, Moscow, Russia (Sole Presenter)
- 01/1982 Cellular and Molecular Events in Skin Cancer, Science Park-Research Division, University of Texas System Cancer Center, Austin, TX (Invited Speaker)
- 01/1982 Cellular and Molecular Events in Skin Cancer, Eppley Cancer Center, Omaha, NE (Invited Speaker)
- 01/1982 PAH Carcinogenesis, Symposium on the Application of Short-Term Bioassays in the Analysis of Complex Environmental Mixtures, Chapel Hill, NC (Sole Presenter)
- 12/1981 Antioxidants and the Prevention of Skin Cancer, NCI Conference on the Role of Natural Inhibitors in Carcinogenesis, Washington, DC (Sole Presenter)
- 11/1981 Mechanisms of Skin Tumor Promotion, University of Tokyo, Tokyo, Japan (Invited Speaker)
- 11/1981 Mechanisms of Skin Tumor Promotion, National Cancer Institute of Japan, Tokyo, Japan (Invited Speaker)
- 11/1981 Inflammation and Skin Cancer, Kyoto University, Kyoto, Japan (Invited Speaker)
- 11/1981 Mechanisms of Tumor Promotion, Symposium on Carcinogenesis and Tumor Promotion, Nagoy, Japan (Sole Presenter)
- 11/1981 Chemical Carcinogenesis, The American College of Toxicology Workshop on In Vivo Carcinogenesis Bioassays, Washington, DC (Sole Presenter)
- 10/1981 PAH Carcinogenesis, Frederick Cancer Center, Frederick, MD (Invited Speaker)
- 10/1981 Inhibition of Tumor Promotion by Antioxidants, International Conference on the Role of Vitamins in Cancer Prevention, Tucson, AZ (Sole Presenter)
- 10/1981 PAH Carcinogenesis, EPA Conference on Diesel Emissions, Raleigh, NC (Sole Presenter)
- 10/1981 Skin Tumor Promotion, International Symposium on Health Effects of Tumor Promotion, Cincinnati, OH (Sole Presenter)
- 09/1981 Prostaglandins and Skin Tumor Promotion, International Conference on Prostaglandins and Cancer, Washington, DC (Sole Presenter)

- 07/1981 Mechanisms in Skin Tumor Promotion, Wistar Institute, Philadelphia, PA (Invited Speaker)
- 07/1981 Mechanisms in Skin Tumor Promotion, Department of Dermatology, University of Pennsylvania, PA (Invited Speaker)
- 06/1981 PAH Carcinogenesis, New York University School of Medicine, New York, NY (Invited Speaker)
- 06/1981 PAH Carcinogenesis, Canadian Atomic Energy Commission, Chalk River, Ontario, Canada (Invited Speaker)
- 03/1981 Cancer Causation and Prevention, National Cancer Institute of Japan, Tokyo, Japan (Invited Speaker)
- 03/1981 Pharbol Esters and Tumor Promotion, University of Tokyo, Tokyo, Japan (Invited Speaker)
- 03/1981 Mechanisms in Chemical Carcinogenesis, U.S.-Japan Meeting on Mutagenesis and Carcinogenesis, Tokyo, Japan (Sole Presenter)
- 03/1981 Skin Tumor Sensitive Mice, NCI-EPA Conference on Species Variation in Carcinogenesis, Raleigh, NC (Sole Presenter)
- 02/1981 PAH Carcinogenesis, ICN-UCLA Conference on Carcinogenesis, Keystone, CO (Sole Presenter)
- 02/1981 Inhibitors of Skin Tumor Promotion, NCI Workshop on Chemoprevention of Cancer, Washington, DC (Sole Presenter)
- 01/1981 Cellular and Molecular Mechanisms in Skin Carcinogenesis, Department of Cell Biology, University of Texas Medical Branch, Galveston, TX (Invited Speaker)
- 12/1980 Pah Carcinogenesis, NIEHS (Invited Speaker)
- 11/1980 PAH Carcinogenesis, Upjohn, Kalamazoo, MI (Invited Speaker)
- 11/1980 Skin Tumor Promotion, NCI Workshop on Tumor Promotion, Washington, DC (Sole Presenter)
- 10/1980 Inflammation and SKin Carcinogenesis, University College of London, London, United Kingdom (Invited Speaker)

- 10/1980 PAH Carcinogenesis, NCI Conference on Biological Carcinogenesis, Detroit, MI (Sole Presenter)
- 10/1980 Skin Tumor Promotion, Conference on Skin Carcinogenesis, Oslo, Norway (Sole Presenter)
- 10/1980 Tumor Promotion and Carcinogenesis, International Symposium on Cocarcinogenesis and Biological Effects of Tumor Promoters, Elmau, Germany (Sole Presenter)
- 07/1980 Inflammation and Tumor Promotion, EPA Conference on Short-Term Assays in Carcinogenesis, Cincinnati, OH (Sole Presenter)
- 06/1980 Mechanisms in Chemical Carcinogenesis, University of Chicago, Chicago, IL (Invited Speaker)
- 04/1980 PAH Carcinogenesis, University of Surrey, United Kingdom (Invited Speaker)
- 04/1980 Sencan Mouse Skin Tumor Promotion, Battelle Laboratory, Geneva, Switzerland (Invited Speaker)
- 04/1980 Critical Events in Skin Tumor Promotion, IAAC, Lyon, France (Invited Speaker)
- 04/1980 Critical Events in Skin Tumor Promotion, German Cancer Center, Heidelberg, Germany (Invited Speaker)
- 04/1980 PAH Carcinogenesis, U.S.-Poland Meeting on Mutagenesis and Carcinogenesis, Warsaw, Poland (Sole Presenter)
- 04/1980 Seminar Presentation, CRC Conference, London, United Kingdom (Sole Presenter)
- 03/1980 Seminar Presentation, EPA Conference on Health Effects of Diesel Emissions, Cincinnati, OH (Sole Presenter)
- 02/1980 Seminar Presentation, Distinguished Lecture Series on Frontiers in Biological Sciences, Medical School, Case-Western Reserve University (Invited Speaker)
- 01/1980 Seminar Presentation, Experimental Pathology Laboratory, NCI (Invited Speaker)
- 12/1979 Seminar Presentation, Department of Radiobiology, University of Arizona, AZ (Invited Speaker)
- 12/1979 Seminar Presentation, International Conference on Chemical Carcinogenesis, Bombay, India

(Sole Presenter)

- 11/1979 Chemical Carcinogenesis, University of Illinois, IL (Invited Speaker)
- 10/1979 Seminar Presentation, EPA Conference on the Health Effects of Diesel Emissions, Williamsburg, VA (Sole Presenter)
- 09/1979 Seminar Presentation, NCI Conference on Retinoic Acid, Washington, DC (Sole Presenter)
- 08/1979 Seminar Presentation, Toxicology Program, General Motors Research Division (Invited Speaker)
- 08/1979 Seminar Presentation, Joint NIH, DOE and EPA Meeting on the Health Effects of Advanced Coal Technologies, Washington, DC (Sole Presenter)
- 07/1979 Seminar Presentation, Gordon Research Conference on Epidermal Differentiation, Tilton, NH (Sole Presenter)
- 07/1979 Mechanisms in Skin Carcinogenesis, U.S.-Japan Meeting on Normal and Abnormal Epidermal Differentiation, Boyne Mountain, MI (Keynote Speaker)
- 04/1979 PAH Carcinogenesis, Annual Biology Division Conference on Environmental Carcinogenesis, Argonne National Laboratory, Argonne, IL (Sole Presenter)
- 02/1979 Mechanisms of PAH Carcinogenesis, Toxicology Program, Duke University, Durham, NC (Invited Speaker)
- 02/1979 Inhibitors of Chemical Carcinogenesis, NCI Conference on Inhibition of Chemical Carcinogenesis, Washington, DC (Sole Presenter)
- 12/1978 Pharbol Ester Tumor Promotion, Department of Entomology, Cornell University, Ithaca, NY (Invited Speaker)
- 12/1978 Mechanisms of PAH Carcinogenesis, Department of Pharmacology, Harvard Medical School, Boston, MA (Invited Speaker)
- 09/1978 Mechanisms of Pharbol Ester Tumor Promotion, Department of Biochemistry, Roswell Park Memorial Cancer Center, Research Triangle Park, NC (Invited Speaker)
- 09/1978 Skin Tumor Promotion, Biochemistry Branch, USEPA, Research Triangle Park, NC (Invited Speaker)

- 06/1978 PAH Carcinogenesis, Institute of Environmental Medicine, New York University School of Medicine, New York, NY (Invited Speaker)
- 06/1978 PAH Carcinogenesis, Gordon Research Conference on Environmental and Genetic Toxicology, Tilton, NH (Sole Presenter)
- 05/1978 PAH Carcinogenesis, Department of Biochemistry and Drug Metabolism, Southwestern Medical School, Dallas, TX (Invited Speaker)
- 05/1978 Pharbol Esters and Skin Tumor Promotion, Cold Spring Harbor Symposium on Phorbol Esters in Culture, Cold Spring Harbor, NY (Sole Presenter)
- 11/1977 PAH Carcinogenesis, Biology Division, Oak Ridge National Laboratory, Oak Ridge, TN (Invited Speaker)
- 11/1977 Mechanisms in Skin Tumor Promotion, Department of Human Development, Michigan State University, East Lansing, MI (Invited Speaker)
- 09/1977 Diol-Oxide and PAH Carcinogenesis, Battelle's Conference on Polynuclear Aromatic Hydrocarbons, Columbus, OH (Sole Presenter)
- 08/1977 Cellular Mechanisms in Tumor Promotion, Carcinogenesis Studies in Human Cells and Tissue Workshop, Aspen, CO (Sole Presenter)
- 07/1977 Critical Events in Epidermal Carcinogenesis, Conference on Biochemical Aspects of Epidermal Differentiation, St. Clair, MI (Sole Presenter)
- 04/1977 Tumor sensitive mice, Symposium on Carcinogenesis and Mutagenesis, Argonne National Laboratory, Argonne, IL (Sole Presenter)
- 10/1976 Mechanism of action of tumor promoters, Workshop on Tumor Promoters, Cocarcinogens and Hormones, NCI Carcinogenesis Program, Woods Hole, MA (Sole Presenter)
- 09/1976 Cancer Prevention by Antioxidants, Colloquium Clinical and Experimental Aspects of Nutrition and Cancer, Knoxville-Oak Ridge Associated Researchers and Clinicians in Cancer, TN (Sole Presenter)
- 08/1976 PAH and Skin Carcinogenesis, Medical and Health Sciences Division, Oak Ridge Associated Universities, Oak Ridge, TN (Invited Speaker)
- 05/1976 Mechanism of action of tumor promotion, Workshop on Future Direction of NCI, NCI Carcinogenesis Program, Washington, DC (Sole Presenter)

- 02/1976 Protective factors in the diet against chemical carcinogenesis, Conference on Diet and Cancer, AAAS, Boston, MA (Sole Presenter)
- 10/1975 Polycyclic hydrocarbon metabolism and tumor initiation in mouse skin, Battelle's Conference on Polynuclear Aromatic Hydrocarbons, Columbus, OH (Sole Presenter)
- 09/1975 Mechanisms of Chemical Carcinogenesis, Biomedical Research Group, University of California; Los Alamos Scientific Laboratory, Los Alamos, NM (Invited Speaker)
- 08/1975 Mechanisms of Chemical Carcinogenesis, Medical Science Department, Stanford Research Institute, Menlo Park, CA (Invited Speaker)
- 07/1975 Mechanisms of Skin Tumor Promotion, Laboratory of Pathophysiology, NIH, Bethesda, MD (Invited Speaker)
- 07/1975 Tumor promotion and inhibition by steroidal anti-inflammatory agents, Fifth Conference on Biochemical Aspects of Epidermal Differentiation, Detroit, MI (Sole Presenter)
- 06/1975 Mechanisms of Chemical Carcinogenesis, Biology Division, Oak Ridge National Laboratory, Oak Ridge, TN (Invited Speaker)
- 06/1975 Skin Tumor Promotion, Frederick Cancer Research Center, Frederick, MD (Invited Speaker)
- 06/1975 Mechanisms of Chemical Carcinogenesis, Department of Biochemistry and Drug Metabolism, Hoffmann-LaRoche, Inc., Nutley, NJ (Invited Speaker)
- 02/1975 Pharbol Ester Tumor Promotion, Experimental Pathology Branch, NCI, NIH, Bethesda, MD (Invited Speaker)
- 01/1975 Mechanisms of Chemical Carcinogenesis, Ciba-Geigy Corporation, Ardsley, NY (Invited Speaker)
- 01/1975 Pharbol Ester Tumor Promotion, Laboratory of Pathophysiology, NIH, Bethesda, MD (Invited Speaker)
- 10/1974 Mechanisms of Carcinogenesis, Department of Pharmacology, University of Washington School of Medicine, Seattle, WA (Invited Speaker)
- 07/1974 Skin Cancer Prevention, Department of Dermatology, University of Washington School of Medicine, Seattle, WA (Invited Speaker)

- 06/1974 Mechanisms of PAH Carcinogenesis, Center in Toxicology; Department of Biochemistry, Vanderbilt University, Nashville, TN (Invited Speaker)
- 06/1974 Cancer Preventions and Mechanisms, Michigan Cancer Foundation, Detroit, MI (Invited Speaker)
- 06/1974 Inflammation and Skin Cancer, Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI (Invited Speaker)
- 02/1974 Multistage Carcinogenesis, Biomedical Division, University of California, Lawrence Livermore Laboratory, Livermore, CA (Invited Speaker)
- 01/1974 Skin Carcinogenesis, Department of Biochemistry and Biophysics, Oregon State University, Corvallis, OR (Invited Speaker)
- 02/1972 Cellular and Molecular Aspects of Skin Carcinogenesis, Pacific Northwest Research Foundation, Seattle, WA
- Seminar Presentation, Gulf Coast Chapter Society of Toxicology, Texas A&M University, College Station, TX (Invited Speaker)
- Seminar Presentation, Rotary Club, Denver, CO (Invited Speaker)
- Seminar Presentation, Workshop on Toxicity, Given Institute, Aspen, CO (Sole Presenter)

## **RESEARCH GRANTS:**

### ***Federal***

**Project #:** 2P30 CA054174

**Funding Agency:** NIH/NCI

**Title:** Cancer Therapy & Research Center at UTHSCSA

**Status:** Active

**Period:** 09/2014 - 07/2019

**Role:** Co-Investigator

**% Effort:**

**Total Costs:**

**Grant Detail:** This cancer center support grant provides research core and program infrastructure support to members of the cancer center for the conduct of their cancer-related research.

**Project #:** R01 CA164159

**Funding Agency:** NIH

**Title:** Anti-promoting effects of triterpenes alone or combined with other phytochemicals

**Status:** Active

**Period:** 07/2014 - 05/2017

**Role:** Co-Principal Investigator

**% Effort:**

**Total Costs:**

**Grant Detail:**

**Project #:**

**Funding Agency:** NIH

**Title:** Anti-Promoting Effects of Triterpenes Alone or Combined with Other Phytochemicals

**Status:** Active

**Period:** 08/2012 - 05/2017

**Role:** Co-Principal Investigator

**% Effort:**

**Total Costs:** \$985,825.00

**Grant Detail:**

**Project #:** P30 CA-54174

**Funding Agency:** NIH/NCI

**Title:** National Cancer Institute/CTRC

**Status:** Complete

**Period:** 10/2009 - 09/2014

**Role:** Co-Investigator

**% Effort:**

**Total Costs:**

**Grant Detail:** This is a Cancer Center Support Grant that provides infrastructure support to members of the cancer center for the conducting of their cancer-related research.

**Project #:** 3R01 CA0796065

**Funding Agency:** NIH

**Title:** Significance of Sirtuin 1 in Skin Carcinogenesis

**Status:** Complete

**Period:** 09/2009 - 09/2011

**Role:** Principal Investigator

**% Effort:**

**Total Costs:**

**Grant Detail:** This award is issued under the American Recovery and Reinvestment Act of 2009 and is subject to special HHS terms and conditions as referenced in Section III. The experiments will allow to see if Sirt1 can inhibit carcinogenesis via GR and establish if a lack of GR reduces or abolishes the effect of Sirt1 activation on inhibition of NF[kappa]B or AP-1 activity and related tumorigenesis.

**Project #:**

**Funding Agency:** CTRC Cancer Pilot Program

**Title:** Thiol oxidative stress and macrophage dysfunction in lung cancer

**Status:** Complete

**Period:** 07/2008 - 06/2009

**Role:** Co-Investigator

**% Effort:** <1

**Total Costs:** \$50,000.00

**Grant Detail:**

**Project #:** CA-0796065-06-A2

**Funding Agency:** NIH/NCI

**Title:** GR impairment in carcinogenesis: Tumor suppressor role

**Status:** Complete

**Period:** 04/2005 - 03/2010

**Role:** Principal Investigator

**% Effort:** 25

**Total Costs:** \$2,083,480.00

**Grant Detail:** Glucocorticoid hormones (GC) are very potent inhibitors of physiological DNA synthesis in keratinocytes in vivo. These hormones are also very effective in preventing carcinogen- and tumor promoter-induced skin hyperplasia, inflammation, and mouse skin tumor formation when applied to skin together with a carcinogen or a tumor promoter. The glucocorticoid control of cellular functions is mediated by the glucocorticoid receptor (GR), a well-known transcription factor. The goal of this study is to prove that glucocorticoid receptors are powerful tumor suppressor genes.

**Project #:** 1R01CA76262-06

**Funding Agency:** NIH/NCI

**Title:** GR impairment in carcinogenesis: Role of the NFkB Proteins (Renewal)

**Status:** Complete

**Period:** 12/2004 - 11/2009

**Role:** Principal Investigator

**% Effort:**

**Total Costs:** \$1,000,000.00

**Grant Detail:**

**Project #:** 1R01CA76262-01CP

**Funding Agency:** NIH, NCI

**Title:** GR impairment in carcinogenesis: Role of NFkB proteins

**Status:** Complete

**Period:** 12/2003 - 06/2005

**Role:** Principal Investigator

**% Effort:** 25

**Total Costs:** \$191,202.00

**Grant Detail:**

**Project #:** CA-102747-01

**Funding Agency:** NIH/NCI

**Title:** Combined natural inhibitors in skin cancer prevention

**Status:** Complete

**Period:** 08/2003 - 07/2008

**Role:** Principal Investigator

**% Effort:** 20

**Total Costs:** \$1,225,000.00

**Grant Detail:** The overall goal of this proposal is to determine the mechanism(s) of synergistic action of the natural source compounds, known to inhibit one or more stages of skin carcinogenesis, i.e., initiation and progression. Our hypothesis is that concurrent topical and systemic (i.e., dietary) treatment with selected natural source inhibitors of different stages of skin carcinogenesis result in synergistic effects leading to more efficient prevention of skin cancer.

**Project #:**

**Funding Agency:** NCI/NCCAM

**Title:** Testing the efficacy of clove extracts vs. pure eugenol in melanoma

**Status:** Complete

**Period:** 07/2003 - 06/2004

**Role:** Co-Principal Investigator **% Effort:** 10

**Total Costs:** \$150,000.00

**Grant Detail:**

**Project #:** 5P30CA4693115S1

**Funding Agency:** NIH/NCI

**Title:** Potential of curcumin derivative in prostate cancer

**Status:** Complete

**Period:** 02/2003 - 01/2004

**Role:** Co-Principal Investigator **% Effort:** 10

**Total Costs:** \$100,000.00

**Grant Detail:**

**Project #:** 2-P30-CA 46934

**Funding Agency:** NIH/NCI

**Title:** University of Colorado Cancer Center Grant

**Status:** Complete

**Period:** 02/2002 - 01/2006

**Role:** Principal Investigator **% Effort:**

**Total Costs:** \$22,040.00

**Grant Detail:**

**Project #:** P30 CA 54174-14

**Funding Agency:** National Institutes of Health

**Title:** San Antonio Cancer Institute

**Status:** Active

**Period:** 09/1998 - Present

**Role:** Principal Investigator **% Effort:** 5

**Total Costs:** \$50,000.00

**Grant Detail:** To identify the cultural, economic, and structural barriers to early phase clinical trial participation faced by patients and oncologists, and to develop effective interventions to reduce these barriers, thereby increasing participation in drug development trials.

**Project #:** CA 79065-01

**Funding Agency:** NCI

**Title:** GR impairment in carcinogenesis - Role of NF Kappa Beta proteins

**Status:** Complete

**Period:** 12/1997 - 12/2002

**Role:** Principal Investigator **% Effort:** 20

**Total Costs:** \$1,262,928.00

**Grant Detail:**

**Project #:** CA 09480-11  
**Funding Agency:** NCI  
**Title:** Research training in carcinogenesis and mutagenesis  
**Status:** Complete  
**Period:** 09/1981 - 06/2001  
**Role:** Principal Investigator **% Effort:** 10  
**Total Costs:**  
**Grant Detail:**

**Private**

**Project #:**  
**Funding Agency:** Morrison Trust  
**Title:** AMPK activation is a critical novel mechanism for the anti-cancer properties of phytonutrient phenethyl isothiocyanate  
**Status:** Active  
**Period:** 09/2015 - 08/2016  
**Role:** Principal Investigator **% Effort:**  
**Total Costs:**  
**Grant Detail:**

**Project #:**  
**Funding Agency:** San Antonio Area Foundation  
**Title:** Novel combination of phytonutrients for lung cancer prevention  
**Status:** Pending  
**Period:** 05/2014 - 04/2015  
**Role:** Principal Investigator **% Effort:**  
**Total Costs:**  
**Grant Detail:** The overall goal of this project is to determine the role of 11-Beta HSD2 in counteracting the anti-proliferative and anti-inflammatory activities of glucocorticoids during skin cancer development.

**Project #:**  
**Funding Agency:** Welch Foundation  
**Title:** Effects of novel combination of steroid receptor modulators and phytochemicals on carcinogen-induced chronic inflammation in lung  
**Status:** Pending  
**Period:** 06/2013 - 05/2016  
**Role:** Principal Investigator **% Effort:**  
**Total Costs:**  
**Grant Detail:** The overall goal of this project is to evaluate the anti-inflammation and anti-proliferative properties of compound A, a nonsteroid glucocorticoid receptor modulatory of plant origin alone or in combination with phytochemical phenethyl isothiocyanate which has anti-proliferation properties against lung cancer.

**Project #:**  
**Funding Agency:** San Antonio Area Foundation

**Title:** A novel approach for lung cancer prevention by combination of GR and PPAR alpha agonists

**Status:** Pending

**Period:** 05/2013 - 04/2014

**Role:** Co-Principal Investigator

**% Effort:**

**Total Costs:**

**Grant Detail:**

**Project #:** 154034

**Funding Agency:** William & Ella Owens Medical Research Foundation

**Title:** Resistance to experimentally induced carcinogenesis in the longest-lived rodent

**Status:** Active

**Period:** 01/2012 - 12/2015

**Role:** Co-Investigator

**% Effort:** 1

**Total Costs:** \$100,000.00

**Grant Detail:** The primary goal is to examine whether experimental interventions may cause skin cancer in naked mole-rats.

**Project #:**

**Funding Agency:** Fujisawa Pharmaceutical Corporation

**Title:** The effects of FK506 on mouse skin tumorigenesis

**Status:** Complete

**Period:** 07/2003 - 06/2005

**Role:** Principal Investigator

**% Effort:** 10

**Total Costs:** \$264,000.00

**Grant Detail:**

**Project #:**

**Funding Agency:** Weidner International/Nutraceutix

**Title:** Glucarate and other natural compounds in cancer prevention

**Status:** Complete

**Period:** 05/1998 - 11/2000

**Role:** Principal Investigator

**% Effort:** 10

**Total Costs:** \$984,214.00

**Grant Detail:**

**Project #:**

**Funding Agency:** Amway

**Title:** Standardized assays for the assessment of phytochemicals, natural antioxidants and related compounds for potential use in disease prevention

**Status:** Complete

**Period:** 09/1997 - 03/2001

**Role:** Principal Investigator

**% Effort:** 10

**Total Costs:** \$1,103,507.00

**Grant Detail:**

**Project #:**

**Funding Agency:****Title:** Olga Keith Weiss Chair for Cancer Research**Status:** Active**Period:** 09/1988 - Present**Role:** Principal Investigator**% Effort:****Total Costs:** \$56,383.00**Grant Detail:****Project #:****Funding Agency:** Monk Cancer Research Foundation**Title:** Validation of surrogate endpoint biomarkers in lung cancer**Status:** Active**Period:** / - Present**Role:** Principal Investigator**% Effort:****Total Costs:** \$112,000.00**Grant Detail:****State****Project #:** 124297**Funding Agency:** University of Texas System**Title:** Integrative Health and Chronic Disease Prevention Program**Status:** Complete**Period:** 05/2007 - 08/2011**Role:** Principal Investigator**% Effort:****Total Costs:** \$350,000.00**Grant Detail:** The goals of this program are to test bioactive nutrient effects in models of multiple chronic diseases, including diabetes, cardiovascular diseases, respiratory disease and cancers.**PATENTS:**

<b><u>Patent Date</u></b>	<b><u>Description</u></b>	<b><u>Patent Category</u></b>
01/2006	Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis, Patent#: Pending, Co-Inventor(s): Slaga TJ	
01/2006	Use of curcumin derivatives in cancer prevention and treatment, Patent#: Pending, Co-Inventor(s): Slaga TJ	
01/2003	The use of eugenol, alone and in combination with other chemopreventative agents as prophylaxis for cancers, Patent#: 6,518,261, Co-Inventor(s): Slaga TJ	
09/2002	Time release formulation of vitamins, minerals and other beneficial supplements , Patent#: 6,451,341, Co-Inventor(s): Slaga TJ, Deluca DL, Sparks WS	

- 06/1998 Tumor marker protein for cancer risk assessment, Patent#: 5,773,215, Co-Inventor(s): Hanausek-Walaszek M, Slaga TJ, Walaszek Z
- 10/1996 Formula and method for the prevention of hypercholesterolemia and cellular hyperproliferative disorders, Patent#: 5,561,160, Co-Inventor(s): Walaszek Z, Slaga TJ, Hanausek M
- 09/1996 Formula and method for the prevention of hypercholesterolemia and cellular hyperproliferative disorders (European Patent), Patent#: EP0528950B1, Co-Inventor(s): Hanausek-Walaszek M, Slaga TJ, Walaszek Z
- 11/1994 Formula and method for the prevention of hypercholesterolemia and cellular hyperproliferative disorders, Patent#: 5,364,644, Co-Inventor(s): Walaszek S, Slaga TJ, Hanausek M
- 05/1994 Tumor marker protein and antibodies thereto for cancer risk assessment and diagnosis, Patent#: 5,310,653, Co-Inventor(s): Hanausek-Walaszek M, Slaga TJ, Walaszek Z,
- 06/1992 Serum-free tissue culture medium to grow epithelial cells, Patent#: 5,126,261, Co-Inventor(s): Morris RJ, Fischer SM, Slaga TJ

## **SERVICE**

### **ADMINISTRATIVE RESPONSIBILITIES:**

<b><u>Dates</u></b>	<b><u>Type</u></b>	<b><u>Description</u></b>	<b><u>Role</u></b>
10/2005-Present	Staff Supervised	Staff and Personnel Currently Supervised - UTHSCSA	Supervisor
<i>Maria Bunegin, Research Assistant</i>			
01/1996-12/1997		Scientific Advisory Committee, AMC Cancer Research Center, Denver CO	Board of Directors
01/1995-12/1997		AMC Cancer Research Center, Denver CO	Board of Directors
01/1995-12/1995		NCI, Cancer Centers and Research Programs Review Committee	Member
09/1993-09/1993		NIH, Cancer Center Support Site Visit	Member
01/1990-12/1995		External Advisory Committee for the AMC Cancer Research Center, Denver CO	Member
01/1985-Present		Advisory Committee, Aspen Cancer Conference, Aspen CO	Advisory Committee Member

**SERVICE TO THE PROFESSION:**

<b><u>Dates</u></b>	<b><u>Type</u></b>	<b><u>Description</u></b>	<b><u>Role</u></b>
09/2013-Present	National	Department of Defense Review Committee	Member
01/2005-Present	National	American Cancer Research Center and Foundation	Board Member
01/2000-02/2003		Oncology Sciences Corporation, Austin TX	Consultant
07/1999-06/2000		Scientific Advisory Board, Cancer League of Colorado, Denver CO	Chair
01/1999-02/2003		BioChemix, Austin TX	Consultant
06/1998-05/2000		Scientific Advisory Board, Cancer League of Colorado, Denver CO	Member
01/1996-Present		Burroughs Wellcome Toxicology	Advisory Committee Member
09/1995-09/1995		Harvard Collaborative Center for Oral Cancer Research, External Review Board	Member
05/1995-05/1995		ACS Research Committee to review Research Professorship Awards	Member
04/1995-04/1995		National Toxicology Program Board of Scientific Counselors' Ad Hoc Working Group <i>to review criteria for Listin substances in the Biennial Report on Carcinogens</i>	Member
04/1995-04/1995		National Toxicology Program Board of Scientific Counselors' Ad Hoc Working Group <i>to review criteria for Listin substances in the Biennial Report on Carcinogens</i>	Member
01/1995-12/1995		Academy of the International Journal of Oncology	Editorial Board Member
01/1995-12/1995		ILSI Health and Environmental Sciences Institute Nominating Committee	Member
01/1994-12/1994		ILSI Membership Development Committee	Member
01/1993-Present		Nutrilite Products, Buena Vista CA	Consultant

01/1993-Present	ILSI Health and Environmental Sciences Institute	Consultant
01/1992-12/1999	Health Effects Institute, E/MF Research Planning Committee, Cambridge MA	Member
01/1992-12/1993	Carcinogenicity Advisory Board for Lescol for SANDOZ Pharmaceuticals Corp, East Hanover NJ	Member
01/1992-Present	Better Life Institute, Grand Rapids MI	Consultant
01/1992-Present	Cosmetic Ingredient Review Expert Panel, Washington DC	Member
01/1991-12/1992	Procter & Gamble Company, Cincinnati OH	Consultant
01/1991-12/1991	Utah Biomedical Test Laboratory, Salt Lake City UT	Consultant
01/1990-02/2002	Board of Trustees, ILSI Health & Environmental Sciences Institute, Washington DC	Member
09/1989-Present	Cancer Metastasis Reviews	Advisory Board Member
07/1989-07/1989	US National Committee for the International Union Against Cancer, National Travel Program Committee, Seattle WA	Member
02/1989-02/1989	NIH Public Health Service special Study Section, Washington DC	Member
01/1989-12/1998	The University of Chicago Review Committee for the Biological and Medical Research Division, Argonne IL	Advisory Committee Member
01/1989-12/1992	Rohm and Haas Company, Philadelphia PA	Consultant
01/1989-12/1992	US National Committee for the International Union Against Cancer, Commission on Life Sciences, Washington DC	Member
01/1989-12/1991	ACS Council for Research and Clinical Investigation Awards, Atlanta GA	Member
01/1989-12/1991	Board of Trustees, Pacific Northwest Research Foundation	Member

01/1989-12/1989		Consensus Development Conference on Sunlight, Ultraviolet Radiation and the Skin, Bethesda MD	Member
01/1989-12/1989		Electric Power research Institute Advisory Panel, San Diego CA	Advisory Committee Member
01/1989-Present		Dermigen, Scientific Advisory Board, Smithville TX	Member
01/1988-12/2000		Cancer Letters	Editor
07/1987-06/1990		Ovablock Inc., Advisory Panel to Evaluate Animal Safety Data	Member
01/1987-12/1996		International Conference on Carcinogenesis and Risk Assessment	Organizing Committee Member
01/1987-05/1992		Arizona Disease Control Research Commission	Member
01/1987-12/1987		Environmental Protection Agency (EPA) Review Committee, Arlington VA	Member
01/1987-Present		Molecular Carcinogenesis	Officer
		<i>Editor-in-Chief</i>	
12/1986-12/1986		Developmental Therapeutics Contracts Review Committee, NIH	Member
01/1986-12/1992		Cancer Information Service Advisory Committee	Member
01/1986-12/1989		AIRC Review Panel, Washington DC	Member
01/1985-Present	National	Aspen Cancer Conference	Board Member
01/1982-12/1987		Cancer Surveys	Editor
		<i>Advances and Prospects in Clinical, Epidemiological and Laboratory Oncology Advisory Board, Cancer and Metasis Reviews</i>	
01/1982-12/1986		Cancer Research	Other
		<i>Associate Editor</i>	
01/1982-12/1986		NTP Peer Review	Member
01/1981-12/1988		UICC Review Committee for International	Chair

		Fellowships, Geneva Switzerland	
01/1981-12/1988		IARC Review Committee for International Fellowships, Lyon France	Member
01/1981-12/1985		AACR Program Committee	Member
01/1981-01/1981		American Cancer Society <i>News Conference Meeting for Cancer Research, Houston Texas</i>	Coordinator
01/1980-12/1983		NAS Review Committee on Diet, Nutrition and Cancer	Member
01/1980-01/1980		NCI Committee for Reviewing Chemical Carcinogens, Safety Monographs	Member
09/1979-10/1980	International	Battelle Conference on Polycyclic Aromatic Hydrocarbons	Chair
01/1978-12/1979		Congressional Committee to Comprehensively Survey the Field of Skin Cancer	Member
01/1978-01/1978		American Cancer Society - News Conference Meeting for Cancer Research, Daytona Beach FL	Coordinator
01/1978-Present		Reviewer for Scientific Journals <i>European Journal of Cancer</i> <i>Journal of Investigative Dermatology</i> <i>Cancer Letters</i> <i>Cancer &amp; Metastasis Reviews</i> <i>International Journal of Cancer</i> <i>Science</i> <i>Carcinogenesis</i> <i>PNAS</i> <i>Cell</i> <i>Nature</i> <i>Journal of the National Cancer Institute</i> <i>Clinical Cancer Research</i> <i>Toxicological Sciences</i> <i>Cancer Research</i>	Reviewer
/ -05/1977	International	American Association for Cancer Research Meeting <i>Session on Tumor Promotion</i>	Chair
/ -Present		Japanese Journal of Cancer Research	Editor

**SERVICE TO THE PUBLIC:**

<b><u>Dates</u></b>	<b><u>Type</u></b>	<b><u>Description</u></b>	<b><u>Role</u></b>
01/1993-12/1998		NIEHS Intramural Research Program Board of Scientific Counselors	Member
02/1990-02/1990		Dept of Energy/Office of health and Environmental Research, Burlingame CA	Advisory Committee Member

**GRANT REVIEWS:**

<b><u>Dates</u></b>	<b><u>Granting Agency</u></b>	<b><u>Panel Name</u></b>	<b><u>Role</u></b>
06/1990-06/1990	ACS	ACS Special Institutional Grants, Atlanta GA	External Ad Hoc Reviewer
01/1988-12/1989	American Cancer Society	American Cancer Society	External Reviewer
01/1978-12/1982	NIH	Study Section on Chemical Pathology	External Chair
01/1976-12/1976	80NIEHS	Study Section for Training Grants for Environmental Technology	External Reviewer
01/1975-Present	NCI	Site Visit Team	External Reviewer
/ -03/1984		NIH Cancer Preclinical Program Project Review	External Reviewer

**PROFESSIONAL AFFILIATIONS:**

<b><u>Dates</u></b>	<b><u>Organization</u></b>
01/1980-12/1985	New York Academy of Sciences
04/1978-03/2005	Society of Toxicology
01/1978-12/1990	Society for Experimental Biology and Medicine

01/1978-Present	American Association for Cancer Research
09/1975-Present	American Society for Investigative Dermatology
01/1975-12/1985	American Society for Pharmacology and Experimental Therapeutics
01/1975-Present	American Association for the Advancement of Science (AAAS)

**COMMITTEES (UTHSCSA Standing Committees):**

***DEPARTMENT***

<b><u>Dates</u></b>	<b><u>Committee</u></b>	<b><u>Role</u></b>
04/2015-03/2018	Promotions and Tenure Committee	Member
04/2011-03/2014	Promotions and Tenure Committee	Member
04/2008-03/2010	Post-Tenure Review Committee	Chair
04/2007-03/2010	Post-Tenure Review Committee	Member

---